

04/05/00

Type a plus sign (+) inside this box

+

04-07-00

PTO/SB/05 (2/98)

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No. 920043.406

First Inventor or Application Identifier

Aaron P. White

Title BACTERIAL FIMBRIAL SYSTEM FOR PRESENTATION OF HETEROLOGOUS PEPTIDE SEQUENCES

Express Mail Label No. EL487465451US

PRO  
525 51340

04/05/00

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  General Authorization Form & Fee Transmittal  
*(Submit an original and a duplicate for fee processing)*2.  Specification [Total Pages] 106  
*(preferred arrangement set forth below)*

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) (35 USC 113) [Total Sheets] 25

4. Oath or Declaration [Total Pages]

- a.  Newly executed (original or copy)
- b.  Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 17 completed)*
  - i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)

5. Incorporation By Reference *(useable if box 4b is checked)* The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment

- \*  Continuation  Divisional  Continuation-In-Part (CIP) of prior Application No.: \_\_\_\_\_


- \* Prior application information: Examiner \_\_\_\_\_ Group / Art Unit \_\_\_\_\_

 Claims the benefit of Provisional Application No. 60/127,888, filed April 5, 1999
**CORRESPONDENCE ADDRESS**

David D. McMasters  
**Seed Intellectual Property Law Group PLLC**  
 701 Fifth Avenue, Suite 6300  
 Seattle, Washington 98104-7092  
 Phone: (206) 622-4900 / Fax: (206) 682-6031

Respectfully submitted,

TYPED or PRINTED NAME KARL R. HERMANNSS

SIGNATURE 

Winword\ddm\9506\v1

REGISTRATION NO. 33,507

Date 4/5/00

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Aaron P. White, Victoria, Canada;  
James L. Doran, Brentwood Bay, Canada;  
S. Karen Collinson, Brentwood Bay, Canada;  
William W. Kay, Victoria, Canada

Filed : April 5, 2000

For : BACTERIAL FIMBRIAL SYSTEM FOR PRESENTATION OF  
HETEROLOGOUS PEPTIDE SEQUENCES

Docket No. : 920043.406

Date : April 5, 2000

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Assistant Commissioner for Patents:

I hereby certify that the enclosures listed below are being deposited with the United States Postal Service "EXPRESS MAIL Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Certificate No. EL487465451US, on April 5, 2000, addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Jeanette West/Susan Johnson

DDM:nr

Enclosures:

Postcard

Check

Form PTO/SB/05

Specification, Sequence Listing, Claims, Abstract (106 pages)

25 Sheets of Drawings (Figures 1-26)

BACTERIAL FIMBRIAL SYSTEM FOR PRESENTATION OF HETEROLOGOUS  
PEPTIDE SEQUENCES

5 CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Application No. 60/127,888, filed April 5, 1999, which application is incorporated by reference in its entirety.

TECHNICAL FIELD OF THE INVENTION

10 The invention relates to the use of thin aggregative fimbriae (TAF; SEF17) from *Salmonella* or its homologue, curli from *Escherichia coli*, to express one or more peptide sequences derived from heterologous, pathogenic organisms (bacteria, viruses, protozoa).

BACKGROUND OF THE INVENTION

15 Creation of Recombinant Salmonella Strains

Several methods for generating *Salmonella* vaccine strains expressing chromosomally integrated foreign DNA have been developed. Three such methods are: 1) specific integration into the *aroC* gene [Strugnell, 1990], 2) using of a defective transposable element [Flynn, 1990], and 3) specific integration into the *his* locus [Hone, 20 1988].

However, use of any of these methods results in chromosomal insertion of the recombinant genes into regions where the wild-type (original) genes are not normally found. Because of this, the native promoter region(s) cannot be utilized for expression. Therefore, the development of strategies for heterologous antigen 25 presentation which address the use of native promoter regions and minimize genetic alterations in the host chromosome are required.

## SUMMARY OF THE INVENTION

A high frequency chromosomal gene replacement method of general utility was developed for *Salmonella enteritidis*. This system uses an unstable, imperfectly segregating, temperature-sensitive replicon, pHSG415, as a carrier of the recombinant gene of interest and allows for site-specific replacement of chromosomal genes without the need for antibiotic resistance markers in the recombinant genes or the use of specific bacterial strains. This strategy was used to replace the chromosomal *agfA* fimbrin genes of *S. enteritidis* 3b with recombinant genes containing a 48 bp DNA fragment encoding PT3, an immunoprotective T cell epitope from GP63 of *Leishmania major*. This represents the first report of fimbrial epitope replacement in the Salmonellae and the first chimeric fimbrin genes that have been reconstituted into a wild-type genetic background for any organism.

Thin aggregative fimbriae (TAF) of *S. enteritidis* were modified to effectively present heterologous epitopes. Sixteen amino acid segments were replaced by PT3 at 10 different sites throughout AgfA, the major fimbrial subunit protein, chosen on the basis of primary protein sequence alignment, secondary structure predictions and comparison to a 3-D model of AgfA structure. All 10 segment replacements resulted in chimeric fimbrin proteins expressed by *S. enteritidis* from the native chromosomal promoter, each representing a replacement of over 10% of the total AgfA protein. Immunogold electron microscopy indicated that 8 of the 10 chimeric fimbriae were effectively assembled into fimbrial fibers expressed at the cell surface of *S. enteritidis*. These results demonstrate that AgfA and thin aggregative fimbriae represents a unique, flexible and fascile system for carrying heterologous peptide sequences.

CsgA and curli, the *E. coli* homologues to AgfA and thin aggregative fimbriae, respectively, as well as the proposed minor subunit proteins, AgfB for TAF and CsgB for curli, which are homologues of AgfA and CsgA, are likely to be equally valid carriers for heterologous sequences.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic of the two step overlap extension or crossover PCR protocol used to generate recombinant *S. enteritidis agfA*. (A) Step one of the protocol

involved a vector-borne (wavy lines) target *S. enteritidis* gene (grey box) that was PCR amplified in two fragments using two pairs of primers, (A/B, C/D, arrows). Internal primers encoded the foreign epitope (solid black line) whereas external primers encoded restriction endonuclease recognition sites (*Eco*RI or *Hind*III) for subsequent cloning.

5 (B) In step two, both purified PCR products were combined with external primers as described in Experimental procedures and PCR was used to generate gene fragments (1 and 4) which annealed to generate the whole chimeric gene. (C) Recombinant *S. enteritidis* *agfA* containing 48 bp foreign *Leishmania major* DNA sequence encoding the 16 amino acid PT3 epitope [Jardim, 1990]; the protein sequence is indicated in bold

10 type.

Figure 2. Generation of *S. enteritidis* strains carrying recombinant *agfA*.

A. Map of pHSG415 indicating positions of unique restriction endonuclease sites, antibiotic resistance genes (black arrows) and temperature-sensitive origin of replication (*ori*). Figure adapted from [Hashimoto-Gotoh, 1981]. B. Gene replacement strategy.

15 Transformed *S. enteritidis* was grown at 42°C with selection pressure to induce a single crossover event and subsequent integration of pHSSP10 into the chromosome. Plasmid cointegrates were grown at 28°C without selection pressure to induce a second crossover event and loss of the pHSG415 sequence, resulting in one of two possibilities: 1) wild-type *agfA* or 2) recombinant *agfA*.

20 Figure 3. PT3 epitope replacement in AgfA. A. Peptide sequence of the PT3 epitope from GP63 of *Leishmania major* [Jardim, 1990]. Predicted secondary structure (Garnier-Robson algorithm, DNASTar software) is listed below the peptide sequence: (-) β-strand ; (x) β-helix. B. Schematic diagram of the mature AgfA protein illustrating the regions replaced by the PT3 epitope sequence; regions A1 to A10 are indicated with the colored boxes above the sequence. The five-fold internal sequence homology of AgfA is represented by regions C5a-e with the consensus sequence Sx<sub>5</sub>QxGx<sub>2</sub>NxAx<sub>3</sub>Q, with the 22-residue N-terminal region listed at the bottom. Predicted secondary structure (Garnier-Robson algorithm, DNASTar software) is listed below the protein sequence: (-) β-strand ; (x) β-helix ; (\*) random coil; (<) turn.

30 Figure 3C. The predicted parallel β-helix model of AgfA (residues 23-130) viewed from the front side [Collinson, 1999]. The five-fold repeat segments (C5a-

e) and colored residues, representing regions in AgfA replaced with PT3, refer back to the diagram in (B). Color Code: Blue = regions A4, A5, A6, A7; Yellow = regions A8, A9, A10; Red = regions A1, A2; Green = blue and yellow overlap; Orange = blue, yellow and red overlap; Purple = blue and red overlap; Grey = unreplaced sequence.

5         Figure 4. Western blot analysis of the 10 different *S. enteritidis* strains containing recombinant *agfA* in the chromosome. Formic acid treated SDS-PAGE sample buffer-glycine insoluble material from scraped whole cells of *S. enteritidis* 3b 2-2a (lane 2), A1 (lane 3), A2 (lane 4), A3 (lane 5), A4 (lane 6), A5 (lane 7), W+ 3b (lane 8), A6 (lane 10), A7 (lane 11), A8 (lane 12), A9 (lane 13), A10 (lane 14) and A+ control  
10 strain (lane 15) grown on T plates. Purified SEF17 is represented in lanes 1 and 9. The molecular mass markers are shown on the left of each blot. A. Blot reacted with immune sera raised to SEF17. B. Blot reacted with immune sera raised to PT3.

15         Figure 5. Immunogold electron microscopy of *S. enteritidis* strains containing recombinant *agfA* in the chromosome. *S. enteritidis* strains analyzed after growth on T plates (A, C, D) or in T broth (B, E, F) for 24h at 37°C, static. Immunogold labeling was performed with antiserum raised to thin aggregative fimbriae followed by protein A-15 nm gold (A, B, C, E) or with antiserum raised to the PT3 epitope followed by goat-anti-rabbit-5 nm gold (D, F). A. *S. enteritidis* A+ control strain grown on T plates, reacted with immune serum raised to thin aggregative  
20 fimbriae. B. *S. enteritidis* A+ control strain grown in T broth, reacted with immune serum raised to thin aggregative fimbriae. C. *S. enteritidis* strain A7 grown on T plates, reacted with immune serum raised to thin aggregative fimbriae. D. *S. enteritidis* strain A7 grown on T plates, reacted with immune serum raised to PT3. E. *S. enteritidis* strain A4 grown in T broth, reacted with immune serum raised to thin  
25 aggregative fimbriae. F. *S. enteritidis* strain A4 grown in T broth, reacted with immune serum raised to PT3.

30         Figure 6. Resistance of the recombinant TAF fibers expressed in *S. enteritidis* to proteinase K treatment. Samples prepared as in Figure 2 but treated with proteinase K (0.5 mg/ml) before loading on SDS-PAGE. *S. enteritidis* 3b 2-2a (lane 2), A1 (lane 3), A2 (lane 4), A3 (lane 5), A4 (lane 6), A5 (lane 7), W+ 3b (lane 8), A6 (lane 10), A7 (lane 11), A8 (lane 12), A9 (lane 13), A10 (lane 14) and A+ control strain (lane

15) are represented. Purified SEF17 is represented in lanes 1 and 9. The blots were reacted with immune serum generated against SEF17. The molecular mass markers are shown on the left of each blot. A. Samples digested with proteinase K for 1 hour. B. Samples digested with proteinase K for 2 hours.

5           Figure 7. The effect of formic acid concentration on the absorbance at 600 nm of 0.5 mg/ml suspensions thin aggregative fimbriae. Inset: Immunoblot of 20 µg of thin aggregative fimbriae treated in one of several formic acid solutions noted above each lane and detected on immunoblots with fimbrin-specific immune serum as described in the Materials and Methods. The size of each protein is noted in kDa to the  
10 right of the blot.

15           Figure 8. Immunoblot analysis of *S. enteritidis* native thin aggregative fimbriae (lanes 1 and 2) or purified fimbriae (lanes 3 and 4). Samples were untreated (lanes 1 and 3) or treated (lanes 2 and 4) with proteinase K before immunoblot analysis as described in the Materials and Methods. The protein band sizes on immunoblots are noted in kDa to the right of the blot.

20           Figure 9. AgfA fimbrin domains and internal amino acid sequence homology. (a) Schematic diagram of the N-terminal (N) and C-terminal (C) domains of AgfA illustrating the relative positions of the two- or five-fold homologous regions C2a-b or C5a-e, respectively, with in the C-terminus. Values in parenthesis denote the number of amino acids present in each segment. (b) Alignment AgfA fragments C2a and C2b. Amino acid identity (•) and conservative replacements (underscored) are indicated with gaps (-) introduced for optimal alignments. (c) Alignment of AgfA fragments C5a to C5e with gaps (-) introduced for optimal alignments. Conserved residues with in each repeat are boxed. (d) The 18 amino acid consensus sequence of the five internal repeats where x is any amino acid. The position of each residue corresponds to the numbered residues in Figure 11c. (e) Position of the conserved ten nonpolar-polar-nonpolar (ifi) triplet motifs within each of the five 22 or 23 residue repeats. Non-conserved residues of each triplet are boxed.

30           Figure 10. Secondary structure predictions of AgfA in which extended (e), helix (h), coil (c) or turn (t) propensity are noted under each amino acid letter designation. The programs Alexsis (alx), Hierarchical Neural Network (hie), Garnier

(gar), Gibrat (gib) and NNPredict (nnp) were used to analyze AgfA as described in the Materials and Methods.

Figure 11. The proposed parallel  $\beta$ -helix model of AgfA for residues 23 to 130 inclusive. Molescript representation of the five coil helix model viewed from the  
 5 (a) front side or (b) top. The C-terminal portion of each coil is labeled to identify the respective 22 or 23 amino acid repeat segment as identified in Figure 9a,c. (c) A wire diagram of the AgfA parallel  $\beta$  helix model viewed as in b but accentuating the vertical alignment of the five consensus segments noted in Figure 9c. The amino acids of each consensus sequence are numbered as indicated in Figure 9d. Carbon atoms (green) are  
 10 distinguished from nitrogen (blue), oxygen (red) and sulfur (yellow).

Figure 12. The proposed parallel  $\beta$  helix model of AgfA viewed as a wire diagram with space filling model representation of (a) internal or (b) surface exposed amino acid side groups viewed from the top as in Figure 11b & c. Space filling model representation of the AgfA  $\beta$  helix model viewed from the (c) front side as  
 15 in Figure 11a or (d) back side. Amino acid residues are coloured as; nonpolar (green), polar (red), basic (blue) or W (yellow). In Figures 12c and d the A, G and internalized residues are grey or white whereas other surface exposed residues are coloured.

Figure 13. (a) Molescript representation of the  $\beta$  barrel model of AgfA. The N-terminus (N) and C-terminal repeat segments (C5a to e) are numbered as in  
 20 Figure 9a,c. (b) Molescript representation of PMP protein using coordinates obtained from SCOP on which the AgfA  $\beta$  barrel model was modeled as described in the Materials and Methods.

Figure 14. (a) Molescript representation of the  $\beta$  prism model of AgfA.  
 (b) Molescript representation of VMO-I protein using coordinates obtained from SCOP  
 25 on which the AgfA  $\beta$  prism model was modeled as described in the Materials and Methods.

Figure 15. Alignment of the five *S. enteritidis* AgfA C-terminal tandem repeat sequences with those of *E. coli* CsgA such that the amino acid residue positions are numbered according to Figure 9d and Figure 11c. Symbols above the numbered  
 30 amino acids indicate the positions of proposed internalized (•), surface exposed (o), turn (t) residues or the two nonpolar-polar-nonpolar triplets (ifi) within the parallel  $\beta$  helix

model of AgfA. Surface or turn residues are colour coded: polar or acidic (red), basic (blue), nonpolar (green), W (yellow) and G (black). Proposed internalized residues are noted in black.

Figure 16. Alignments of AgfA with  $\beta$  structural motifs of the three template proteins of known structure used to assemble AgfA models. AgfA sequence was aligned with the (a)  $\beta$  roll motif sequence of *Serratia marcescens* protease (SMP) (Baumann, 1994; Braunagel & Benedik, 1990) (b)  $\beta$  barrel motif of bovine myelin P2 protein (PMP) (Jones *et al.*, 1988), (c)  $\beta$  prism motif of the vitelline membrane outer layer protein I (VMO-I) (Shimizu & Morikawa, 1996). Bold characters indicate nonpolar-polar-nonpolar motifs, gaps (-) were introduced for optimal alignments. Residues are numbered according to published sequences.

Figure 17. Schematic of the two step overlap extension or crossover PCR protocol used to generate chimeric *S. enteritidis* genes. (A) Step one of the protocol involved a plasmid-borne (wavy lines) target *S. enteritidis* gene (grey box) that was PCR amplified in two fragments using two pairs of primers, (A/B, C/D, arrows). Internal primers encoded the foreign epitope (solid black line) whereas external primers encoded restriction endonuclease recognition sites (*Eco*RI or *Hind*III) for subsequent cloning. (B) In step two, both purified PCR products were combined with external primers as described in Experimental procedures and PCR was used to generate gene fragments (1 and 4) which annealed to generate the whole chimeric gene. (C) Chimeric *S. enteritidis* *sefA* and *agfA* fimbrin genes containing 48 bp foreign *Leishmania major* DNA sequence encoding the 16 amino acid PT3 epitope [25]; the protein sequence is indicated in bold type.

Figure 18. Generation of *S. enteritidis* strains carrying chimeric fimbrin genes. A. Map of pHSG415 indicating positions of unique restriction endonuclease sites, antibiotic resistance genes (black arrows) and temperature-sensitive origin of replication (*ori*). Figure adapted from [20]. B. Gene replacement strategy (shown for *sefA::PT3*). Transformed *S. enteritidis* was grown at 42°C with selection pressure to induce a single crossover event and subsequent integration of pHSSP10 into the chromosome. Plasmid cointegrates were grown at 28°C without selection pressure to

induce a second crossover event and loss of the pHSG415 sequence, resulting in one of two possibilities: 1) wild-type fimbrin gene or 2) chimeric fimbrin gene.

Figure 19. Western blot analysis to detect expression of chimeric *sefA::PT3* and *agfA::PT3* in *E. coli*. A. Whole cell lysates of *E. coli* XL-1 Blue harboring pGP1-2 with pTZ18R (lane 1), pTZSef (lane 2), and pTZSP10 (lane 3) reacted with anti-SEF14 and -SEF21 immune serum. Purified SEF14 is represented in lane 4. B. Whole cell lysates of *E. coli* XL-1 Blue harboring pGP1-2 and pTZ18R (lanes 2 and 5), pTZAfg (lanes 3 and 6), or pTZAP7 (lanes 4 and 7) with (+FA) or without (-FA) formic acid treatment reacted with immune sera raised to SEF17. Lane 1 contains FA treated, purified, thin aggregative fimbriae. The sizes (kDa) of the molecular mass markers are indicated on the left.

Figure 20. Western blot analysis of Ap<sup>S</sup> *S. enteritidis* strains after *sefA::PT3* gene replacement. Whole cell lysates of strains #11 (lane 2), #13 (lane 3), #192 (lane 4), #197 (lane 5), and W<sup>+</sup> 3b (lane 6) reacted with anti-SEF14 and -SEF21 immune serum. Purified SEF14 is represented in lane 1. The sizes (kDa) of the molecular mass markers are indicated on the left.

Figure 21. Western blot analysis of Ap<sup>S</sup> *S. enteritidis* strains after *agfA::PT3* gene replacement. Whole cell SDS-PAGE sample buffer-glycine extracts of *S. enteritidis* strains #91 (lane 2), #102 (lane 3), #103 (lane 4), #104 (lane 5), W<sup>+</sup> 3b (lane 6) and strain #27 (lane 7) without formic acid treatment (A; -FA), and SDS-PAGE sample buffer-glycine insoluble material with formic acid treatment (B; +FA) reacted with immune sera raised to SEF17. Purified SEF17 is represented in lane 1. The sizes (kDa) of the molecular mass markers are indicated on the left.

Figure 22. Western blot analysis of T-broth culture supernatant proteins from *S. enteritidis* strains containing *agfA::PT3*. SDS-PAGE sample buffer-glycine extracts of acetone-precipitated culture supernatant proteins from *S. enteritidis* strains #102 (lane 2 and 5) and #103 (lane 3 and 6). Purified SEF17 is represented in lanes 1 and 4. Lanes 1-3 were reacted with immune sera raised to whole SEF17, whereas Lanes 4-6 were reacted with immune sera raised to PT3 peptide. The sizes (kDa) of the molecular mass markers are indicated on the left.

Figure 23. PT3 epitope replacement in SefA. A. Peptide sequence of the PT3 epitope from GP63 of *Leishmania major* (Jardim et al., 1990). B. Schematic diagram of the mature SefA protein illustrating the regions replaced by the PT3 epitope sequence; regions S1 to S10 are indicated with the colored boxes above the sequence.

5 Color Code: Black = region S1; Orange = region S10; Blue = regions S2, S3, S4, S5; Green = regions S6, S7, S8, S9.

Figure 24. Footpad inflammation of vaccinated BALB/c mice after *Leishmania major* challenge. Mice were vaccinated with a single oral dose (A, C) of *S. enteritidis* 3b or A4 ( $10^5$  organisms/mouse) or PBS alone or two oral doses (B, D) of *S. enteritidis* 3b or A4 ( $10^5$  and  $10^3$  organisms/mouse) or PBS alone spaced 2 weeks apart. They were challenged with *L. major* in the footpad 6 weeks (A, B;  $10^7$  organisms/mouse) or 8 weeks (C, D;  $5 \times 10^6$  organisms/mouse) after first vaccination. Footpad inflammation was measured weekly as the increase in footpad thickness (subtracting the thickness of uninfected footpad from that of the infected footpad).

10 15 Symbols on graphs: (circle) *S. enteritidis* A4 vaccinated mice; (triangle) *S. enteritidis* 3b vaccinated mice; and (square) PBS-vaccinated control mice. Data are means +/- standard errors of the mean ( $n = 5$ ).

Figure 25. Quantification of *Leishmania major* parasites in popliteal ganglia from infected BALB/c mice. *L. major* carrying a reporter gene was quantified by measuring reporter gene activity after performing a limiting dilution assay (Titus et al., 1985). Columns represent total reporter gene units (A) and reporter gene units per mg of organ (B) as the mean values from each group: 3-1, one dose of PBS only; 3-2 and 3-3, one vaccination with  $10^5$  *S. enteritidis* 3b or A4, respectively; 3-4, two doses of PBS only; 3-5 and 3-6, two vaccinations with  $10^5$  and  $10^3$  *S. enteritidis* 3b or A4, respectively. All groups of mice were challenged in the footpad with  $5 \times 10^6$  live *L. major* eight weeks after first vaccination. Standard errors of the mean for each group are listed below the appropriate columns at the bottom of each graph.

Figure 26. Measurement of serum antibodies against PT3 peptide, SEF17 and AgfA. BALB/c mouse serum was tested in triplicate (1 in 100 dilution) by ELISA against 1  $\mu\text{g}/\text{well}$  of PT3 peptide (A), polymerized SEF17 (B), or depolymerized SEF17 pre-treated with 90% formic acid (C; Collinson et al., 1991).

Results shown are the mean absorbance values from each group of mice: 1-1, 2-1, 3-1, one dose of PBS only; 1-2, 2-2, 3-2, one vaccination with  $10^5$  *S. enteritidis* 3b; 1-3, 2-3, 3-3, one vaccination with  $10^5$  *S. enteritidis* A4; 1-4, 2-4, 3-4, two doses of PBS only; 1-5, 2-5, 3-5, two vaccinations with  $10^5$  and  $10^3$  *S. enteritidis* 3b; 1-6, 2-6, 3-6, two 5 vaccinations with  $10^5$  and  $10^3$  *S. enteritidis* A4. Groups 1-1 to 1-6 and 2-1 to 2-6 were challenged in the footpad with  $10^7$  live *L. major* four and six weeks after first vaccination, repectively, and groups 3-1 to 3-6 were challenged in the footpad with 5 x  $10^6$  live *L. major* eight weeks after first vaccination.

10 Sequence Listing

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the 15 displayed strand.

- SEQ ID: 1 shows the *agfA* DNA sequence  
SEQ ID: 2 shows the *agfB* DNA sequence  
SEQ ID: 3 shows the *csgA* DNA sequence  
SEQ ID: 4 shows the *csgB* DNA sequence  
20 SEQ ID: 5 shows the AgfA amino acid sequence  
SEQ ID: 6 shows the AgfB amino acid sequence  
SEQ ID: 7 shows the CsgA amino acid sequence  
SEQ ID: 8 shows the CsgB amino acid sequence  
SEQ ID: 9 shows the DNA sequence encoding the *Leishmania major* PT3 epitope  
25 SEQ ID: 10 shows the *Leishmania major* PT3 epitope amino acid sequence  
SEQ ID: 11 shows the *agfA::PT3#1* DNA sequence  
SEQ ID: 12 shows the AgfA::PT3#1 amino acid sequence  
SEQ ID: 13 shows the *agfA::PT3#2* DNA sequence  
SEQ ID: 14 shows the AgfA::PT3#2 amino acid sequence  
30 SEQ ID: 15 shows the *agfA::PT3#3* DNA sequence

- SEQ ID: 16 shows the AgfA::PT3#3 amino acid sequence  
 SEQ ID: 17 shows the *agfA*::*PT3#4* DNA sequence  
 SEQ ID: 18 shows the AgfA::PT3#4 amino acid sequence  
 SEQ ID: 19 shows the *agfA*::*PT3#5* DNA sequence  
 5 SEQ ID: 20 shows the AgfA::PT3#5 amino acid sequence  
 SEQ ID: 21 shows the *agfA*::*PT3#6* DNA sequence  
 SEQ ID: 22 shows the AgfA::PT3#6 amino acid sequence  
 SEQ ID: 23 shows the *agfA*::*PT3#7* DNA sequence  
 SEQ ID: 24 shows the AgfA::PT3#7 amino acid sequence  
 10 SEQ ID: 25 shows the *agfA*::*PT3#8* DNA sequence  
 SEQ ID: 26 shows the AgfA::PT3#8 amino acid sequence  
 SEQ ID: 27 shows the *agfA*::*PT3#9* DNA sequence  
 SEQ ID: 28 shows the AgfA::PT3#9 amino acid sequence  
 SEQ ID: 29 shows the *agfA*::*PT3#10* DNA sequence  
 15 SEQ ID: 30 shows the AgfA::PT3#10 amino acid sequence

#### DETAILED DESCRIPTION OF THE INVENTION

##### Definitions

Fimbriae (pili): Fimbriae are proteinaceous, hairlike appendages produced on the surface of a wide range of bacteria. Fimbriae are generally shorter (several hundred or thousand nm long) and more numerous than flagella (between 100 and 1000 fimbriae per cell) and are usually not involved in cellular motility. Detailed studies of several fimbriae from a variety of animal and human pathogens have revealed that in some case these appendages facilitate bacterial adherence to host tissues [Hultgren, 1996]. Fimbriae are composed of a repeated major subunit protein (fimbrin) and sometimes several minor subunit-like proteins. Fimbrins are polymerized by hydrophobic and hydrophilic interactions to form either thick (7 to 8 nm), rigid structures, thin (2 to 4 nm), flexible filaments or composites of both [Low, 1996].

Thin aggregative fimbriae: Thin aggregative fimbriae (TAF; SEF17) from *S. enteritidis* are thin fibers (3 to 4 nm in diameter) expressed by cells in stationary

phase and under conditions of starvation or low osmolarity [Collinson, 1991]. They are extremely aggregative, mediate fibronectin binding [Collinson, 1993], and their expression confers a rough aggregative colony morphology. These fimbriae are characterized as being extremely stable structures; they are not solubilized in 5M NaOH 5 or in boiling 0.5% deoxycholate, 8M urea, or 1 to 2% sodium dodecyl sulfate (SDS) with or without 5%  $\beta$ -mercaptoethanol [Collinson, 1991]. Furthermore, these fimbriae remain structurally intact after digestion with proteinase K for up to 2 hours [Collinson, 10 1999]. Thus far, depolymerization of the fimbriae and release of the fimbrin subunit proteins has only been accomplished by exposing the fimbriae to 90% formic acid [Collinson, 1991; Collinson, 1999]. To our knowledge, this is the only fimbrial type to require such harsh conditions for depolymerization and are thus considered super-stable fimbriae.

#### Fimbriae as Carriers of heterologous epitopes

Fimbriae are proteinaceous, filamentous cell surface structures primarily 15 composed of helically arranged, identical, protein subunits called fimbrins. There are up to 1000 fimbrins per fimbriae and as many as 500 fimbriae per cell. They are found on a wide variety of pathogenic bacteria and are thought to be involved in the colonization of host cell surfaces [Hultgren, 1993]. Therefore, fimbriae may be important for the disease process *in vivo*.

Advantages of a fimbrial presentation system are the following: 1) the 20 heterologous antigens will be presented in high numbers (up to 500,000 copies per cell), 2) the hybrid fimbrin protein may possess both the immunogenicity and adhesion properties relevant for an efficient live vaccine, 3) the carrier fimbrial subunit proteins are usually strong immunogens, which may be important for directing an immune 25 response against the inserted epitope, and 4) hybrid fimbriae are easy and inexpensive to purify in large amounts (could be used as a vaccine themselves) [Pallesen, 1994]. These advantages make a fimbrial expression system very attractive.

Several strains of *E. coli* produce fimbriae named curli which are highly 30 related to thin aggregative fimbriae from *Salmonella* spp. Both TAF and curli are primarily composed of one major subunit protein, AgfA and CsgA, respectively. The

primary sequence of AgfA and CsgA are 74% identical and 86% conserved [Collinson, 1996]; no other characterized fimbrial proteins in existing sequence databases have notable sequence similarity to either protein. Curli have also been extensively characterized [Bian, 1997; Hammar, 1995; Hammar, 1996; Olsén, 1993; Römling, 5 1998; Römling, 1998]; the operon encoding curli production has been sequenced and characterized in *E. coli* [Hammar, 1995] and was recently shown to be conserved (identity of 78%) in *Salmonella typhimurium* [Römling, 1998], which also produces thin aggregative fimbriae. This evidence indicates that thin aggregative fimbriae and curli are both members of the same distinct class of fimbriae. The gene for TAF, *agfA* 10 (*csgA*) has been detected in 99.8% (603/604) of *Salmonella* isolates, but is less representative in other members of the *Enterobacteriaceae*, including only 19.0% (26/137) *E. coli* strains [Doran, 1993]. *agfA* is therefore genotypic of *Salmonella* spp. and occasionally found in *E. coli* and its subspecies, suggesting its origins were in *Salmonella* spp. and coopted into *E. coli*.

15 AgfA is characterized as having a two-domain structure with a 22 residue protease-susceptible N-terminal region and a 109 residue protease-resistant C-terminal core region [Collinson, 1999]. This C-terminal core region has five-fold sequence homology as represented in Fig 5B and is predicted to comprise a primarily β-sheet structure. The first 18 amino acids of each of the five segments conformed to 20 the consensus sequence Sx<sub>5</sub>QxGx<sub>2</sub>NxAx<sub>3</sub>Q separated by 4 or 5 additional residues except for the terminal repeat which ended in Y. Analysis of this five-fold sequence homology has yielded a hypothetical, parallel β-helix, three-dimensional structure for AgfA [Collinson, 1999] and this model is displayed in Figure 5C.

AgfB is proposed to be a minor component of thin aggregative fimbriae 25 and shares high secondary structure similarity to AgfA. It is the same size as AgfA and the overall primary sequence homology is 22% identity and 42% similarity. The majority of conserved residues keep the consensus sequence intact (described above for AgfA); based on this, AgfB is proposed to have a similar three dimensional structure.

Assembly of thin aggregative fimbriae: The majority of fimbrial 30 assembly systems in Gram negative bacteria follow the chaperone/usher pathway [Hultgren, 1996]. In this system, the chaperone protein facilitates the release of fimbrin

subunits from the cytoplasmic membrane, prevents premature aggregation and targets the subunits to the usher protein in the outer membrane which allows them to pass through and assemble into fimbrial fibers [Thanassi, 1998]. The prototypical fimbriae for this system are the Pap or P fimbriae from *E. coli* and Type 1 fimbriae from *E. coli* and *Salmonella* [Hultgren, 1996]. Another well characterized assembly system is that of Type IV fimbriae produced by *Pseudomonas aeruginosa*, *Neisseria* spp., *Moraxella bovis*, *Dichelobacter nodosus*, and *Vibrio cholerae*. These fimbriae apparently bypass the need for specialized chaperone and usher proteins and utilize a branch of the general secretion pathway (type II) which is widely used for the secretion of many other extracellularly targeted proteins [Salmond, 1996]. Many homologues to the fimbrial types described above have been characterized; almost without exception, growth of the fimbrial fiber is achieved from the base by addition of the subunits from the periplasmic side of the outer membrane.

In contrast, thin aggregative fimbriae (curli) are proposed to assemble via a unique and novel mechanism described as extracellular, nucleator-dependent assembly [Hammar, 1996]. In this model, AgfA monomers are secreted from the cell (across the outer membrane) in a soluble, polymerization-competent form and are proposed to polymerize into insoluble fimbrial fibers on the cell surface upon interaction with a cell-bound nucleator. AgfB is proposed to function as the nucleator, inducing a conformational change in soluble AgfA leading to polymerization [Bian, 1997]. Once an initial interaction has occurred between AgfB and an AgfA monomer, the extension of the fiber is probably self-driven with the addition of AgfA monomers to the free, distal end. AgfB is also proposed to be a minor component of the fibers. Several other proteins are involved in biogenesis of TAF; AgfG may perform a chaperone-like function to protect AgfA and AgfB from proteolytic degradation or may form a multimeric channel in the outer membrane to allow passage of AgfA or AgfB [Loferer, 1997], AgfD acts as a positive transcriptional regulator for TAF expression [Hammar, 1995], AgfE is proposed to be involved in Congo red and fibronectin binding and AgfF is proposed to be involved in nucleation [Römling, 1998].

The conformational change proposed to occur in AgfA might involve a conversion from a partially disordered structure in the monomeric state to readily

ordered secondary structures in the polymeric state as has been observed with assembly of the bacterial flagellar filament [Aizawa, 1990]. TAF assembly would be driven then by conformationally altered AgfA which could bind the next soluble AgfA monomer and induce a similar conformational change. Repetition of this process would result in 5 the formation of the long-insoluble fibers observed with TAF and bears similarity to the scrapie protein changing from soluble to insoluble upon formation of rod-like prion superstructures [Cohen, 1994]. This assembly model is unique among bacterial surface organelles characterized to date.

Epitope: An epitope refers to an immunologically active region of an 10 immunogen (protein) that binds to specific membrane receptors for antigen on lymphocytes or to secreted antibodies [Kuby, 1994]. To generate an immune response to a foreign antigen, lymphocytes and antibodies recognize these specific regions (epitopes) of the antigen rather than the entire molecule.

B cell epitope: The region of an immunogen (protein, polysaccharide, or 15 lipid) which is recognized by B cells when it binds to their membrane bound antibody. The B cells which recognize that particular region then proliferate and secrete antibody molecules which are specific for that region of the immunogen. B cell epitopes tend to be highly accessible regions on the exposed surface of the immunogen. Stimulation of the immune system by B cell epitopes results in “humoral” immunity.

T cell epitope: The region (epitope) of an immunogen which is 20 recognized by a receptor on T cells after being processed and presented on the surface of an antigen presenting cell (APC) in the context of a major histocompatibility complex (MHC) class I or II molecule. T cells can be split into two distinct groups, T helper cells ( $T_h$ ) and T cytotoxic cells ( $T_c$ ). T helper cells recognize epitopes bound to 25 MHC class II molecules whereas T cytotoxic cells recognize epitopes bound to MHC class I molecules. T helper cells can be further subdivided into two classes,  $T_{h1}$  and  $T_{h2}$ , Th1 being responsible for stimulation of cell-mediated immunity and Th2 cells stimulating the humoral arm of the immune system. When a given T cell recognizes the epitope-MHC complex at the surface of the APC it becomes stimulated and 30 proliferates, leading to the production of a large number of T cells with receptors

specific for the stimulating epitope. Stimulation of the immune system by T cell epitopes normally results in “cell-mediated” immunity.

Chromosomal gene replacements: This refers to the replacement of a wild-type gene sequence in the bacterial chromosome with an *in vitro*-altered recombinant gene sequence.

Attenuated Bacterial Vaccine: This refers to bacterial strains which have lost their pathogenicity while retaining their capacity for transient growth within an inoculated host. Because of their capacity for transient growth, such vaccines provide prolonged immune-system exposure to the individual epitopes on the attenuated organisms, resulting in increased immunogenicity and memory-cell production, which sometimes eliminates the need for repeated booster injections. The ability of many attenuated vaccines to replicate within host cells makes them very suitable to induce a cell-mediated immunity. Typically, bacterial strains are made attenuated by introducing multiple defined gene mutations into the chromosome thereby impairing growth *in vivo*.

Recombinant Vector Vaccine: This refers to the introduction of genes (or pieces of genes) encoding major antigens (or epitopes) from especially virulent pathogens into attenuated viruses or bacteria. The attenuated organism serves as a vector, replicating within the host and expressing the gene product of the pathogen.

Sequence Identity: Identity between two nucleic acid sequences, or two amino acid sequences is expressed in terms of the level of identical residues shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences are.

Sequence Similarity: Similarity between two amino acid sequences is expressed in terms of the level of sequence conservation, including shared identical residues and those residues which differ but which share a similar size, polarity, charge or hydrophobicity. Sequence similarity is typically expressed in terms of percentage similarity; the higher the percentage, the more similar the two sequences are.

Recombinant: A recombinant nucleic acid is one that has a sequence that is not normally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often

accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

Oligonucleotide (oligo): A linear polymer sequence of up to about 100 nucleotide bases in length.

5 Probes and primers: Nucleic acid probes and primers may readily be prepared based on the amino acid and DNA sequence provided by this invention. A probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Methods for labeling and guidance in the choice of labels  
10 appropriate for various purposes are discussed, e.g., in Sambrook et al. [Sambrook, 1989].

Primers are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand, and then extended along the target DNA strand by a DNA polymerase  
15 enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, for example, in Sambrook, 1989, Ausubel, 1987, and Innis, 1990. PCR primer pairs can be  
20 derived from a known sequence, for example, by using computer programs intended for that purpose such as DNASTar Lasergene software. One of skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, for example, a primer comprising 20 consecutive nucleotides will anneal to a target with a higher specificity than a corresponding primer of only 15 nucleotides.  
25 Thus, in order to obtain greater specificity, probes and primers may be selected that comprise 20, 25, 30, 35, 40, 50 or more consecutive nucleotides.

Isolated: An “isolated” biological component (such as nucleic acid or protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally  
30 occurs, i.e., other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins that have been “isolated” include nucleic acids

and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids. An “isolated” bacterial strain or colony is purified away from other colonies and yields a pure culture without any contaminants 5 upon plating on selective media.

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the 10 art. A “temperature-sensitive” vector is one which replicates normally at a low growth temperature (i.e., 28°C) and will not replicate at a higher growth temperature (i.e., 42°C) due to mutations at or near the origin of replication. An “imperfectly segregating” vector is one which is not stably inherited by new daughter cells at the time of cell division in the absence of selection pressure due to mutations within the 15 vector sequence.

Operon: An operon is the term used to describe a DNA sequence that codes for one or more polypeptides (structural genes), usually of related function, and a DNA sequence that regulates the expression of these genes.

#### Selection of *Salmonella* and thin aggregative fimbriae

20 *Salmonella* spp. are well developed vaccine vectors [Hackett, 1993]. Attenuated *Salmonella* strains can elicit protective immunity and induce secretory, humoral and cellular anti-*Salmonella* responses in hosts following oral immunization [Levine, 1996]. In addition, most *Salmonella* spp. are facultative intracellular pathogens [Fields, 1986] with a highly characterized invasion pathway [Galán, 1996] 25 and can express antigens inside of host cells. These features, when combined with the ease of genetic manipulation in *Salmonella* spp., makes these facultative intracellular pathogens excellent candidates as vaccine vectors for the presentation of protective heterologous antigens [Curtiss III, 1994].

Thin aggregative fimbriae were selected as the carriers of heterologous 30 sequences because they represented a novel, super-stable class of fimbriae among the

enterobacteriacea [Low, 1996]. They can be expressed at high levels and are surface-exposed [Collinson, 1991]. The biochemical and immunological characteristics of the major subunit protein, AgfA, have been well characterized [Collinson, 1991; Collinson, 1992; Collinson, 1993] and most of the genes in the operon required for assembly have 5 been identified [Hammar, 1995; Collinson, 1996; Römling, 1998]. The structural gene, *agfA*, of TAF was found to be widely distributed and is probably common among *Salmonella* spp. All of these factors made TAF an ideal choice for testing as a carrier of heterologous sequences.

#### Selection of the PT3 epitope

10 Several immunoprotective T cell epitopes have been identified from the GP63 protein of *Leishmania major*, and were found to stimulate the proliferation of lymphocytes from mice immunized with whole GP63 [Jardim, 1990]. One of these epitopes, PT3, comprising residues 154-168 of the mature protein, specifically induced proliferation of CD4<sup>+</sup> T cells of the T<sub>h1</sub> subset, known to be involved in the 15 development of cell-mediated immunity [Jardim, 1994]. A further study proved that a single immunization with synthetic PT3 in adjuvant was able to protect Balb/c mice against challenge with *L. major* promastigotes [Spitzer, 1998]. Furthermore, studies with *Salmonella* vaccine strains expressing GP63 from an extrachromosomal vector have demonstrated that oral vaccination against *Leishmania* infection is possible 20 [McSorley, 1997]. Therefore, PT3 is a good candidate for developing and testing a heterologous fimbrial vaccine system in *Salmonella*.

#### Method of gene replacement within the *Salmonella enteritidis agfBAC* operon

Several methods of chromosomal gene replacement have been developed for the creation of *Salmonella* vaccine vectors (discussed above). However, these 25 methods insert the recombinant genes into the chromosome at non-native sites. As a consequence, expression of the recombinant genes would be predicted to be altered. There is a need for a method of chromosomal gene replacement in *Salmonella* to insert recombinant genes into native regions normally occupied by the wild-type genes. Two such methods exist for chromosomal gene replacements in *E. coli*. The method by

Hamilton et al. (1989) relies on the use of a temperature sensitive pSC101-derived vector to perform the replacements. Gene replacement by this method does not leave (or add) any extraneous DNA elements and one drawback is having to cure final strains of freely replicating vectors. A more recent method proposed by Link et al. (1997) uses 5 a vector related to the one used by Hamilton et al. (1989) with the addition of the *sacB* selectable marker to the vector to allow for selection for loss of the vector sequence upon gene replacement.

The method of chromosomal gene replacement according to the present invention also uses a temperature-sensitive pSC101-derived vector, pHSG415 10 [Hashimoto-Gotoh, 1981], but has some notable differences.

#### Generation of recombinant *S. enteritidis* fimbrin genes.

The *S. enteritidis* 3b *agfA* fimbrin gene was chosen to receive a site-specific epitope replacement with the PT3 epitope. The two-step overlap extension PCR method of Horton *et al.* [Horton, 1989] was used (Figure 1A, B) to replace 48 bp 15 of the fimbrin gene with 48 bp encoding the PT3 T cell epitope from *L. major* (Figure 1C). The PCR-generated gene encoded an AgfA protein carrying the PT3 epitope within a specific region (residues 111-126 in AgfA). The resultant *agfA::PT3* PCR products were sequenced and cloned into pHSG415 (Figure 2A) to generate the recombinant temperature-sensitive vector pHsap7.

#### Gene Replacement in *S. enteritidis*.

*S. enteritidis* 3b cells were transformed with pHsap7 and grown 24h in liquid media (Terrific broth with Ampicillin; TFB/Ap). This culture was transferred five consecutive times into fresh media for a total growth period of 120 h before plating on LB/Ap. 50 isolated colonies were picked and 100% were identified by PCR to contain 25 the integrated vector sequence. Four pHsap7 cointegrate colonies were selected and grown at the permissive temperature of 28°C in liquid media (TFB) without Ap selection pressure for 24 h and transferred five consecutive times into fresh media for a total growth period of 120 h at 28°C. Colonies were plated onto LB and LB/Ap plates to determine the percentage of Ap<sup>s</sup> colonies. 184 isolated colonies were picked from

each cointegrate culture, yielding 27%, 15%, 10% and 9% Ap<sup>S</sup> from the four pHsap7 cointegrates as shown in Table 1.

5

Table 1. Efficiency of *agfA* chromosomal gene replacement in *S. enteritidis*.

Plasmid cointegrate colonies (%)	Ap <sup>S</sup> colonies <sup>a</sup> #	Chimeric gene %	replacements
<b>pHSAP7</b>			
Isolate #2	18	10	7 <sup>b</sup>
Isolate #3	28	15	10 <sup>b</sup>
Isolate #9	49	27	4 <sup>b</sup>
Isolate #10	17	9	8 <sup>b</sup>

<sup>a</sup> 184 individual colonies picked in total.

<sup>b</sup> Frequency of *agfA::PT3* containing *S. enteritidis* estimated by CR binding morphology (TCR).

10

#### Genetic analysis of *S. enteritidis* strains containing recombinant *agfA::PT3*.

To identify *S. enteritidis* strains containing the chimeric *agfA::PT3* gene, five of the final Ap<sup>S</sup> colonies were chosen and were analyzed by PCR. Three strains were identified as having the PT3 DNA sequence within *agfA* and all five strains were negative for the pSC101 *ori* sequence as above. PCR products from each strain were the same size as PCR products of *agfA* from *S. enteritidis*, indicating that there was no additional plasmid sequence inserted in this region. Final confirmation of the genotypes of these strains was obtained by DNA sequencing proving that three strains contained *agfA::PT3* and two strains contained wild-type *agfA*. Thus, these data confirmed the creation of *S. enteritidis* strains containing chimeric *sefA::PT3* or *agfA::PT3* fimbrin genes by precise recombination events.

The existing methods of chromosomal gene replacement are less favorable than the present method. The method of Hamilton *et al.* [Hamilton, 1989] results in final strains containing freely replicating plasmids which must be cured before

selecting gene replacements, whereas the method of the invention results in a high proportion of final strains which have lost the excised plasmid altogether and can be screened directly by PCR. The method of Link *et al.* [Link, 1997] includes the *Bacillus subtilis* *sacB* system to enable direct selection for excision and loss of integrated plasmids. However, when creating deletion mutants without the use of selectable markers, these authors reported lower frequencies than are reported here (Table 1). A recent study by Edwards *et al.* [Edwards, 1998] reported the replacement of *sefA* or *agfA* within *S. enteritidis* at lower frequencies than reported here, even with the use of a Km<sup>R</sup> marker in the recombinant genes. This supports the usefulness of the present method and demonstrates that the high replacement frequencies reported here are not simply due to the ease of *sefA* or *agfA* replacement. Therefore, this method has broad application and appeal for gene replacement in *Salmonella* and other enteric bacteria capable of supporting the replication of pSC101-derived plasmids. In addition, the present results suggest that the use of similar "unstable" plasmids in other organisms could represent a more generalized mutagenesis strategy.

A closer look at the properties of pHSG415 can help explain why this gene replacement method is so efficient. In contrast to pSC101, pHSG415 was shown to be extremely unstable in liquid culture in the absence of selection pressure, with as few as 60% of cells carrying the plasmid after 24 hr [Caulcott, 1987]. These authors speculated that the difference between pSC101 and pHSG415 was due to the absence of most of the *par* locus in pHSG415. The pSC101 *par* locus has been very well characterized; it has been shown to alter the binding of proteins within the origin region [Ingmer, 1993] and thus to enhance DNA replication [Manen, 1990]. In addition, it contains a preferential binding site for DNA gyrase [Wahle, 1988] and alters the negative supercoiling of DNA [Miller, 1990]. Through a combination of these effects the *par* locus promotes partitioning of plasmids to daughter cells at the time of cell division [Meacock, 1980]. Due to the deletion of the *par* locus, pHSG415 is proposed to have a defect in its segregating properties causing unequal partitioning of plasmid molecules to daughter cells at the time of cell division [Caulcott, 1987]. Although the present invention is not bound by a specific mechanisms,, it is proposed that the present method uses the unstable properties of pHSG415 to advantage, and in the absence of

selection pressure, integrated plasmids are lost immediately after the second crossover event or are retained for several generations and then lost. Thus, a replacement of the *agfA* gene in a wild-type strain of *S. enteritidis* was performed at an efficiency of 10% without any accompanying antibiotic resistance markers in the target genes.

5 Specific DNA sequence replacements within *agfA*

Expression of Heterologous Epitopes in *E. coli* Fimbriae

Several *E. coli* fimbrial types have been utilized for the presentation of heterologous sequences. The fimbriae used as carriers thus far have been type 1 fimbriae [Hedegaard, 1989; Stentebjerg-Olesen, 1997], K88 fimbriae [Bakker, 1990; 10 Thiry, 1989], P fimbriae [van der Zee, 1995; van Die, 1990], CS31A fimbriae [Der Vartanian, 1997] and type 4 fimbriae [Jennings, 1989]. All were chosen because their expression systems and biochemical properties were relatively well characterized in comparison to other fimbrial types of *E. coli*.

In summary, foreign antigenic determinants (epitopes) from various 15 organisms were tested for insertion or replacement into the major structural subunit protein of the fimbriae, such as: epitopes from the hepatitis B virus surface antigen, foot-and-mouth disease virus (FMDV), Poliovirus type 1, cholera toxin B, *Mycobacterium leprae*, *Plasmodium falciparum*, Transmissible gastroenteritis virus (TGEV), human influenza virus, *Neisseria gonorrhoeae* fimbrin subunit as well as the 20 hormones gonadotropin releasing hormone and somatostatin. Positions for insertion or replacement were typically selected based on hydrophilicity profiles of the subunit sequence, sequence variability among different serovars and/or linker scanning mutagenesis. In each study, the foreign sequence (epitope) was detected using antibodies directed against these sequences. In many cases fimbriae were expressed, 25 but this depended on the size and sequence of the foreign epitope and the position used within the subunit protein. These studies have shown that it is possible to construct bacterial strains expressing recombinant fimbriae carrying immunologically active foreign sequences without seriously affecting the properties of the fimbriae. There were some problems with these fimbrial expression systems, however. In each study,

expression of the mutant fimbrin genes was directed from a recombinant vector transformed into *E. coli* and the researchers had to reconstitute the expression of the fimbriae. Therefore, conditions for expression might not represent the physiological conditions in wild-type cells.

5 No similar studies using *Salmonella* fimbriae as carriers of heterologous antigens have been published to date. This is due in part to the fact that *Salmonella* fimbriae have not been as well characterized as their *E. coli* counterparts. Flagella, on the other hand, have been quite well characterized in *Salmonella*. Accordingly, studies have been done in *Salmonella* using flagella as carriers of heterologous antigens. The  
10 results of these studies are outlined below.

#### Expression of Heterologous Epitopes in Salmonella Flagella

Research into the area of expression of epitopes on flagella has been previously published [Newton, 1989; Newton, 1991; Newton, 1995; Wu, 1989; Verma, 1995; Verma, 1995; Cattozzo, 1997]. Flagellin studies have involved the insertion of  
15 various foreign DNA sequences into a single, hypervariable region of the major phase-1 flagellin subunit gene of an attenuated strain of *Salmonella*. Some of the epitopes that have been tested in this system are from Cholera toxin B, Hepatitis B surface antigens, *Streptococcus pyogenes* M protein, HIV-1, Influenza A hemagglutinin, *Plasmodium* spp., Rotavirus, *Corynebacterium diphtheriae*, *Listeria monocytogenes* listeriolysin and  
20 Moth cytochrome c. Like the fimbrial systems described above, production of assembled flagella on the surface of the *Salmonella* cells was dependent on the sequence and length of the foreign epitope. Many of the studies tested the immunogenicity of the heterologous epitopes inserted in *Salmonella* flagellin by injecting the whole strain into mice, rabbits or guinea pigs; almost all immunized  
25 animals developed an Ab response to the epitope, proving that these sequences were still antigenic when expressed in flagella. Other studies showed that cell-mediated immunity could be obtained also [Verma, 1995; Verma, 1995] although this may depend on the particular epitope tested [Vanegas, 1997]. Finally, purified recombinant flagella can elicit humoral and cell-mediated immune responses when administered  
30 alone [Levi, 1996].

The data obtained from these flagella studies indicate that an epitope can retain its immunogenicity even when expressed in the context of an unrelated protein. They also prove the effectiveness of *Salmonella* as a live attenuated vaccine. However, there are some problems, the major one being the relatively low expression levels of 5 flagella on bacterial cells (<10 copies per cell) compared to high-expression levels of fimbriae (100-1000 per cell) or other cell-surface organelles.

#### AgfA as a carrier of the PT3 epitope

Ten different 16 amino acid segments within AgfA were chosen for replacement with the PT3 epitope and are highlighted in Figure 5B and 5C. These 10 replacement regions were chosen using several criteria: primary sequence alignment, regions A1 and A2 (red); protease-susceptibility data [Collinson, 1999], region A3 (black; not represented in Figure 5C); secondary structure predictions matching the  $\beta$ -sheet half of PT3 with  $\beta$ -sheet regions in AgfA, regions A4-A7 (blue); and secondary structure predictions matching the a-helical half of PT3 with  $\beta$ -sheet regions 15 of AgfA, regions A8-A10 (yellow). In total, all 131 residues within AgfA, except 6 in the N-terminal region and 8 at the extreme C-terminus, were replaced with the PT3 sequence in at least one of the chimeric fimbrin constructs.

#### Generation of *S. enteritidis* strains containing the *agfA::PT3* genes

All recombinant *agfA::PT3* genes were generated by PCR, sequenced 20 and introduced into the chromosome of *S. enteritidis*, replacing the *W<sup>+</sup> agfA* gene, using the procedure described above. All bacterial strains used are outlined below in Table 2.

Table 2. *S. enteritidis* strains used in this study.

<u>Strain</u>	<u>Description and relevant genotypes</u>
3b	wild-type
2-2a	<i>agfA::TnphoA</i> fusion in chromosome
A+	similar to wild-type
A1	<i>agfA::PT3#1</i> in chromosome

A2	<i>agfA::PT3#2</i> in chromosome
A3	<i>agfA::PT3#3</i> in chromosome
A4	<i>agfA::PT3#4</i> in chromosome
A5	<i>agfA::PT3#5</i> in chromosome
A6	<i>agfA::PT3#6</i> in chromosome
A7	<i>agfA::PT3#7</i> in chromosome
A8	<i>agfA::PT3#8</i> in chromosome
A9	<i>agfA::PT3#9</i> in chromosome
A10	<i>agfA::PT3#10</i> in chromosome

---

Western blot analysis of *S. enteritidis* strains containing *agfA::PT3* in the chromosome.

The recombinant *S. enteritidis* strains A1-A10 were grown on T plates at 37°C for 24h and were analyzed for production of recombinant AgfA proteins containing the PT3 epitope. Replicate Western blots are shown in Figure 2A and 2B, reacted with either anti-TAF or anti-PT3 immune sera. All 10 chimeric strains were expressing their corresponding recombinant AgfA::PT3 proteins, although strains A1 and A10 (Figure 6, lanes 3 and 14) expressed much lower levels. All chimeric fimbrin proteins differed from AgfA in that they could be detected to some degree on Western blots without formic acid pre-treatment. Proteins from strains A5, A6, A8, and A9 (Figure 6A lanes 7, 10, 12, and 13, respectively) appear smaller than purified AgfA (17kDa; Figure 6A lanes 1 and 9). The nature of these size or mobility differences was not investigated. These data confirmed the expression of the 10 chimeric AgfA::PT3 proteins from the chromosome of *S. enteritidis*.

15 Immunogold electron microscopy of *S. enteritidis* strains containing *agfA::PT3*.

To determine whether the recombinant AgfA fimbrins expressed by *S. enteritidis* strains A1-A10 were being assembled into fimbrial fibers, immunogold labeling was performed with immune sera against TAF or PT3. Recombinant fimbrial fibers were observed on the surface of cells from strains A2-A9 in 8 out of 10 strains 20 (representative EMs are shown in Figure 3). These fibers were distinct with definite

cell surface contact points and looked very similar to W<sup>+</sup> TAF from *S. enteritidis* 3b (Figure 3), although the number of chimeric fimbrial fibers was slightly reduced in all cases. Strains A3, A4, A5 and A8 were judged to be the most similar to W<sup>+</sup> *S. enteritidis* 3b in terms of number of fibers per cell, the frequency of labelled cells, and 5 the distinctness of the individual fibers. In contrast to the other *S. enteritidis* strains, A1 and A10 did not display consistent labeled fimbrial fibers at the cell surface, although some individual cells did show labeling. Thus, these results indicated that 8 of the 10 recombinant AgfA::PT3 proteins were efficiently assembled into fimbrial fibers displayed at the cell surface of *S. enteritidis*.

10 Since growth on solid media is a relatively static environment, the production of recombinant fimbrial fibers in broth culture was examined to determine whether they were stably attached to the *S. enteritidis* cell surface. Immunogold electron microscopy was performed as above on cells grown at 37°C for 24h in T broth; representative EMs are shown in Figure 3. These results were very similar to those 15 observed for cells grown on T plates, although more non-cell-associated fimbrial fibers were observed on the T broth grids. Again, *S. enteritidis* strains A2-A9 had significant amounts of cell-associated recombinant fimbrial fibers with strains A3, A4, A5, and A8 being the most similar to W<sup>+</sup> *S. enteritidis* 3b. However, like the T plate samples, A2- 20 A9 were judged to have slightly fewer and less distinct fimbrial fibers than W<sup>+</sup>. No consistent cell-associated chimeric fimbrial fibers were observed for *S. enteritidis* strains A1 and A10. These results confirmed that 8 of the 10 AgfA::PT3 fimbrial proteins were efficiently assembled into recombinant fimbrial fibers present at the cell surface of *S. enteritidis* and proved that their attachment to the cell surface was relatively stable. These results are further summarized in Table 3.

25

Table 3. Properties of *S. enteritidis* strains containing recombinant *agfA*.

Strain	Protein Size (kDa)		T Plates		T Broth
	Predicted	Experimental	+FA	Fibers	Fibers
3b	13.4	17	+++	+++	+++
2-2a		>60	++	-	-
A1	13.6	17.5	+	+/-	-
A2	13.7	17	+++	++	++

A3	13.7	17	++	++	++
A4	13.6	17	+++	++	++
A5	13.8	14.5	+++	++	++
A6	13.5	15.5	++	++	+
A7	13.7	17	++	+	+
A8	13.5	15.5	++	++	++
A9	13.6	14.5	++	++	++
A10	13.4	17	-	+/-	+/-
A+	13.4	17	+++	+++	+++

Resistance of the recombinant TAF fibers to proteinase K digestion.

Although the recombinant fimbrial fibers looked similar to W<sup>+</sup> TAF, it further analysis was conducted to determine if they retained some of their stable properties. Western blot analysis of the *S. enteritidis* strains A1-A10 after proteinase K digestion for 1 or 2 hr is represented in Figure 5A and 5B. Most of the chimeric fimbrial fibers were resistant to proteinase K, with all strains except A6, A9, and A10 (Figure 5, lanes 10, 13, and 14) displaying immunoreactive protein bands after 2hr of digestion. The immunoreactive band observed for strain A1 (Figure 5, lane 3) suggested that this strain might also possess a small number of polymerized chimeric fimbrial fibers even though they were not consistently present at the cell surface when viewed by EM. As expected, AgfA from *S. enteritidis* 3b or the A<sup>+</sup> control strain remained intact (Figure 5, lanes 8 and 15), the dimer demonstrating the two domain structure of AgfA [Collinson, 1999]. Multiple immunoreactive bands were observed for strains A4, A5, A7 (Figure 5, lanes 6, 7, and 11). These results indicated that most of the chimeric fimbrial fibers produced in *S. enteritidis* possessed a stable, ordered superstructure that was protease resistant, very similar to W<sup>+</sup> or mature thin aggregative fimbriae.

20 REFERENCES CITED IN THE FOREGOING DESCRIPTION

- Aizawa, S-I, et al. (1990). *J.Mol. Biol.*, **211**:673-677.  
 Ausubel, ea (1987). *Current protocols in molecular biology*, Greene Publishing Associates and Wiley-Intersciences.

- Bakker, D., et al. (1990). *Microb, Pathog.*, **8**:343-352.
- Bian, Z. and S. Normark (1997). *EMBO Journal*, **16**: 5827-5836.
- Cattozzo, E.M., et al. (1997). *J. Biotech.*, **56**:191-203.
- Caulcott, C.A., et al. (1987). *J. Gen. Microbiol.*, **133**:1881-1889.
- 5 Cohen, F.C., et al. (1994). *Science*, **264**:530-531.
- Collinson, S.K., et al. (1996). *J. Bacteriol.*, **178**:662-667.
- Collinson, S.K., et al. (1993). *J. Bacteriol.*, **175**:12-18.
- Collinson, S.K., et al. (1991). *J. Bacteriol.*, **173**:4773-4781.
- Collinson, S.K., et al. (1992). *J. Bacteriol.*, **174**:4490-4495.
- 10 Collinson, S.K., et al. (1999). *J. Mol. Biol.*, **accepted**.
- Curtiss III, R., et al. (1994). *Dev. Biol. Stand.*, **82**:23-33.
- Der Vartanian, M. et al. (1997). *Vaccine*, **15**:111-120.
- Doran, J.L., et al. (1993). *J. Clin. Microbiol.*, **31**:2263-2273.
- Edwards, R.A., et al. (1998). *Gene*, **207**:149-157
- 15 Fields, P.A., et al. (1986). *Proc. Natl. Acad. Sci. U.S.A.*, **83**:5189-5193
- Flynn, J.L., et al. (1990). *Mol. Microbiol.*, **4**:2111-2118.
- Galán, J.E. (1996). *Mol. Micro.*, **20**:263-271.
- Hackett, J. (1993). *Curr. Opin Biotech.*, **4**:611-615.
- Hamilton, C.M., et al. (1989). *J. Bacteriol.*, **171**:4617-4622.
- 20 Hammar, M., et al. (1995). *Molecular Microbiology*, **18**:661-670.
- Hammar, M., et al.. (1996). *Proc. Natl. Acad. Sci. USA*, **93**:6562-6566.
- Hashimoto-Gotoh, T., et al. (1981). *Gene*, **16**:227-235.
- Hedegaard, L. and P. Klemm (1989). *Gene*, **85**:115-124.
- Hone, D., et al. (1988) *Microb. Pathog.*, **5**:407-418.
- 25 Horton, R.M., et al. (1989). *Gene*, **77**:61-68.
- Hultgren, S.J., et al. (1993). *Cell*, **73**:897-901.
- Hultgren, S.J., et al. (1996). *Bacterial adhesins and their assembly. Escherichia coli and Salmonella*, American Society for Microbiology.
- Ingmer, H. and S.N. Cohen (1993). *J. Bacteriol.*, **175**:6046-6048.
- 30 Innis, ea (1990)..
- Jardim, A., et al. (1990). *J. Exp. Med.*, **172**:645-648.

- Jardim, A.J. (1994). Immunological and biochemical characterization of the major surface membrane proteins gp63 and the lipophosphoglycan associated protein of *Leishmania*, University of Victoria.
- Jennings, P.A., et al. (1989). *Protein Engineering*, **2**:365-369.
- Kuby, J. (1994). *Immunology*, W.H. Freeman and Company.
- Levi, R. and R. Arnon (1996). *Vaccine*, **14**:85-92.
- Levine, M.M., et al. (1996). *J. Biotech.*, **44**:193-196.
- Link, A.J., et al. (1997). *J. Bacteriol.*, **179**:6228-6237.
- Loferer, H., et al. (1997). *Molecular Microbiology*, **26**:11-23.
- Low, D., et al. (1996). *Fimbriae. Escherichia coli and Salmonella*, American Society for Microbiology.
- Manen, D., et al. (1990). *Mol. Microbiol.* **4**:1839-1846.
- McSorley, S.J., et al. (1997). *Infect. Immun.*, **65**:171-178.
- Meacock, P.A. and S.N. Cohen (1980). *Cell*, **20**:529-542.
- Miller, C.A., et al. (1990). *Cell*, **62**:127-133.
- Mol. O. and B. Oudega (1996). *FEMS Microbiol. Rev.*, **19**:25-52.
- Newton, S.M.C., et al. (1989). *Science*, **244**:70-72.
- Newton, S.M.C., et al. (1995). *Res. Microbiol.*, **146**:203-216.
- Newton, S.M.C., et al., (1991). *Infect. Immun.*, **59**:2158-2165.
- Olsén, Al., et al. (1993). *Molecular Microbiology*, **7**:523-536.
- Pallesen, L. and P. Klemm (1994). *Chimeric fimbrial vaccines. Fimbriae, Adhesion, Genetics, Biogenesis and Vaccines*, CRC Press.
- Römling, U., et al. (1998a). *Journal of Bacteriology*, **180**:722-731.
- Römling, U., et al. (1998b). *Mol. Microbiol.*, **28**:249-264.
- Salmond, G.P.C. (1996). *Trends in Microbiology*, **4**:474-476.
- Sambrook, J., et al. (1989). *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory.
- Spitzer, N., et al. (1998). *Vaccine*: In press.
- Stentebjerg-Olesen, B., et al. (1997). *Microbiology*, **143**:2027-2038.
- Strugnell, R.A., et al. (1990). *Gene*, **88**:57-63.
- Thanassi, D.G., et al. (1998). *Proc. Natl. Acad. Sci. U.S.A.*, **95**:3146-3151.

- Thiry, G., et al. (1989). *App. Env. Microbiol.*, 55:984-993.
- Van der Zee, A., et al. (1995). *Vaccine*, 13:753-758.
- van Die, I., et al. (1990). *Mol. Gen. Genet.*, 222:297-303.
- Vanegas, R.A., et al. (1997). *Vaccine*, 15:321-324.
- 5 Verma, N.K., et al. (1995a). *Vaccine*, 13:235-244.
- Verma, NK., et al. (1995b). *Vaccine*, 13:142-150.
- Wahle, E. and A. Kornberg (1988). *EMBO J.*, 7:1889-1895.
- Wu, J.Y., et al. (1989). *Proc. Natl. Acad. Sci. U.S.A.*, 86:4726-4730.

10

## EXAMPLE 1

## STRUCTURAL PREDICTIONS OF AGFA, THE INSOLUBLE FIMBRIAL SUBUNIT OF

*SALMONELLA* THIN AGGREGATIVE FIMBRIAE

The unusually stable and multifunctional, thin aggregative fimbriae common to all *Salmonella* spp. are principally polymers of the fimbrin subunit, AgfA.

15 AgfA of *Salmonella enteritidis* consisted of two domains: a protease-sensitive, 22 amino acid N-terminal region and a protease-resistant, 109 residue C-terminal core. The unusual amino acid sequence of the AgfA core region comprised 2-, 5- and 10-fold internal sequence homology patterns reflected in 5 conserved, 18-residue tandem repeats. These repeats had the consensus sequence, Sx<sub>5</sub>QxGx<sub>2</sub>NxAx<sub>3</sub>Q and were linked

20 together by 4 or 5 residues, (x)xAx<sub>2</sub>. The predicted secondary structure for this unusual arrangement of tandem repeats in AgfA indicated mainly extended conformation with the β-strands linked by 4 to 6 residues. Candidate proteins containing motifs of alternating β-strands and short loops were selected from folds described in SCOP as a source of coordinates for AgfA model construction. Three all-β class motifs selected

25 from the *Serratia marcescens* metalloprotease, myelin P2 protein or vitelline membrane outer protein I were used for initial AgfA homology build-up procedures ultimately resulting in three structural models, β barrel, β prism and parallel β helix. The β barrel model suggested a compact, albeit irregular structure, with the β-strands arranged in two antiparallel β-sheet faces. The β prism model did not reflect the five- or ten-fold

30 symmetry of the AgfA primary sequence. The favored, parallel β helix model was a compact coil of ten helically arranged β-strands forming two parallel β -sheet faces.

This arrangement predicted a regular, potentially stable, C-terminal core region consistent with the observed tandem repeat sequences, protease-resistance and strong tendency of this fimbrin to oligomerize and aggregate. Positional conservation of amino acid residues in AgfA and the *E. coli* AgfA homologue, CsgA, provided strong 5 evolutionary support for this model. The parallel  $\beta$  helix model of AgfA offers an interesting solution to a multifunctional fimbrin molecular surface having solvent exposed areas, regions for major and minor subunit interactions as well as fiber-fiber interactions common to many bacterial fimbriae.

Fimbriae and pili are terms, often used interchangeably, for fine, hairlike 10 structures that protrude from the surface of many bacteria (Firth *et al.*, 1996; Low *et al.*, 1996; Mol & Oudega, 1996; Tennent & Mattick, 1994). These ubiquitous fibres have received considerable attention mainly due to their pivotal role in facilitating bacterial adherence in diverse circumstances including host tissue colonization (Gaastra & de Graaf, 1982; Low *et al.*, 1996; Tennent & Mattick, 1994), bacterial cell-cell interactions 15 (Marceau *et al.*, 1995; Whittaker *et al.*, 1996), conjugal transfer of DNA including exchange of antibiotic resistance genes (Firth *et al.*, 1996; Silverman, 1997) or transfer of genetic information into susceptible hosts (Fullner *et al.*, 1996; Lai & Kado, 1998). Many diverse fimbrial and pili systems have been studied in detail to understand the molecular basis for fiber function, assembly and regulation. This information has 20 furthered the understanding of fundamental physiological phenomena including protein processing, transport and organelle assembly (de Graaf & Bakker, 1992; Firth *et al.*, 1996; Hung *et al.*, 1996, Kuehn, 1994; Leathart & Gally, 1998; Low *et al.*, 1996; Mol & Oudega, 1996; Smyth *et al.*, 1996; Strom & Lory, 1993). In addition, these studies have furnished biotechnological advances in disease detection and prevention in the 25 form of fimbrial-based diagnostics and therapeutics, fimbrial vaccine formulations and passive immunization methodologies (Abraham *et al.*, 1985; Der Vartanian *et al.*, 1994; Doran *et al.*, 1993; Levine *et al.*, 1994; Ogawa *et al.*, 1997; Pallesen & Klemm, 1994; Thorns *et al.*, 1994).

Fimbriae are complex polymers, 2 to 9 nm wide and several hundred or 30 thousand nm long. Structurally, they are comprised mainly of a single fimbrin (or pilin) protein subunit type polymerized to form the bulk of the fiber (Low *et al.*, 1996;

Paranchych, 1990; Silverman, 1997; Tennent & Mattick, 1994). Additional constituents have been identified in many fimbriae (Low *et al.*, 1996). These include minor fimbrin-like proteins required for the fidelity of fiber biogenesis (de Graaf & Bakker, 1992; Klemm & Krogfelt, 1994; Kuehn *et al.*, 1994) and/or specialized adhesin 5 subunits required for specific receptor recognition (Low *et al.*, 1996). In other cases, as with K88 fimbriae, receptor binding specificity is an apparent function of the major fimbrin subunit itself (de Graaf & Bakker, 1992).

Low resolution X-ray and optical diffraction studies of laterally aggregated or paracrystalline arrangements of thin (2 to 5 nm) and thick (7 to 9 nm) 10 fimbriae indicate that, in both fiber types, the major fimbrin subunits are helically arranged within the fiber (Brinton Jr, 1965; Gong & Makowski, 1992; Heck *et al.*, 1996; Paranchych, 1990; Silverman, 1997; Simons *et al.*, 1994). High resolution, freeze fracture electron microscopy studies of native and mutant *E. coli* Pap pili ultrastructure revealed that this 7 nm pili polymer terminates with a thin, 2 nm wide, 15 fibril of open helically arranged minor subunits that display the terminal adhesin subunit required for specific binding of the fiber to its respective target receptor (Klemm & Krogfelt, 1994; Kuehn *et al.*, 1992). This complex architecture is shared by other thick fimbriae of *E. coli* including type I, S and *Haemophilus* pili (Hung *et al.*, 1996; Jones *et al.*, 1997; St. Geme III *et al.*, 1996). In addition, the structural plasticity 20 of fimbriae is evident after certain chemical treatments that “unravel” thick fimbriae into thin fibrils or “wind” thin fibres into thicker structures (Mol & Oudega, 1996). However, the ultrastructure of thin fimbriae is largely unknown.

The *Neisseria gonorrhoea* Type IV pilin subunit is the sole fimbrin to date to be crystalized and for which a 3-D structure has been determined (Parge *et al.*, 25 1995). This novel  $\alpha$ - $\beta$  roll pilin structure was modeled into a helically polymerized 7 nm fiber based upon the steric considerations and physicochemical surface characteristics of the pilin subunits (Parge *et al.*, 1995). Otherwise, no tertiary structural information is available for other fimbriins. The pronounced tendency of unassembled or depolymerized fimbrin monomers to aggregate or repolymerize 30 complicates crystal formation and consequently precludes 3-D structural elucidation.

The present Example relates to the structural elucidation of thin aggregative fimbriae of *Salmonella*. Thin aggregative fimbriae are one, of at least 8 fimbrial types produced by various strains of these important animal pathogens (Bäumler & Heffron, 1995; Doran *et al.*, 1993; Low *et al.*, 1996). The exact role(s) of 5 thin aggregative fimbriae (3-4 nm) in *Salmonella* pathogenesis is as yet uncertain (Sukupolvi *et al.*, 1997a), even though these fibres have been shown to bind various host proteins (Collinson *et al.*, 1993; Sjöbring *et al.*, 1994) and promote interaction of *Salmonella* with mouse small intestinal epithelial cells (Sukupolvi *et al.*, 1997b). Given 10 the extreme stability and unusually aggregative nature of these fibres, their importance to *Salmonella* pathogenesis may also be related to their role in promoting *Salmonella* autoaggregation (Collinson *et al.*, 1993; Collinson *et al.*, 1991). This feature has broad implications for host infection (Collinson *et al.*, 1991) and *Salmonella* biofilm formation on inert surfaces (Austin *et al.*, 1998).

Virtually all *Salmonella* spp. tested to date possess the *agfA* fimbрин 15 gene (Bäumler *et al.*, 1997; Collinson *et al.*, 1996b; Doran *et al.*, 1993). *Escherichia coli* also possess an *agfA* fimbрин homologue, *csgA*, that assembles into fibres named curli (Olsén *et al.*, 1993). *Salmonella* thin aggregative fimbriae and *E. coli* curli are biochemically (Collinson *et al.*, 1992; Doran *et al.*, 1993; Olsén *et al.*, 1993), genetically (Collinson *et al.*, 1996a; Römling *et al.*, 1998), and functionally (Austin *et* 20 *al.*, 1998; Collinson *et al.*, 1993; Collinson *et al.*, 1992; Hammar *et al.*, 1995; Olsén *et al.*, 1993; Vidal *et al.*, 1998) analogous. This is consistent with the fact that both fimbрин genes are highly conserved homologues from an ancient operon in the progenitor of *Salmonella* and *E. coli* (Bäumler *et al.*, 1997).

Thin aggregative fimbriae were purified by an unconventional procedure 25 from *Salmonella enteritidis* (Collinson *et al.*, 1991). In addition, brief exposure of the fimbriae to 90% formic acid (Collinson *et al.*, 1991) is the only pretreatment known to depolymerize these fibres to release the AgfA fimbрин monomers. Since this initial characterization, very little biophysical data have emerged for thin aggregative fimbriae due to their extreme aggregative nature and the existence of multiple isoforms 30 (Collinson *et al.*, 1991). However, such information is needed to understand the molecular basis for the aggregative nature and unusual stability of these fibres as well as

to provide the molecular framework for the design of AgfA-based heterologous *Salmonella* vaccines (White *et al.*, 1999).

As a novel approach to explore AgfA tertiary structure, homology buildup and molecular modeling techniques were applied to the prediction of AgfA 5 tertiary structure taking into account the intriguing primary amino acid sequence repeat motif in AgfA and the discovery of the protease resistant AgfA C-terminal core region. As the first modeling study of any bacterial fimbrial or pilin tertiary structure, the initial goal was to obtain a working model of AgfA molecular structure for future experimental design and testing.

10

## Materials and Methods

### Purification and depolymerization of thin aggregative fimbriae, SEF17.

Thin aggregative fimbriae were isolated and purified from *Salmonella enteritidis* 27655-3b grown on solid T medium as previously described (Collinson *et al.*, 1991). 15 Purified fimbriae samples were routinely treated with 90% formic acid to depolymerize the AgfA fimbrial subunits prior to electrophoretic or immunoblot analysis (Collinson *et al.*, 1993; Collinson *et al.*, 1991).

The effect of formic acid concentration on disaggregation and depolymerization of thin aggregative fimbriae was determined on fimbrial suspensions 20 of 0.5 mg/ml. The large clumps of fimbriae were broken using a 2 ml Micro Tissue Grinder (VWR Canlab). Homogenized suspensions of fimbriae were aliquoted into microfuge tubes and the fimbriae recovered by centrifugation (15,600 x g, 10 min) before being resuspended in formic acid solutions and recording the absorbance at 600 nm ( $A_{600}$ ). A subsample of each fimbrial suspension containing approximately 20 µg of 25 protein was lyophilized and subjected to electrophoresis and immunoblot analysis.

SDS-PAGE and immunoblot analysis. SDS-PAGE was performed according to the method of Laemmli (Laemmli, 1970). Immunoblot analysis of AgfA was performed as previously described (Collinson *et al.*, 1993; Collinson *et al.*, 1991) using rabbit polyclonal immune serum generated to purified thin aggregative fimbriae.

30 N-terminal amino acid analyses. N-terminal amino acid sequence analyses were performed as previously described (Collinson *et al.*, 1991).

Protease treatment of thin aggregative fimbriae. Whole *S. enteritidis* 3b cells possessing thin aggregative fimbriae or purified thin aggregative fimbriae were resuspended in Laemmli sample buffer (Laemmli, 1970), boiled for 10 min, cooled and then brought to a final concentration of 0.5 mg/ml proteinase K before incubation for 1 hr at 60°C. Samples were boiled, fimbriae recovered by centrifugation (15,600 × g, 10 min), depolymerized with 90% formic acid (Collinson *et al.*, 1991) and then analysed by SDS-PAGE or immunoblotting for products of digestion.

Secondary structural analysis of AgfA. Secondary structure analysis of AgfA was determined using several programs including: Alexis version 1.2 SEQSEE (Wishart *et al.*, 1994), PPSP (Parker & Hodges, 1991a; Parker & Hodges, 1991b), Sequences Annotated by Structure ([www.biochem.ucl.ac.uk/cgi-bin/sas](http://www.biochem.ucl.ac.uk/cgi-bin/sas)), Gibrat Secondary Struture Prediction and Hierarchical Neural Network ([pbil.ibcp.fr/NPSA](http://pbil.ibcp.fr/NPSA)), NNPredict ([www.cmpharm.ucsf.edu/cgi-bin/nnpredict.pl](http://www.cmpharm.ucsf.edu/cgi-bin/nnpredict.pl)), PhDsec ([www.embl-heidelberg.de/predictprotein](http://www.embl-heidelberg.de/predictprotein)) and Predator ([www.embl-heidelberg.de/predator](http://www.embl-heidelberg.de/predator)).

Homology alignment and selection of proteins for homology buildup. The AgfA amino acid sequence was compared to sequences of proteins with known tertiary structures defined by analysis of X-ray crystallography using SEQSEE (Wishart *et al.*, 1994), HomologyPlot (Parker & Hodges, 1991b) and PropSearch (Hobohm & Sanders, 1995). Several candidate proteins for structural alignment were chosen by scanning protein folds described in the Protein Data Bank (PDB) (Bernstein *et al.*, 1977) and the program SCOP (Murzin *et al.*, 1995) to identify several proteins containing β-strand structures connected by short loops. Two proteins, the *Serratia marcescens* protease (SMP) (Baumann *et al.*, 1995) and the C-terminal region of the bovine myelin P2 protein (PMP) (Cowan *et al.*, 1993; Jones *et al.*, 1988), contained a repeating pattern of hydrophobic residues analagous to that proposed for AgfA. SMP and PMP were chosen as templates for the β barrel and parallel β helix models, respectively (Fig 16 a, b). The β prism fold of the vitelline membrane outer layer protein I (VMO-I) (Shimizu & Morikawa, 1996; Shimizu *et al.*, 1994) was chosen as a third structural template on the basis of the VMO-I primary sequence alignment with that of AgfA (Figure 16 c).

AgfA Parallel  $\beta$ -helix model homology buildup procedure. The parallel  $\beta$ -helix structure of AgfA was built using Insight II and Discover programs (BioSym Technologies Inc.). Initially, the  $\alpha$ -carbon distance restraints of amino acid residues 327 to 343 of the known x-ray structure for SMP (Baumann, 1994; Braunagel & Benedik, 1990) were used to build the first  $\beta$ -turn- $\beta$  structure corresponding to amino acid residues 23 to 39 of AgfA (Figure 16a). Amino acid residues in SMP were replaced with those corresponding to the AgfA sequence and the AgfA structure was built manually to residue 52. The resulting 30-residue AgfA template, which no longer resembled the SMP structure due to differing loop sizes and longer  $\beta$ -strands, was used repeatedly with dynamics simulations to build successive levels of the AgfA structure. The completed AgfA structure was then minimized using various distance restraints, manual changes in sidechain and backbone torsion angles with regular checks on the chiral status of the backbone configurations. Distance restraints were gradually removed until a low energy structure of 80 kCal was obtained using only Ca restraints. Unfavorable angles and distances were removed using molecular dynamics (MD) simulations of 1 ps with a full set of distance restraints. The optimized structure was then subjected to 50 ps of MD simulations with no constraints to further reduce the energy of the structure. The distance restraints used were briefly tested by simulated annealing. Further improvements to the model were accomplished by generating a distance and dihedral restraint file using the average Ca to Ca distances observed in the respective predicted structure and the x-ray structure used to the model. The preliminary dihedral restraint for the angle  $f$  and  $y$  was set for an extended structure. The structure was minimized with and without their respective restraint files. The dynamics procedure was used to futher improve the  $f$  and  $y$  angles.

AgfA  $\beta$ -barrel model homology buildup. The  $\beta$ -barrel structure of AgfA was built up by homlogy modeling using coordinates of the ten  $\beta$ -strand  $\beta$ -barrel of PMP as the inital template. Residues 40 to 86, comprising the first 5  $\beta$ -strands of PMP, were the most homologous with residues 25 to 72 of AgfA (Figure 16b). This PMP sequence was converted to the correct AgfA sequence to build the first AgfA region. This first region was then duplicated and the N-terminal residues L25 to I27 of AgfA were overlapped with C-terminal residues I70 to L72 to form the template for the

second set of 5  $\beta$ -strands. The amino acids in this second region were then changed to correspond to the later half of the actual AgfA sequence. Visual inspection removed several obvious side chain contacts before the model was subjected to steepest descent and conjugate gradient minimization.

5 AgfA  $\beta$  prism model homology buildup. The  $\beta$  prism AgfA structure was built based upon alignment of AgfA sequence with VMO-I taking into account three core loops and conserved nonpolar-polar-nonpolar motifs at the N-terminal region of the AgfA core and conserved VMO-I D and E residues that are N and Q in AgfA (Figure 16c). The first of three interal repeats was mutated form VMOI sequence to  
10 AgfA using options in InSightII (Biosym). Occasionally, side chains were moved manually when unfavorable interactions were encountered. The model was subjected to conjugate gradient minimization with the  $C_a$  carbons fixed.

15 Statistical evaluation of models. The VADAR (Wishart *et al.*, 1995) and PROCHECK (Morris *et al.*, 1992) statistical analysis programs were used to evaluate the models at several stages during the buildup procedure as an indication of improvement in successive models. Statistics and energy minima of the three prototype AgfA fimbrin model structures are presented in Table 4.

Table 4. Summary of Procheck and VADAR statistics for the AgfA model structures

Statistic Parameter	AgfA Model Structure		
	parallel $\beta$ helix	$\beta$ barrel	$\beta$ prism
Template protein <sup>a</sup>	SMP	PMP	VMO-I
Free energy (kCal)	-64	-49	-40
Total energy (kCal)	-240		
f/y core <sup>b</sup>	68%	63%	56%
Total accessible surface area ( $\text{\AA}^2$ )	5524	5848	7625
Total volume packing ( $\text{\AA}^3$ )	12875	12783	12500

% β-strand predicted	93	71	40
----------------------	----	----	----

- a SMP, *Serratia marcescens* protease (Baumann *et al.*, 1995); PMP, bovine myelin P2 protein (Cowan *et al.*, 1993; Jones *et al.*, 1988); VMO-I, vitelline membrane outer layer protein I (Shimizu & Morikawa, 1996; Shimizu *et al.*, 1994).
- 5 b f/y core calculated using Procheck™ (Morris *et al.*, 1992) and VADAR (Wishart *et al.*, 1995).

## RESULTS

Two-domain character of AgfA fimbrin. Treatment of thin aggregative fimbriae with at least 70% formic acid was required to ensure at least partial depolymerization to release the 17,000 Da AgfA fimbrin (Figure 7). Concomitant with the depolymerization of thin aggregative fimbriae was the release of a 15,500 Da protein (Figure 7). N-terminal amino acid sequence analysis of the 15,500 Da species indicated that this minor protein was a truncated form of AgfA missing 22 N-terminal amino acids. This fragmentation of AgfA was probably not due to its exposure to concentrated formic acid since prolonged treatment of AgfA with 90% formic acid for up to 3 h at 50°C does not increase the amount of the 15,500 Da fragment (Collinson *et al.*, 1991). Moreover, AgfA lacks acid cleavable Asp-Pro bonds in the predicted AgfA sequence (Collinson *et al.*, 1996a). However, the first 17 N-terminal amino acids of AgfA could be cleaved from the fimbrin by proteinase K treatment of intact native or purified, thin aggregative fimbriae (Figure 8, lanes 2 and 4) as confirmed by N-terminal amino acid sequence analysis of the truncated proteins. However, once depolymerized by pretreatment with formic acid, AgfA was completely susceptible to digestion with proteinase K. These results suggested that polymerized AgfA fimbriins possessed two domains, a short, protease-susceptible N-terminal domain of 17 to 22 amino acids and a protease-resistant C-terminal core region comprised of 109 to 114 amino acid residues.

Two-, five- and ten-fold internal amino acid sequence homology of AgfA. The AgfA primary amino acid sequence possessed features consistent with a two-domain protein. The glycine-rich, N-terminal 22 amino acid sequence was distinguished from the C-terminal core region comprising amino acids 23 to 131 mainly on the basis of a striking two-, five- and ten-fold internal sequence homology within the

C-terminus (Figure 9). A two-fold homology was evident between the segments C2a and C2b that shared 41% amino acid identity or 56% homology if conservative substitutions were considered (Figure 9b).

The five-fold sequence homology within the 109 residue C-terminal core region was extremely regular and consisted of five, tandemly arranged segments (Figure 9c). The first 18 amino acids of each of these five segments conformed to the consensus sequence Sx<sub>5</sub>QxGx<sub>2</sub>NxAx<sub>3</sub>Q separated by 4 or 5 additional residues except for the terminal repeat which ended in Y (Figure 9c). Homology comparisons between segments C5a:C5d and C5c:C5e were the highest with 50% identity compared to segments C5b:C5d or C5d:C5e with 44% residue identity (Figure 9a,c). The other segment pairs were 39% identical.

The ten-fold sequence homology of the AgfA C-terminus was evident as paired hydrophobic regions centered at positions 3 to 5 and 14 to 16 within each consensus motif (Figure 9d,e). Each hydrophobic region possessed three amino acids arranged to conserve a nonpolar-polar-nonpolar (ifi) triplet motif (Figure 9e). Together, these multiple primary sequence patterns were suggestive of highly regular, repeated secondary structure motifs.

Secondary structure analysis of AgfA. Several secondary structure prediction programs were used to analyse AgfA secondary structure as described in the Materials and Methods. All of the programs predicted several regions of extended structure separated by short regions of 4 to 10 residues possessing coil conformation (Figure 10). Frequently, the programs predicted that AgfA residues 34 to 41 adopted a helical structure where as residues 80 to 87 and 103 to 107 were predicted to be helical with less frequency (Figure 10). No potential membrane spanning sequences were predicted. The ten repeating hydrophobic core regions within AgfA suggested that this protein posessed regular, repeating secondary structural units of 3 to 7 amino acids connected by loops of 4 to 7 residues.

The Protein Data Bank and SCOP were extensively searched to identify protein structures with multiple extended regions separated by coil regions of 4 to 10 residues suitable for model construction as described in the Materials and Methods. Several structures with low homology to AgfA were identified but none of these

candidate protein structures contained helical motifs. For this reason, only the extended and coil secondary structures predicted for AgfA were used to predict the tertiary structure of AgfA.

Parallel  $\beta$ -helix model of AgfA. The regular pattern of extended  $\beta$ -strand conformations proposed for AgfA C-terminal region secondary structure was used to select coordinates of candidate template proteins of known tertiary structure suitable for model construction (see Material and Methods). A  $\beta$ -turn- $\beta$  motif within the  $\beta$  roll structure of the *Serratia marcescens* metalloprotease (SMP) 3-D crystal structure (Baumann *et al.*, 1995) was judged as the best template on which to build the initial turn of the AgfA model structure. Successive layers of AgfA tertiary structure were then built using standard homology modeling techniques (see Materials and Methods). The parallel  $\beta$  helix AgfA tertiary structure model that emerged from this process was a highly regular, compact, right handed, five-coil helix comprised of four coils of 22 or 23 amino acids ending with 18 amino acids of the fifth coil followed by a terminal Y (Figure 11a). This arrangement of vertically stacked, slightly flattened coils created two prominent five-strand parallel  $\beta$ -sheet faces (Figure 5a) oriented into a slightly wedge-shaped, oval molecule (Figure 11b). Each coil consisted of a “ $\beta$ -sandwich” in which the nonpolar residues of the two nonpolar-polar-nonpolar (if)  $\beta$ -strand triplets at positions 3 to 5 and 14 to 16 of each 18-residue repeat were internalized forming a tight 4-residue turn ( $xGx_2$ ) centered about the conserved G at position 9 (Figs. 9e & 11c). The successive  $\beta$ -sandwiches were joined by a less constrained turn of 4 or 5 residues (Figs. 9e & 11c).

Consequently, the five, vertically stacked  $\beta$ -sandwiches were aligned such that the conserved residues of each consensus sequence were in the same relative position resulting in vertical stacks of like residues in the internal core of the AgfA model structure (Figs. 11c, 12a & 12b). Thus, the AgfA parallel  $\beta$  helix model possessed a 19-residue hydrophobic core comprised of nonpolar residues at positions 3, 5, 14 or 16 of the consensus sequence (Figs. 11 c & 12 a). Flanking one side of this non-polar core region were two stacks of five internalized Q and N residues located at positions 7 and 12, respectively, of each consensus sequence (Figs. 11c & 12a). These polar amides, Q29,52,74,97,119 and N34,57,79,102,124, respectively, flanked either

side of each successive tight turn such that the C<sub>a</sub>R amide sidegroups were hydrogen bonded to the peptide backbone (Figs. 11c & 12a). The other side of the hydrophobic core was similarly flanked by two stacks of five polar residues internalized at positions 1 (S23,46,68,91,113) and 18 (Q40,63,85,108,130) of each successive consensus 5 sequence (Figs. 11c & 12a).

A second consequence of the helical arrangement of successive  $\beta$  sandwiches was the clustering of chemically similar residues on the surface of the proposed AgfA model. Hydrophobic patches were present on this AgfA model on the frontside (W86, L37, L39, L105) (Figure 12c, green and yellow) and end (Y28, Y30, 10 Y98, F77, F122, V120) (Figure 12d, green) of the molecule. Otherwise, the proposed AgfA surface was mainly comprised of polar or charged residues (Figs. 12b,c,d, red). The acidic residues E47,71 and D42,60,66,84,92,112 (Figure 12 c,d, red) were predicted to be exposed on the end of the molecule opposite to the hydrophobic cluster of Y and F residues (Figure 12d, green) such that they out numbered the basic amino acids (Figure 15 1, blue) 8 to 3. The back face of the AgfA model comprised mainly exposed polar amino acids (Figure 12d, red). Several residues with exposed hydroxyl groups were present including S26,114; T24,49,51,69,73,94 and Y28,30,98 (Figure 12d, red). This compact, highly regular parallel  $\beta$ -helix model of AgfA was consistent with the repeating primary amino acid sequence and predicted secondary structure of repeated 20  $\beta$ -strand conformations.

$\beta$ -barrel and  $\beta$ -prism models of AgfA. In an effort to determine whether the AgfA parallel  $\beta$ -helix structure was a reasonable model, the AgfA primary sequence was also modeled on two other proteins of known structure, also selected for possessing motifs arranged in a series of extended  $\beta$ -strands.

The AgfA  $\beta$ -barrel model (Figure 13a) was built using the coordinates of the ten-stranded  $\beta$ -barrel structure of bovine myelin P2 protein (PMP) 3-D crystal structure (Cowan *et al.*, 1993; Jones *et al.*, 1988) as the template (Figure 13b) as described in the Material and Methods. In this AgfA prototype model, each of the five consensus repeat motifs were folded about the central QxGx<sub>2</sub>N sequence such that the 30 predicted  $\beta$ -strands were bonded in antiparallel fashion (Figure 13a). Segments C5a, C5b and the C-terminal half of C5e formed one antiparallel  $\beta$ -sheet face of the barrel

where as the other face was formed by C5c, C5d and the N-terminal half of C5e (Figs. 9a & 13a). Several key features of the AgfA  $\beta$ -barrel model included: a hydrophobic core region comprised mainly of internalized nonpolar residues of the ten nonpolar-polar-nonpolar (ifi) triplets; surface exposure of the aromatic residues Y28,30,55 and F77, 122 at the same end of the molecule; basic residues R44 and K45,89 clustered at one end of the molecule on the protruding loop between segments C5a and C5b and a general lack of clustering of acidic and hydroxyl-containing residues.

The AgfA  $\beta$ -prism model (Fig 14a) was based on coordinates from the X-ray crystal structure of vitelline membrane outer protein, VMO-I (Shimizu & Morikawa, 1996; Shimizu *et al.*, 1994) (Figure 14b). This AgfA model predicted a fairly compact, elongated structure with several short  $\beta$ -strand regions of 3 to 6 residues joined by loops of random coil (Figure 14a). The  $\beta$ -prism model did not reflect the five-repeat symmetry of the primary sequence but rather an organization of three repeats based upon the first, third and fifth repeat. The nonpolar residues were internalized to generate a hydrophobic core but the conserved N and Q residues of the five consensus repeats were generally surface exposed. The acidic residues and many of the hydroxyl-containing S and T residues were clustered towards the same end of the molecule where as basic residues were featured at both ends of the molecule. The F and Y residues were surface exposed but no extensive surface hydrophobic patches were predicted.

AgfA Model Quality. Each of the three model structures obtained for AgfA by homology modeling represented a reasonable, preliminary protein structure based on the VADAR statistical analyses performed (Table 4). Further refinements were not attempted at this stage since physical data on AgfA structure are not yet available to corroborate a given model. Each model predicted a series of  $\beta$ -strands separated by turns with the predicted surface-exposed residues in general agreement with proposed buried and surface exposed residues in each of the tertiary structure models (Figs. 12, 13 & 14). However, the  $\beta$ -prism model deviated somewhat from the predicted surface exposed residues of AgfA in this respect.

Evolutionary conservation of *Salmonella* AgfA primary amino acid consensus sequence. Previous alignment of the AgfA fimbrin subunit of *Salmonella*

thin aggregative fimbriae with that of *E. coli* curli fimbriae indicated that these two proteins, including the signal sequence, were 74% identical and 86% similar (Collinson *et al.*, 1996a). A more detailed analysis of the alignments of these two related fimbriins was performed to determine the pattern and extent of conservative versus non-conservative amino acid substitutions (Figure 15, Table 5). The 22-residue N-terminal segment of AgfA was 82% (18/22) identical, but 91% (20/22) similar to CsgA if conserved residues were considered (Table 5). The 109 amino acids of the C-terminal domain were 71% (77/109) identical and 80% similar if ten additional conservative residue replacements were considered.

10

Table 5. Amino acid conservation between *Salmonella* AgfA and *E. coli* CsgA.

Consensus sequence position <sup>a</sup>	Protein	Identity	Percent <sup>b</sup> (number of residues/total)	
			Conservative	Different
Inside (•):				
(1,3,5,7, 12,14,16,18)	AgfA/CsgA	92.5 (37/40)	5.0(2/40)	2.5(1/40)
Outside (o):				
(2,4,6,13,15,17)	AgfA/CsgA	50.0 (15/30)	20.0 (6/30)	30.0 (9/30)
Turns (t):				
20 (8-11,19-23)	AgfA/CsgA	64.1 (25/39)	5.1 (2/39)	30.8 (12/39)

a The position of amino acids in each consensus sequence are labeled (•, o, t) according to parallel β helix model as in Figure 9.

b Each residue of the AgfA fimbrin was compared to the respective amino acid in CsgA and assessed whether the pairs were identical, similar or different and scored according to the following groups; hydroxyl (T, S); acidic (E, D); basic (R, K, H); amide (Q, N); aromatic (Y, F, W); aliphatic (A, M, I, L, V) or glycine (G).

30 The distribution of identical and conserved residues compared to that of non-conserved residues within the repeated segments of the two fimbriins was very distinctive. In general, residues predicted to be internalized in the parallel β-helix model of AgfA were more highly conserved between the two fimbriin proteins than residues predicted to be on the β-sheet surfaces or at the predicted turn positions

(Figure 15, Table 5). Residues at positions 1,3,5,7 and 12,14,16,18 of each repeat motif were 92.5% identical and 5.0% conserved (Figure 15, Table 5). However, residues occupying the alternate positions in the consensus sequence at predicted surface-exposed positions 2,4,6 and 13,14,15 of each repeat motif were only 50% (15/30) identical with an additional 20% (6/30) of the residues conserved for a 70% overall similarity (Figure 15, Table 5). Similarly, the two regions comprising expected turns at positions 8,9,10,11 and 19,20,21,22,23 had an overall similarity of 69.2% (Figure 15, Table 5).

## 10 DISCUSSION

Three hypothetical, all- $\beta$  class tertiary structure models were assembled for AgfA, the fimbrin subunit protein of *Salmonella* thin aggregative fimbriae. These models represent the first predictions of a bacterial fimbrin or pilin tertiary protein structure using homology buildup and molecular modeling techniques. The primary amino acid sequence repeat motif comprising the protease-resistant AgfA C-terminal core facilitated this novel approach to explore the tertiary structure of an aggregative structural protein.

One feature of the AgfA fimbrin of *Salmonella* thin aggregative fimbriae is the highly conserved, five-fold repeated consensus sequence, SxifixQxGx<sub>2</sub>NxAfixQ(x)x<sub>3</sub>, comprising 109 residues of the protease resistant C-terminal core region of the fimbrin. This region is preceded by a distinctive, protease-susceptible glycine-rich N-terminus of 17 to 22 residues. Except for the AgfA fimbrin homologue of *E. coli* curli, CsgA (Hammar *et al.*, 1996), no other fimbrial proteins possess highly conserved, tandem primary amino acid sequence repeat motifs.

Analysis of other fimbrios and pilins using common predictive algorithms for secondary structure indicate that like AgfA, these structural proteins have  $\beta$ -strand conformations distributed throughout the subunit protein (Girardeau *et al.*, 1991; Klemm, 1984; Linterman *et al.*, 1988). An analysis of 24 various bacterial fimbrios and pilins by the method of Garnier *et al.* (1978) similarly indicated 31% to 69% predicted  $\beta$ -strand content often with multiple  $\beta$ -strand motifs present throughout the protein (Collinson *et al.*, unpublished data). The presence of amphipathic  $\beta$ -strands

within various *Enterobacteriaceae* fimbrial components also has been recognized by hydrophobic cluster analysis (HCA) (Girardeau & Bertin, 1995; Méchin *et al.*, 1995). Using HCA, fimbrial protein components of thick (7 nm) fimbriae that possess a cysteine loop are distinct structurally from those comprising thin fimbriae and lacking a cysteine loop (Girardeau & Bertin, 1995; Méchin *et al.*, 1995). However, the AgfA C-terminal core is predicted to adopt a very unusual, regular repeating secondary structural pattern with most of the ten nonpolar-polar-nonpolar triplet motifs adopting extended secondary structure separated by short regions of coil structure. *Salmonella* AgfA, and the *E. coli* AgfA homologue, CsgA (Hammar *et al.*, 1996), may be an extreme case in which the obvious, highly conserved amino acid residues in the primary sequence repeat motifs reflect a regular predicted secondary structure pattern.

Several features of the AgfA primary sequence and predicted secondary structure suggest that AgfA probably adopts a tertiary structure distinct from the Figure  $\alpha$ - $\beta$  roll described for the gonococcal pilin of *Neisseria* type IV pili. Notably, AgfA lacks the 55 amino acid hydrophobic,  $\alpha$ -helical N-terminal region proposed to occupy an internal position in intact pili (Paranchych & Frost, 1988; Parge *et al.*, 1995). The four central anti-parallel  $\beta$  strands of the gonococcus pilin are flanked between the C-terminal portion of the 55-residue N-terminal  $\alpha$ -helix and the externally exposed disaccharide-containing loop and disulfide region (Parge *et al.*, 1995). AgfA lacks extensive regions of predicted  $\alpha$ -helical structure and does not contain cysteine residues (Collinson *et al.*, 1996a; Collinson *et al.*, 1991). Post translational modification of AgfA has not been demonstrated but two putative NAT O-glycosylation sites exist at residues 80 to 82 and 115 to 117 analogous to the N(T/S)S O-glycosylation site of gonococcal and meningococcal pilins (Marceau *et al.*, 1998). Predictably, the actual *S. enteritidis* AgfA fimbrin tertiary structure likely differs significantly from the  $\alpha$ - $\beta$  roll of gonnococcal pilin.

The parallel  $\beta$  helix model of AgfA is the most alluring tertiary structure emerging from this study for several reasons. Firstly, this model predicts a very regular, compact structure congruent with the conserved, primary sequence repeats found in the C-terminus of AgfA. In addition, the proposed molecular mechanisms stabilizing the AgfA parallel  $\beta$  helix model structure are reminiscent of those of the di-strand  $\beta$  roll

motif of the *S. marcescens* metallo-protease on which this AgfA model was based (Baumann, 1994) and the structurally related tri-strand parallel  $\beta$  helix motif of the pectate lyases (Lietzke *et al.*, 1994; Pickersgill *et al.*, 1994; Yoder & Jurnak, 1995) and *Salmonella* P22 phage tail spike protein (Steinbacher *et al.*, 1994; Yoder & Jurnak, 1995) with potentially important differences. The predicted parallel  $\beta$  helix AgfA structure would be expected to be more stable than the above helical structures. This is because the parallel  $\beta$  helix model of AgfA predicts that four residues in each of the five coils would be internalized forming a larger hydrophobic core compared to the two residues normally seen in the previously described  $\beta$  roll and parallel  $\beta$ -helix motifs (Yoder & Jurnak, 1995). The intriguing arrangement of two internalized stacks of five Q and five N residues at positions 7 and 12, respectively, that flank the relatively sharp turn centered at the conserved G residue at position 9 of each coil could apparently stabilize the turns by extensive H-bonding with the peptide chain backbone (Figure 11c). Similarly, two internalized stacks of five S and five Q residues at positions 1 and 18 flank the turns joining each coil. The pectate lysases, which demonstrate polar stacks of up to 6 N residues and 3 S residues merely possess a single polar stack on one side of each turn (Yoder & Jurnak, 1995). Similarly, ribonuclease inhibitor, a protein containing leucine-rich repeats folded in a helix of alternating strand and a helical regions possesses an N ladder at one end of the strand motif \_ ADDIN ENRef \_(Kobe & Deisenhofer, 1993). Conversely, the barrel and prism AgfA model structures apparently lack certain molecular interactions important for the stability of respective template proteins. The PMP barrel structure possesses many hydrophilic residues that project into the interior of the barrel and form an extensive network of hydrogen bonds and salt bridges with a non-central hydrophobic pocket within the barrel structure that interacts with lipids \_ ADDIN ENRef \_(Cowan *et al.*, 1993; Jones *et al.*, 1988). Furthermore, the AgfA barrel model is less extensively hydrogen bonded than its PMP template. In addition, AgfA lacks cysteine residues, eight of which apparently stabilize the prism structure of VMO-I and enhance heat stability by forming four internal S-S bridges \_ ADDIN ENRef \_(Shimizu & Morikawa, 1996).

Thirdly, the conservation of residues in the AgfA and CsgA fimbrin homologues is a strong evolutionary argument in support of the AgfA parallel helix

model. The hypothetical contribution of the internal, conserved polar and nonpolar residues to the stability of this model is further strengthened by the fact that 37 of these 40 residues are identical in the AgfA homologue, CsgA. The residues forming the stacks of internalized polar residues are perfectly conserved and there is only one non-conservative replacement of L for T in AgfA within the predicted hydrophobic core (Figure 15, Table 5). In this context, it is more difficult to envision the necessity for conserving these residues in the proposed barrel model of AgfA which predicts internal positions of these polar residues but without an obvious role in stability given the less extensive participation in main chain hydrogen bonding. Similarly, structural integrity and stability of the prism model would not conceivably require the conservation of N and Q residues which are predicted to be mainly surface exposed in this model. Conservation of residues is a strong argument for eliminating barrel and the prism models. If AgfA forms a parallel helix structure, this would be the first fimbrin recognized to do so.

Parallel sheet structures, like those described for the proposed AgfA parallel helix model are often associated with protein-protein interactions. Although metalloproteases \_ ADDIN ENRef (Baumann *et al.*, 1995; Baumann *et al.*, 1993) and pectate lyases (Yoder & Jurnak, 1995) form coiled fold motifs that do not exist in multimeric form, the P22 tailspike protein forms a native trimer that is resistant to proteases, thermostable beyond 80°C and is not dissociated by exposure to SDS (Steinbacher *et al.*, 1994). The stability of the P22 tailspike trimer is attributed to the interaction of the hydrophilic  $\beta$  sheet surfaces (Steinbacher *et al.*, 1994). The possibility that the unusual stability of polymerized AgfA and the aggregative nature of the fimbriae is due in part to electrostatic interactions between monomers is consistent with the observed resistance of thin aggregative fimbriae to depolymerization by treatment with SDS (Collinson *et al.*, 1991), octylglucoside or Tween-20 (Collinson, unpublished data). Salt bridges as well as hydrophobic interactions contribute to the maintenance of trimeric forms of carbonic anhydrase, the monomers of which assume a left hand parallel  $\beta$  helix structure (Kisker *et al.*, 1996). Very little is known concerning the molecular basis for fimbrin polymerization and stability. Forces important in the *Neisseria* Type IV model implicate a combination of a hydrophobic N-terminus in the

central core of the fiber and electrostatic forces stabilizing subunit-subunit interactions in the globular head (Parge *et al.*, 1995). Fimbrins and pilins are not covalently linked but assemble into very stable structures resistant to proteases and chemical denaturants such as chaotropes and alkali (Collinson *et al.*, 1991; Eshdat *et al.*, 1981; Ho *et al.*, 1990; Korhonen *et al.*, 1980; Parge *et al.*, 1995). The distribution of those amino acid residues predicted to comprise the external face of the amphipathic  $\beta$ -strands in the parallel  $\beta$  helix AgfA model are primarily polar with hydrophobic, acidic and basic “patches” consistent with a requirement for interactive surfaces to stabilize polymers of AgfA. The glycine rich N-terminal region of AgfA, while susceptible to protease digestion, also posses a sequence consistent with two glycine loops as defined by Steinert *et al.* (1991) which have been hypothesized to form interactions that stabilize higher stuctures. The parallel  $\beta$  helix model of AgfA offers an interesting solution to a multifunctional fimbrin molecular surface that must be able to have regions for subunit-subunit interaction, solvent exposed areas, interaction with minor subunits and fiber-fiber interactions common to many fimbriae.

The three all- $\beta$  class tertiary structure models of AgfA enable rational experimental design to facilitate investigations into *Salmonella* thin aggregative fimbriae structure and biogenesis. The quest to obtain soluble AgfA monomers for future physical analysis or structural studies may be aided by considering the information offered by the hypothetical AgfA model structures, especially that of the AgfA parallel  $\beta$  helix model. Optimal conditions for depolymerization of thin aggregative fimbriae in conditions less severe than 90% formic acid or prevention of AgfA polymerization by introducing minor tertiary structural perturbations by site specific mutagenesis may be ways to obtain soluble fimbrin monomers. Selective mutagenesis of AgfA to identify structurally and functionally important regions of this fimbrin is currently in progress (White *et al.*, 1999). Site specific mutagenesis to alter key amino acid residues conserved in the AgfA primary sequence should provide important information on fimbrin structure and stability and the importance of each of the five C-terminal repeat segments in AgfA. Site specific mutagenesis of the K99 fimbrin penultimate Y prevents fiber formation (Simons *et al.*, 1990). The role of the terminal Y of AgfA is not known, however, this residue is positioned 3 and 5 residues

C-terminally to the two hydrophobic residues of the tenth  $\beta$ -strand and 9 residues from F122, an arrangement reminiscent of the less conserved  $\beta$ -zipper motif of fimbrins assembled by the FGL chaperones (Hung *et al.*, 1996). The possibility of chaperone involvement in AgfA assembly has not been ruled out. Thus, the AgfA structural models presented herein provide a theoretical basis from which to further our knowledge of the structure and biogenesis of the stable, thin aggregative fimbriae of *Salmonella*.

#### REFERENCES CITED IN EXAMPLE 1

- 10 Abraham, S. N., Babu, J. P., Giampapa, C. S., Hasty, D. L., Simpson, W. A. & Beachey, E. H. (1985). Protection against *Escherichia coli*-induced urinary tract infections with hybridoma antibodies directed against type 1 fimbriae or complementary D-mannose receptors. *Infection and Immunity* 48, 625-628.
- 15 Austin, J. W., Sanders, G., Kay, W. W. & Collinson, S. K. (1998). Thin aggregative fimbriae enhance *Salmonella enteritidis* biofilm formation. *FEMS Microbiology Letters* 162, 295-301.
- Baumann, U. (1994). Crystal structure of the 50 kDa metallo-protease from *Serratia marcescens*. *Journal of Molecular Biology* 242, 244-251.
- 20 Baumann, U., Bauer, M., Létoffé, S., Delepelaire, P. & Wandersman, C. (1995). Crystal structure of a complex between *Serratia marcescens* metallo-protease and an inhibitor from *Erwinia chrysanthemi*. *Journal of Molecular Biology* 248, 653-661.
- 25 Baumann, U., Wu, S., Flaherty, K. M. & McKay, D. B. (1993). Three-dimensional structure of the alkaline protease of *Pseudomonas aeruginosa*: a two-domain protein with a calcium binding parallel beta roll motif. *EMBO Journal* 12, 3357-3364.
- Bäumler, A. J., Gilde, A. J., Tsolis, R. M., van der Velden, A. W. M., Ahmer, B. M. M. & Heffron, F. (1997). Contribution of horizontal gene transfer and deletion events to development of distinctive patterns of fimbrial operons during 30 evolution of *Salmonella* serotypes. *Journal of Bacteriology* 179, 317-322.

- Bäumler, A. J. & Heffron, F. (1995). Identification and sequence analysis of *lpfABCDE*, a putative fimbrial operon of *Salmonella typhimurium*. *Journal of Bacteriology* 177, 2087-2097.
- Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T. & Tasumi, M. (1977). The Protein Data Bank: a computer-based archival file for macromolecular structures. *Journal of Molecular Biology* 112, 535-542.
- Braunagel, S. C. & Benedik, M. J. (1990). The metalloprotease gene of *Serratia marcescens* strain SM6. *Molecular and General Genetics* 222, 446-451.
- Brinton Jr, C. C. (1965). The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria. *Transactions of the New York Academy of Sciences* 27, 1003-1054.
- Collinson, S. K., Clouthier, S. C., Doran, J. L., Banser, P. A. & Kay, W. W. (1996a). *Salmonella enteritidis agfBAC* operon encoding thin, aggregative fimbriae. *Journal of Bacteriology* 178, 662-667.
- Collinson, S. K., Doig, P. C., Doran, J. L., Clouthier, S., Trust, T. J. & Kay, W. W. (1993). Thin, aggregative fimbriae mediate binding of *Salmonella enteritidis* to fibronectin. *Journal of Bacteriology* 175, 12-18.
- Collinson, S. K., Emödy, L., Müller, K.-H., Trust, T. J. & Kay, W. W. (1991). Purification and characterization of thin, aggregative fimbriae from *Salmonella enteritidis*. *Journal of Bacteriology* 173, 4773-4781.
- Collinson, S. K., Emödy, L., Trust, T. J. & Kay, W. W. (1992). Thin aggregative fimbriae from diarrheagenic *Escherichia coli*. *Journal of Bacteriology* 174, 4490-4495.
- Collinson, S. K., Liu, S.-L., Clouthier, S. C., Banser, P. A., Doran, J. L., Sanderson, K. E. & Kay, W. W. (1996b). The location of four fimbrin-encoding genes, *agfA*, *fimA*, *sefA* and *sefD*, on the *Salmonella enteritidis* and/or *S. typhimurium* *XbaI-BlnI* genomic restriction maps. *Gene* 169, 75-80.
- Cowan, S. W., Newcomer, M. E. & Jones, T. A. (1993). Crystallographic studies on a family of cellular lipophilic transport proteins. *Journal of Molecular Biology* 230, 1225-1246.

- de Graaf, F. K. & Bakker, D. (1992). Properties and synthesis of K88 fimbriae. In *Molecular recognition in Host-Parasite Interactions* (Korhonen, T. K., ed.), pp. 39-46. Plenum Press, New York.
- Der Vartanian, M., Méchin, M.-C., Jaffeux, B., Bertin, Y., Félix, I. & Gaillard-Martinie, B. (1994). Permissible peptide insertions surrounding the signal peptide-mature protein junction of the ClpG prepilin: CS31A fimbriae of *Escherichia coli* as carriers of foreign sequences. *Gene* 148, 23-32.
- Doran, J. L., Collinson, S. K., Burian, J., Sarlós, G., Todd, E. C. D., Munro, C. K., Kay, C. M., Banser, P. A., Peterkin, P. I. & Kay, W. W. (1993). DNA-based diagnostic tests for *Salmonella* species targeting *agfA*, the structural gene for thin, aggregative fimbriae. *Journal of Clinical Microbiology* 31, 2263-2273.
- Eshdat, Y., Silverblatt, F. J. & Sharon, N. (1981). Dissociation and reassembly of *Escherichia coli* type 1 pili. *Journal of Bacteriology* 148, 308-314.
- Firth, N., Ippen-Ihler, K. & Skurray, R. A. (1996). Structure and function of the F factor and mechanism of conjugation. In *Escherichia coli and Salmonella Cellular and Molecular Biology* 2nd edit. (Neidhardt, F. C., ed.), pp. 2377-2401. American Society for Microbiology Press, Washington, D.C.
- Fullner, K. J., Lara, J. C. & Nester, E. W. (1996). Pilus assembly by *Agrobacterium* T-DNA transfer genes. *Science* 273, 1107-1109.
- Gaastra, W. & de Graaf, F. K. (1982). Host-specific fimbrial adhesins of noninvasive enterotoxigenic *Escherichia coli* strains. *Microbiological Reviews* 46, 129-161.
- Girardeau, J.-P. & Bertin, Y. (1995). Pilins of fimbrial adhesins of different member species of Enterobacteriaceae are structurally similar to the C-terminal half of adhesin proteins. *FEBS Letters* 357, 103-108.
- Girardeau, J.-P., Bertin, Y., Martin, C., Der Vartanian, M. & Boeuf, C. (1991). Sequence analysis of the *clpG* gene, which codes for surface antigen CS31A subunit: evidence of an evolutionary relationship between CS31A, K88 and F41 subunit genes. *Journal of Bacteriology* 173, 7673-7683.
- Gong, M. & Makowski, L. (1992). Helical structure of P pili from *Escherichia coli*. *Journal of Molecular Biology* 228, 735-742.

- Hammar, M., Arqvist, A., Bian, Z., Olsen, A. & Normark, S. (1995). Expression of two *csg* operons is required for production of fibronectin- and congo red-binding curli polymers in *Escherichia coli* K-12. *Molecular Microbiology* 18.
- Hammar, M., Bian, Z. & Normark, S. (1996). Nucleator-dependent intercellular assembly of adhesive curli organelles in *Escherichia coli*. *Proceedings of the National Academy of Science* 93, 6562-6566.
- Heck, D. V., Trus, B. L. & Steven, A. C. (1996). Three-dimensional structure of *Bordetella pertussis* fimbriae. *Journal of Structural Biology* 116, 264-269.
- Ho, A. S. Y., Mietzner, T. A., Smith, A. J. & Schoolnik, G. K. (1990). The pili of *Aeromonas hydrophila*: identification of an environmentally regulated "mini pilin". *Journal of Experimental Medicine* 172, 795-806.
- Hobohm, U. & Sanders, C. (1995). A sequence property approach to searching protein databases. *Journal of Molecular Biology* 251, 390-399.
- Hung, D. L., Knight, S. D., Woods, R. M., Pinkner, J. S. & Hultgren, S. J. (1996). Molecular basis of two subfamilies of immunoglobulin-like chaperones. *EMBO Journal* 15, 3792-3805.
- Jones, C. H., Danese, P. N., Pinkner, J. S., Silhavy, T. J. & Hultgren, S. J. (1997). The chaperone-assisted membrane release and folding pathway is sensed by two signal transduction systems. *EMBO Journal* 16, 6394-6406.
- Jones, T. A., Bergfors, T., Sedzik, J. & Unge, T. (1988). The three-dimensional structure of P2 myelin protein. *EMBO Journal* 7, 1597-1604.
- Kisker, C., Schindelin, H., Alber, B. E., Ferry, J. G. & Rees, D. C. (1996). A left-handed  $\beta$ -helix revealed by the crystal structure of a carbonic anhydrase from the archaeon *Methanosarcina thermophila*. *EMBO Journal* 15, 2323-2330.
- Klemm, P. (1984). The *fimA* gene encoding the type-1 fimbrial subunit of *Escherichia coli*. *European Journal of Biochemistry* 143, 395-399.
- Klemm, P. & Krogfelt, K. A. (1994). Type 1 fimbriae of *Escherichia coli*. In *Fimbriae adhesion, genetics, biogenesis, and vaccines* (Klemm, P., ed.), pp. 9-26. CRC Press, Baco Raton.
- Kobe, B. & Deisenhofer, J. (1993). Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. *Nature* 366, 751-756.

- Korhonen, T. K., Nurmiaho, E.-L., Ranta, H. & Eden, C. S. (1980). New method for isolation of immunologically pure pili from *Escherichia coli*. *Infection and Immunity* 27, 569-575.
- Kuehn, M. J., Haslam, D., Normark, S. & Hultgren, S. J. (1994).
- 5 Structure, function and biogenesis of *Escherichia coli* P pili. In *Fimbriae adhesion, genetics, biogenesis, and vaccines* (Klemm, P., ed.). CRC Press, Boca Raton.
- Kuehn, M. J., Heuser, J., Normark, S. & Hultgren, S. J. (1992). P pili in uropathogenic *E. coli* are composite fibres with distinct fibrillar adhesive tips. *Nature* 356, 252-255.
- 10 Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680-685.
- Lai, E.-M. & Kado, C. I. (1998). Processed VirB2 is the major subunit of the promiscuous pilus of *Agrobacterium tumefaciens*. *Journal of Bacteriology* 180, 2711-2717.
- 15 Leathart, J. B. S. & Gally, D. L. (1998). Regulation of type 1 fimbrial expression in uropathogenic *Escherichia coli*: heterogeneity of expression through sequence changes in the *fim* switch region. *Molecular Microbiology* 28, 371-381.
- Levine, M. M., Girón, J. A. & Noriega, F. R. (1994). Fimbrial vaccines. In *Fimbriae adhesion, genetics, biogenesis and vaccines* (Klemm, P., ed.), pp. 255-270.
- 20 CRC Press, Boca Raton.
- Lietzke, S. E., Yoder, M. D., Keen, N. T. & Jurnak, F. (1994). The three-dimensional structure of pectate lyase E, a plant virulence factor from *Erwinia chrysanthemi*. *Plant Physiology* 106, 849-862.
- Lintermans, P., Pohl, P., Deboeck, F., Bertels, A., Schlicker, C.,
- 25 Vandekerckhove, J., van Damme, J., van Montagu, M. & de Greve, H. (1988). Isolation and nucleotide sequence of the F17-A gene encoding the structural protein of the F17 fimbriae in bovine enterotoxigenic *Escherichia coli*. *Infection and Immunity* 56, 1475-1484.
- Low, D., Braaten, B. & van der Woude, M. (1996). Fimbriae. In
- 30 *Escherichia coli and Salmonella Cellular and Molecular Biology* 2nd edit. (Neidhardt, F. C., ed.), pp. 146-157. American Society for Microbiology Press, Washington, D.C.

- Marceau, M., Beretti, J.-L. & Nassif, X. (1995). High adhesiveness of encapsulated *Neisseria meningitidis* to epithelial cells is associated with the formation of bundles of pili. *Molecular Microbiology* 17, 855-863.
- Marceau, M., Forest, K., Béretti, J.-L., Tainer, J. & Nassif, X. (1998).
- 5 Consequences of the loss of O-linked glycosylation of menningococcal type IV pilin on piliation and pilus-mediated adhesion. *Molecular Microbiology* 27, 705-715.
- Méchin, M.-C., Bertin, Y. & Girardeau, J.-P. (1995). Hydrophobic cluster analysis and secondary structure predictions revealed that major and minor structural subunits of K88-related adhesins of *Escherichia coli* share a common overall
- 10 fold and differ structurally from other fimbrial subunits. *FEBS Letters* 364, 319-324.
- Mol, O. & Oudega, B. (1996). Molecular and structural aspects of fimbriae biosynthesis and assembly in *Escherichia coli*. *FEMS Microbiology Reviews* 19, 25-52.
- Morris, A. L., MacArthur, M. W., Hutchinson, E. G. & Thornton, J. M.
- 15 (1992). Stereochemical quality of protein structure coordinates. *Proteins* 12, 345-364.
- Murzin, A. G., Brenner, S. E., Hubbard, T. & Chothia, C. (1995). SCOP: A structural classification of proteins database for the investigation of sequences and structures. *Journal of Molecular Biology* 247, 536-540.
- Ogawa, T., Ogo, H. & Kinoshita, A. (1997). Antagonistic effect of
- 20 synthetic peptides corresponding to the binding regions within fimbrial subunit protein from *Porphyromonas gingivalis* to human gingival fibroblasts. *Vaccine* 15, 230-236.
- Olsén, A., Arnqvist, A., Hammar, M., Sukupolvi, S. & Normark, S.
- (1993). The RpoS sigma factor relieves H-NS-mediated transcriptional repression of
- csgA, the subunit gene of fibronectin-binding curli in *Escherichia coli*. *Molecular*
- 25 *Microbiology* 7, 523-536.
- Pallesen, L. & Klemm, P. (1994). Chimeric fimbrial vaccines. In
- Fimbriae adhesion, genetics, biogenesis, and vaccines* (Klemm, P., ed.), pp. 271-276.
- CRC Press, Boca Raton.
- Paranchych, W. (1990). Molecular studies on N-methylphenylalanine
- 30 pili. *The Bacteria* XI, 61-78.

- Paranchych, W. & Frost, L. S. (1988). The physiology and biochemistry of pili. *Advances in microbial physiology* 29, 53-114.
- Parge, H. E., Forest, K. T., Hickey, M. J., Christensen, D. A., Getzoff, E. D. & Tainer, J. A. (1995). Structure of the fiber-forming protein pilin at 2.6 Å resolution. *Nature* 378, 32-38.
- Parker, J. M. R. & Hodges, R. S. (1991a). Prediction of surface and interior regions in proteins - Part I: Linear tripeptide sequences identify structural boundaries in proteins. *Peptide Research* 4, 347-354.
- Parker, J. M. R. & Hodges, R. S. (1991b). Prediction of surface and interior regions in proteins - PartII: predicting secondary structure in regions bound by surface exposed regions. *Peptide Research* 4, 355-363.
- Pickersgill, R., Jenkins, J., Harris, G., Nasser, W. & Robert-Baudouy, J. (1994). The structure of *Bacillus subtilis* pectate lyase in complex with calcium. *Structural Biology* 1, 717-723.
- Römling, U., Bian, Z., Hammar, M., Sierralta, W. D. & Normark, S. (1998). Curli fibers are highly conserved between *Salmonella typhimurium* and *Escherichia coli* with respect to operon structure and regulation. *Journal of Bacteriology* 180, 722-731.
- Shimizu, T. & Morikawa, K. (1996). The β-prism: a new folding motif. *Trends in Biochemical Sciences* 21, 3-6.
- Shimizu, T., Vassylyev, D. G., Kido, S., Doi, Y. & Morikawa, K. (1994). Crystal structure of vitelline membrane outer layer protein I (VMO-I): a folding motif with homologous Greek key structures related by an internal three-fold symmetry. *EMBO Journal* 13, 1003-1010.
- Silverman, P. M. (1997). Towards a structural biology of bacterial conjugation. *Molecular Microbiology* 23, 423-429.
- Simons, B. L., Mol, O., van Breemen, J. F. L. & Oudega, B. (1994). Morphological appearances of K88ab fimbriae and optical diffraction analysis of K88 paracrystalline structures. *FEMS Microbiology Letters* 118, 83-88.
- Simons, B. L., Rathman, P., Malij, C. R., Oudega, B. & de Graaf, F. K. (1990). The penultimate tyrosine residue of the K99 fibrillar subunit is essential for

stability of the protein and its interaction with the periplasmic carrier protein. *FEMS Microbiology Letters* 67, 107-112.

Sjöbring, U., Pohl, G. & Olsén, A. (1994). Plasminogen, absorbed by *Escherichia coli* expressing curli or by *Salmonella enteritidis* expressing thin aggregative fimbriae, can be activated by simultaneously captured tissue-type plasminogen activator (t-PA). *Molecular Microbiology* 14, 443-452.

Smyth, C. J., Marron, M. B., Twohig, J. M. G. J. & Smith, S. G. J. (1996). Fimbrial adhesins: similarities and variations in structure and biogenesis. *FEMS Immunology and Medical Microbiology* 16, 127-139.

10 St. Geme III, J. W., Pinkner, J. S., Krasan, G. P., Heuser, J., Bullitt, E., Smith, A. L. & Hultgren, S. J. (1996). *Haemophilus influenzae* pili are composite structures assembled via the HifB chaperone. *Proceedings of the National Academy of Science* 93, 11913-11918.

15 Steinbacher, S., Seckler, R., Miller, S., Steipe, B., Huber, R. & Reinemer, P. (1994). Crystal structure of P22 tailspike protein: interdigitated subunits in a thermostable trimer. *Science* 265, 383-386.

Strom, M. S. & Lory, S. (1993). Structure-function and biogenesis of the type IV pili. *Annual Review of Microbiology* 47, 565-596.

20 Sukupolvi, S., Edelstein, A., Rhen, M., Normark, S. J. & Pfeifer, J. D. (1997a). Development of a murine model of chronic *Salmonella* infection. *Infection and Immunity* 65, 838-842.

25 Sukupolvi, S., Lorenz, R. G., Gordon, J. I., Bian, Z., Pfeifer, J. D., Normark, S. J. & Rhen, M. (1997b). Expression of thin aggregative fimbriae promotes interaction of *Salmonella typhimurium* SR-11 with mouse small intestinal epithelial cells. *Infection and Immunity* 65, 5320-5325.

Tennent, J. M. & Mattick, J. S. (1994). Type 4 fimbriae. In *Fimbriae adhesion, genetics, biogenesis, and vaccines* (Klemm, P., ed.), pp. 127-146. CRC Press, Boca Raton.

30 Thorns, C. J., McLaren, I. M. & Sojka, M. G. (1994). The use of latex particle agglutination to specifically detect *Salmonella enteritidis*. *International Journal of Food Microbiology* 21, 47-53.

- Vidal, O., Longin, R., Prigent-Combaret, C., Dorel, C., Hooreman, M. & Lejeune, P. (1998). Isolation of an *Escherichia coli* K-12 mutant strain able to form biofilms on inert surfaces: involvement of a new *ompR* allele that increases curli expression. *Journal of Bacteriology* 180, 2442-2449.
- 5 White, A. P., Collinson, S. K., Burian, J., Clouthier, S. C., Banser, P. A. & Kay, W. W. (1999). High efficiency gene replacement in *Salmonella enteritidis*: Chimeric fimbriins containing a T cell epitope from *Leishmania major*. *Vaccine*, In press.
- Whittaker, C. J., Klier, C. M. & Kolenbrander, P. E. (1996). Mechanisms 10 of adhesion by oral bacteria. *Annual Review of Microbiology* 50, 513-552.
- Wishart, D. S., Boyko, R. F., Willard, L., Richards, F. M. & Sykes, B. D. (1994). SEQSEE: a comprehensive program suite for protein sequence analysis. *Computer Applications in the Biosciences* 10, 121-132.
- Wishart, D. S., Willard, L., Richards, F. M. & Sykes, B. D. (1995). 15 VADAR: a comprehensive program for protein structure evaluation. Version 1.2. University of Alberta, Edmonton, Canada. .
- Yoder, M. D. & Jurnak, F. (1995). The parallel  $\beta$  helix and other coiled folds. *FASEB Journal* 9, 335-342.
- 20 EXAMPLE 2
- HIGH EFFICIENCY GENE REPLACEMENT IN *SALMONELLA ENTERITIDIS*: CHIMERIC FIMBRINS  
CONTAINING A T CELL EPITOPE FROM *LEISHMANIA MAJOR*.
- The present invention provides for a simple, highly efficient method for 25 gene replacement within the chromosome of *Salmonella*. This method is advantageous because it allows for gene replacement at native sites in the chromosome without the need for specific recombination-proficient bacterial strains or the use of selectable markers within the recombinant genes. Thus, the incorporation of non-target DNA in the chromosome is avoided. To illustrate the utility of this method, *sefA* and *agfA*, encoding the fimbrin subunit proteins of SEF14 [8] and thin aggregative fimbriae 30 (SEF17) [11], respectively, were engineered to contain the DNA sequence encoding an immunoprotective T cell epitope from the *Leishmania major* surface protein, GP63

[25], and were replaced into the chromosome of *S. enteritidis*. To our knowledge, this study presents the first chimeric *Salmonella* fimbrial genes and reports the first example of chimeric fimbrial genes reconstituted into the chromosome of an otherwise wild-type organism.

5

## Materials and Methods

Bacterial strains, media, and growth conditions. *S. enteritidis* 27655 strain 3b has been previously described [16]. *E. coli* XL-1 Blue (Stratagene) was used as the host for pTZ18R, pHSG415, pGEM-T, pGP1-2 and their derivatives (Table 6).

10

Table 6. Plasmids used in this study.

Plasmid	Description and relevant genotypes	Reference/Source
pTZ18R	Standard cloning vector with T7 promoter; Ap <sup>R</sup>	Pharmacia Biotech Inc.
pHSG415	Temperature-sensitive pSC101 <i>ori</i> ; Cm <sup>R</sup> , Km <sup>R</sup> , Ap <sup>R</sup>	[20]
pGEM-T	A-T cloning vector; Ap <sup>R</sup>	Stratagene
pGP1-2	T7 RNA polymerase cloned under the control of <i>lp<sub>L</sub></i> and <i>cI857, P15A ori</i> ; Km <sup>R</sup>	[44]
pTZ18 pil	pTZ18R, <i>sefABC</i>	[8]
pHAG	pUC18, <i>agfBAC</i>	[9]
pTZSef	pTZ18R, <i>sefA</i>	This study
pTZSP10	pTZ18R, <i>sefA::PT3</i>	This study
pTZAfg	pTZ18R, <i>agfA</i>	This study
pTZAP7	pTZ18R, <i>agfA::PT3</i>	This study
pHSSP10	pHSG415, <i>sefA::PT3</i>	This study
pHSAP7	pHSG415, <i>agfA::PT3</i>	This study

*E. coli* XL-1 Blue harboring recombinant plasmids was grown in Luria-Bertani (LB) broth [39] or Terrific broth (TFB) [40] for 20-24 h at 28°C, 37°C or 42°C as specified below. Media were supplemented with ampicillin (Ap, 100 mg ml<sup>-1</sup>), kanamycin (Km, 50 mg ml<sup>-1</sup>), 5-bromo-4-chloro-3-indolyl-β-D-glactopyranoside (X-gal, 40 mg ml<sup>-1</sup>), or isopropyl-β-D-thiogalacto-pyranoside (IPTG, 1 mM) as required.

SefA or AgfA fimbriins were analyzed from *S. enteritidis* cells grown in CFA broth [15] or T broth [11] statically at 37°C for 48 h or incubated on T medium (T) and T medium Congo red indicator plates (TCR) as previously described [10].

Recombinant DNA Techniques and Sequencing. Electroporation of *S. enteritidis* and *E. coli* using purified plasmids (QIAprep spin kit, Qiagen) was performed using standard techniques (Gene pulser electroprotocol, BioRad). Recombinant plasmids were routinely purified using standard alkaline lysis plasmid preps [40]. Restriction enzyme digestions (New England Biolabs) and ligation reactions (Gibco-BRL, Stratagene) were performed as described by the manufacturers.

10 DNA fragments or PCR products were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide [40]. DNA fragments purified from agarose gels using the Sephadex bandprep kit (Pharmacia) or QIAquick gel extraction kit (Qiagen) were used for subcloning and sequencing. All PCR and sequencing primers were synthesized using an Applied Biosystems Model 391 PCR-MATE EP

15 DNA synthesizer (Applied Biosystems Inc.).

Polymerase Chain Reaction. The two step overlap extension PCR reaction [22] to generate *sefA::PT3* or *agfA::PT3* required four primers, A, B, C, and D (Figure 17). Primers B and C were the internal primers containing 48 nucleotides encoding the PT3 epitope followed by 30 nucleotides of *sefA* or *agfA* sequence at the

20 desired site of insertion, and A and D were the two external primers containing *Eco*RI or *Hind*III restriction sites (Table 7). In the first PCR step, two separate 100 ml PCR reactions were performed using primers A/B and C/D, respectively (Figure 17). Each amplification reaction contained 20 ng of plasmid template DNA, 50 pmol of each primer, 0.4 mM of each deoxynucleotide triphosphate (Boehringer Mannheim) and 2.5

25 U *Pfu* DNA polymerase (Stratagene) in buffer supplied by the manufacturer. The second PCR step required 50 ng each of the two purified PCR products from the first PCR step as template DNA with 50 pmol of each external primer. After an initial 4 min denaturation step at 94°C, the *Pfu* enzyme was added and thermocycling was performed in a PTC-100TM Programmable Thermal Controller (MJ Research Inc.) with 30 cycles

30 of denaturation (94°C, 45 s), annealing (55°C, 45 s), elongation (72°C, 1 min), followed by a 10 min elongation at 72°C. Wild-type *sefA* or *agfA* genes were amplified using the

external primers (A and D) only under the same conditions as the first PCR step described above.

Table 7. PCR primers used to generate *sefA::PT3* or *agfA::PT3*<sup>a</sup>

5

Primers <sup>b</sup>	Length	Sequence <sup>c</sup> (5'-3')
14-A	39	<b>TTGGAAATTCTTCTTAAATTTAAAATGGCGTTGAGTAT</b>
14-B	78	<u>AGCATGAGCCATT</u> CATGTGAACAACACGTGTAACGAGCTGATCA <u>TATGCAATAGTAAC</u> CGCTGCCTGAACCACTGC
14-C	78	<u>TATGATCAGCTCGTTACACGTGTTACACATGAAATGGCTCATGC</u> <u>TGGGCCTGCTGTT GCTGCTGGTCAGAAAGTT</u>
14-D	39	ATTAAGCTTATAACATAATCCCTTTAACGTTTGATG
17-A	39	GCAGAATT CAGCAGTTGTAGTGCAGAACAGTCGCATAT
17-B	78	<u>TGCATGTGCCATT</u> CATGGGTAAACAACACGGGTAAACCAGCTGATCA <u>TAGTTTTAGCGTT CCACTGGTCGATGGTGGC</u>
17-C	78	<u>TATGATCAGCTGGTTACCCGTGTTACCCATGAAATGGCACATGC</u> <u>AAATCAGACCGCA TCTGATTCCAGCGTAATG</u>
17-D	39	AGACGCAAGCTTCGTTAATGTGACCTGAGGGATCACCG

<sup>a</sup> Primers used to generate *sefA::PT3* or *agfA::PT3* as noted in Fig 17.

<sup>b</sup> Primers prefixed with 14- or 17- used to generate *sefA* (SEF14) or *agfA* (SEF17) recombinants, respectively.

10 <sup>c</sup> Underlined sequence corresponds to the 48 bp PT3 DNA sequence; bold letters correspond to *Eco*RI (GAATTC) or *Hind*III (AAGCTT) restriction endonuclease sites.

To amplify regions surrounding *sefA* and *agfA* in Ap<sup>S</sup> *S. enteritidis* strains after gene replacement, primers IN1 (5'-GGG ATG TTG TGT AAA GAT AAA AAA ATA GTG-3') and IN2 (5'-TGC CCA ATC TTA GGC CAT AAT ATT TTT GTG-3') or TAF59 (5'-AGG AAG GAT CAA AAC TAT TGT CCG TTA TTT CAC-3') and TAF60 (5'-TAT ATT TAC ACT AAG ACG AGA CAA CTC AAT CGG-3') were used, respectively. To obtain template DNA for each *S. enteritidis* strain sequenced, cells from a 1 mL overnight LB culture were harvested and boiled for 10 min. in 1 mL dH<sub>2</sub>O. 100 ml PCR reactions contained 20 ml of the boiled whole cell supernatant, 50 pmol of each primer, 0.2 mM of each deoxynucleotide triphosphate and 4 U of *Taq* DNA polymerase (Boehringer Mannheim) in buffer supplied by the manufacturer. After an initial 5 min denaturation step at 95°C, *Taq* enzyme was added and thermocycling was performed as above with 30 cycles of denaturation (94°C, 1

min), annealing (55°C or 60°C, 1 min), elongation (72°C, 1 min), followed by a 10 min elongation at 72°C.

Gene replacement procedure in *S. enteritidis* 3b. *S. enteritidis* 3b containing pHSSP10 or pHsap7 was grown for 24 h in 5ml TFB/Ap (42°C, 250 rpm). 5 ml of this culture was used to inoculate 5 ml TFB/Ap and cells were grown at 42°C for 24 h; this transfer step was repeated four times. To select Ap<sup>R</sup> colonies, dilutions of the final 42°C culture were plated on LB/Ap plates and grown overnight at 42°C. pHSSP10 and pHsap7 cointegrate colonies were grown individually in 5 ml TFB (28°C, 250 rpm, 24 h). 5 ml of each culture was used to inoculate 5 ml TFB and cells 10 were grown at 28°C for 24 h; this transfer step was repeated four times. Serial dilutions from each of the final 28°C cultures were plated on LB medium and incubated at 28°C for 24 h. To select Ap<sup>S</sup> colonies, isolated colonies were picked from LB and replicated onto LB/Ap plates.

DNA sequence analysis. Recombinant *sefA::PT3* and *agfA::PT3* 15 generated by PCR were cloned into pTZ18R for sequence analysis. For analysis of Ap<sup>S</sup> *S. enteritidis* strains after gene replacement, PCR-generated products from the chromosome containing *sefA* or *agfA* and surrounding region were ligated into the A-T cloning vector, pGEM-T. To ensure the correct DNA sequence was obtained and to resolve errors due to *Taq* DNA polymerase, three individual pGEM-T isolates from 20 each *S. enteritidis* strain were sequenced. Plasmid DNA used for sequence analysis was prepared using the QIAprep spin miniprep kit (Qiagen, CA). Sequencing primers used were the M13 universal forward and reverse primers. Sequencing was carried out using an Applied Biosystems Model 377 DNA Sequencing System and the PRISM Big Dye Primer or Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer). 25 Sequence data was analyzed using DNASTAR Lasergene software (DNASTAR, Inc.).

Expression of chimeric fimbrin genes in *E. coli*. Expression of *sefA::PT3* and *agfA::PT3* in *E. coli* using T7 RNA polymerase was performed according to the method of Tabor and Richardson [44]. *E. coli* XL-1 Blue was co-electroporated with purified plasmids pTZAP7, pTZAgf, pTSP10, pTZSef or pTZ18R 30 (control) along with pGP1-2. Cultures were grown in TFB/ApKm for 18 h (28°C, 200 rpm), one volume of pre-warmed media was added and the cultures were grown at 42°C

for 3 h to induce production of the cloned gene products. Cells were harvested at 4,000 rpm, normalized to 1.0 A<sub>600</sub>, and processed as reported for *S. enteritidis* 3b [10] before SDS-PAGE and Western blotting.

Preparation of immune serum. Purified synthetic PT3 peptide was coupled to soluble keyhole limpet hemocyanin (KLH; Sigma) using glutaraldehyde [19]. Purified KLH-PT3 (330 mg) was resuspended in dH<sub>2</sub>O and emulsified in complete Freund's adjuvant prior to subcutaneous and intramuscular injections of a female New Zealand White rabbit. Two booster doses of KLH-PT3 (330 mg) emulsified in incomplete Freund's adjuvant were given at 4 week intervals. Titers of the immune serum were determined by enzyme-linked immunosorbent assay (ELISA) against the PT3 peptide. The rabbit was exsanguinated 4 weeks following the final booster injection. This serum was passaged over an immunoaffinity column which was prepared by coupling PT3 to CNBr-activated Sepharose 4B (Pharmacia) following procedures outlined by the manufacturer. The eluate from this column was pooled, tested for reactivity to PT3 by ELISA, and concentrated 10-fold using an ultrafiltration cell (Amicon model #8010) with a YM10 membrane (Amicon). This concentrated antibody solution was used as the final PT3-specific immune serum. Immune sera to whole SEF14 and SEF17 fimbriae have been previously described [8,11].

SDS-PAGE and Western blot analysis. For analysis of *S. enteritidis* strains after *sefA::PT3* gene replacement, cells from 1ml of 1 A<sub>600</sub> culture were harvested, resuspended in 200 ml of SDS-PAGE sample buffer supplemented with 0.2 M glycine (pH 2), and boiled for 10 min. This cell extract was clarified by spinning in a microcentrifuge (13,200 rpm, 5 min.) and used directly for SDS-PAGE analysis [7]. For analysis of *S. enteritidis* strains after *agfA::PT3* gene replacement, cells were scraped from TCR plates using a glass slide and resuspended in 1 ml Tris buffer (10mM Tris, pH 7.5). Aliquots of this cell slurry were mixed with an equal volume of 2 x SDS-PAGE sample buffer supplemented with 0.2 M glycine (pH 2) and boiled for 10 min. The cell extract was clarified as above and used directly for SDS-PAGE. The insoluble glycine extracted cell material was washed 3 x in 0.5 ml dH<sub>2</sub>O and treated with 90% formic acid before SDS-PAGE analysis as previously described [11]. For analysis of acetone-precipitated culture supernatant proteins, 1ml of T broth culture was clarified as

above and 250 ml of culture supernatant was aliquoted and mixed with 1 ml of ice-cold acetone. The precipitated proteins were sedimented (13,200 rpm, 20 min, 4°C), the supernatant was discarded and the protein pellet was dried for 20 min under vacuum. The pellet was resuspended and boiled for 10 min in 1x SDS-PAGE sample buffer 5 supplemented with 0.2 M glycine (pH 2) before loading onto SDS-PAGE. SDS-PAGE was carried out according to the method of Laemmli [27] with a 5% stacking gel and 12% resolving gel. Proteins separated by SDS-PAGE were electrophoretically transferred to nitrocellulose using an LKB Multiphor II Electrophoresis System (Pharmacia Biotech) and were detected by Western blot techniques using fimbriae- or 10 PT3-specific antisera and goat-anti-rabbit immunoglobulin G-alkaline phosphatase conjugates (Cedarlane) as described previously [11].

## Results

Generation of chimeric *S. enteritidis* fimbrin genes The *S. enteritidis* 3b 15 fimbrin genes, *sefA* and *agfA* were chosen as target DNA sequences to receive a site-specific epitope replacement. The two-step overlap extension PCR method of Horton *et al.* [22] was used (Figure 17A, B) to replace 48 bp of the fimbrin gene with 48 bp encoding the PT3 T cell epitope from *L. major* (Figure 17C). The PCR-generated genes encoded chimeric SefA and AgfA proteins carrying the PT3 epitope within specific 20 regions of the mature protein (residues 18-33 in SefA and residues 111-126 in AgfA). The resultant *sefA::PT3* and *agfA::PT3* PCR products were sequenced to confirm the fidelity of PCR and were cloned into pHSG415 (Figure 18A) to generate recombinant temperature-sensitive plasmids pHSSP10 and pHSP7, respectively (Table 6).

Gene Replacement in *S. enteritidis*. The recombinant temperature- 25 sensitive pSC101-derivative plasmids, pHSSP10 and pHSP7, were used to replace the native genes in *S. enteritidis* 3b (Figure 18B). Cells were transformed with pHSSP10 or pHSP7 and directly plated on selective media (LB/Ap) at the non-permissive temperature (42°C), but virtually no plasmid cointegrates were obtained. Therefore, cells were grown 24h in liquid media (TFB/Ap) and transferred five times into fresh 30 media for a total growth period of 120 h before plating on LB/Ap. Of the 50 isolated colonies picked for both pHSSP10 and pHSP7, 100% of colonies were identified by

PCR to contain an integrated plasmid. Three pHSSP10 cointegrate colonies and four pHsap7 cointegrate colonies were then selected and grown at the permissive temperature of 28°C in liquid media (TFB) without Ap selection pressure for 24 h and transferred three times into fresh media for a total growth period of 72 h. Dilution plating of these final colonies resulted in the same number of CFU on both LB and LB/Ap plates, suggesting that the majority of cells were still Ap<sup>R</sup> (42°C). However, after an additional growth period of 48 h (120 h total) at 28°C, a high percentage of Ap<sup>S</sup> colonies was obtained. 184 isolated colonies were picked from each cointegrate culture, yielding 65%, 55%, and 5% Ap<sup>S</sup> from the three pHSSP10 cointegrates, and 27%, 15%, 10% and 9% Ap<sup>S</sup> from the four pHsap7 cointegrates (Table 8). pHSSP10 and pHsap7 cointegrate colonies were also grown at the non-permissive temperature (42°C) without Ap selection pressure (120 h). In contrast to the cultures grown at 28°C, no Ap<sup>S</sup> colonies were obtained.

15 Table 8. Efficiency of *sefA::PT3* and *agfA::PT3* gene replacement in *S. enteritidis*.

Plasmid cointegrate colonies	Ap <sup>S</sup> colonies <sup>a</sup> #	Chimeric gene %	replacements (%)
<b>pHSSP10</b>			
Isolate #1	119	65	33 <sup>b</sup>
Isolate #2	8	4	2 <sup>b</sup>
Isolate #19	101	55	23 <sup>b</sup>
<b>pHSAP7</b>			
Isolate #2	18	10	7 <sup>c</sup>
Isolate #3	28	15	10 <sup>c</sup>
Isolate #9	49	27	4 <sup>c</sup>
Isolate #10	17	9	8 <sup>c</sup>

<sup>a</sup> 184 individual colonies picked in total.

<sup>b</sup> Frequency of *sefA::PT3* containing *S. enteritidis* estimated by preliminary PCR results.

20 <sup>c</sup> Frequency of *agfA::PT3* containing *S. enteritidis* estimated by CR binding morphology (TCR).

Genetic analysis of *S. enteritidis* strains containing chimeric *sefA::PT3* or *agfA::PT3* fimbrin genes. To identify *S. enteritidis* strains containing the chimeric

sefA::PT3 gene, twenty-eight of the final Ap<sup>S</sup> colonies were chosen and analyzed by PCR. Sixteen colonies were identified as having the PT3 DNA sequence within sefA and all twenty-eight colonies were negative for the pSC101 ori sequence found in pHSG415. Furthermore, PCR products were the same size as PCR products of sefA from *S. enteritidis* 3b indicating that no extra plasmid sequence was inserted in this region. Four *S. enteritidis* strains were further analyzed by Southern blotting using DNA probes specific for the PT3 DNA sequence, the region within sefA replaced by the PT3 DNA sequence, the region in sefA 3' to the PT3 insertion site, or the entire EcoRI and HindIII digested pHSG415 plasmid sequence. These data confirmed the PCR results; two of the strains contained sefA::PT3, two strains contained wild-type sefA, and all four strains did not contain any pHSG415 plasmid sequence. Final confirmation of the genotype of these four strains was obtained by DNA sequencing (see Materials and Methods), proving that all four strains contained the correct, predicted gene sequences.

To identify *S. enteritidis* strains containing the chimeric agfA::PT3 gene, five of the final Ap<sup>S</sup> colonies were chosen and were analyzed by PCR. Three strains were identified as having the PT3 DNA sequence within agfA and all five strains were negative for the pSC101 ori sequence as above. PCR products from each strain were the same size as PCR products of agfA from *S. enteritidis*, indicating that there was no additional plasmid sequence inserted in this region. Final confirmation of the genotypes of these strains was obtained by DNA sequencing proving that three strains contained agfA::PT3 and two strains contained wild-type agfA. Thus, these data confirmed the creation of *S. enteritidis* strains containing chimeric sefA::PT3 or agfA::PT3 fimbrin genes by precise recombination events.

Plasmid-based expression of sefA::PT3 and agfA::PT3 in *E. coli*. To ensure that the chimeric genes used for gene replacement in *S. enteritidis* could be readily transcribed and translated into protein, these genes were expressed in *E. coli* XL-1 Blue utilizing T7 RNA polymerase [44]. Expression of the sefA and sefA::PT3 genes from pTZSef and pTZSP10 was demonstrated by Western blot analysis (Figure 19A). Both the recombinant SefA::PT3 proteins and wild-type SefA proteins were expressed at comparable levels (Figure 19A, lanes 2 and 3) and two distinct

immunoreactive protein bands (14 kDa and 16-17 kDa) were seen in each lane. The larger protein was thought to be unprocessed wild-type or chimeric SefA possessing the 22-amino acid signal sequence as observed previously [37]. The smaller protein was identified as the mature form of the fimbrin, since the band co-migrated with SefA from purified SEF14 (Figure 19A, lane 4). Repeat of these blots with PT3-specific immune serum did not reveal either the 14 or 16 kDa protein band in lane 3, suggesting that the PT3 epitope was inaccessible or not exposed on the surface of the chimeric SefA::PT3 protein.

Western blotting also showed expression of the *agfA* and *agfA::PT3* genes from pTZAgf and pTZAP7 in *E. coli* (Figure 19B). Both the recombinant AgfA::PT3 proteins and wild-type AgfA proteins were observed in SDS-PAGE sample buffer-glycine-insoluble material from whole cells treated with formic acid (Figure 19B, lanes 5 and 6). Both were expressed at comparable levels and were the same size as mature AgfA from purified thin aggregative fimbriae (17 kDa; Figure 19B, lane 1), although a second 10 kDa band was seen for AgfA::PT3 (Figure 19B, lane 6), suggesting that some degradation had occurred. AgfA was not detected in SDS-PAGE sample buffer-glycine extracts of whole cells (Figure 19B, lane 2). In contrast, AgfA::PT3 was observed in these samples (Figure 19B; lane 3), indicating that AgfA::PT3 was more soluble than wild-type AgfA. Repeat of these blots with PT3-specific immune serum confirmed that the bands in lanes 3 and 6 were indeed chimeric AgfA::PT3 protein.

Chromosome-based expression of *sefA::PT3* in *S. enteritidis*. Western blot analysis of the four *S. enteritidis* strains which were shown to contain either *sefA::PT3* or *sefA* after gene replacement is shown in Figure 20. Strains containing *sefA::PT3* (#13 and 192) were negative for the chimeric fimbrin protein SefA::PT3 (Figure 20, lanes 3 and 4), whereas strains containing *sefA* (#11 and 197) were positive for the wild-type fimbrin protein SefA (Figure 20, lanes 2 and 5). All strains were positive for the expression of FimA (21 kDa), the subunit protein of Type 1 fimbriae (Figure 20, lanes 2-6). The predicted SefA::PT3 protein was not found when Westerns were repeated using a mixture of monoclonal antibodies against SefA. Furthermore, SefA::PT3 was not being secreted into the culture supernatant since trichloroacetic acid

(TCA) precipitation of *S. enteritidis* culture supernatant followed by SDS-PAGE/Western blotting did not reveal the recombinant protein. Further Western analysis of strain #13 confirmed that the strain was not producing SefA::PT3 under 16 different growth conditions. Similar results were obtained for all recombinant *S. enteritidis* strains that were PCR-positive for the *sefA::PT3* gene. These results demonstrated that *S. enteritidis* strains containing *sefA::PT3* were not expressing the chimeric fimbrin protein.

Chromosome-based expression of *agfA::PT3* in *S. enteritidis*. Since *S. enteritidis* 3b forms distinct dark red, aggregative colonies when grown on T media with Congo Red (TCR) and expression of AgfA (thin aggregative fimbriae) is associated with both properties [10], all Ap<sup>s</sup> *S. enteritidis* strains obtained after *agfA::PT3* gene replacement were streaked onto TCR plates. Based on previously established nomenclature [10], three distinct phenotypes were observed: a) red, aggregative (rough) (RR) colonies, b) orange, non-aggregative (smooth) (OS) colonies, and c) pink, non-aggregative (smooth) (PS) colonies; of 112 Ap<sup>s</sup> colonies obtained and characterized, 60 were RR, 39 were OS, and 13 were PS. The two *S. enteritidis* strains shown to contain wild-type *agfA* sequence (#91 and 104) were identified as being RR like *S. enteritidis* 3b. On the other hand, of the three *S. enteritidis* strains shown to contain *agfA::PT3* sequence, two displayed the OS phenotype (#102 and 103), while the third displayed the PS phenotype (#27).

Western blot analysis of these five *S. enteritidis* strains scraped from TCR plates (see Materials and Methods) is shown in Figure 21. As expected, the two RR strains expressed wild-type AgfA which was only present in SDS-PAGE sample buffer-glycine-insoluble material treated with 90% formic acid (Figure 21B, lanes 2 and 5), as demonstrated for *S. enteritidis* 3b (Figure 21B, lane 6). The two OS strains produced an immunoreactive 17 kDa protein (Figure 21A or B, lanes 3 and 4), indicating they were producing chimeric AgfA::PT3 protein. Furthermore, the 17 kDa protein was present in both SDS-PAGE sample buffer-glycine extracts of whole cells and glycine-insoluble material treated with formic acid, confirming that AgfA::PT3 was more soluble than wild-type AgfA as previously observed in *E. coli* (above). Immunoreactive higher M<sub>r</sub> bands representing multimers of AgfA::PT3 were also

observed (Figure 21B, lanes 3 and 4), suggesting that some polymerization of AgfA::PT3 subunits had occurred. In contrast to the OS strains analyzed, the PS strain #27 was negative for AgfA::PT3 when grown on TCR plates (Figure 22A or B, lane 7).

To investigate whether the *S. enteritidis* OS strains were secreting soluble AgfA::PT3 into the media, they were grown in T broth and the culture supernatant proteins were precipitated and analyzed by SDS-PAGE and Western blotting. Figure 22 represents replicate Western blots of these protein samples boiled in SDS-PAGE sample buffer with glycine, one reacted with immune serum generated against whole SEF17 (Figure 22, lanes 1-3) and the other reacted with immune serum generated against the PT3 peptide (Fig 22, lanes 4-6). Both OS strains revealed a soluble immunoreactive 18kDa protein which was recognized by both SEF17- and PT3-specific antiserum (Figure 22, lanes 2 and 5, 3 and 6), confirming that they were expressing chimeric AgfA::PT3 and secreting large amounts into the media. Amino-terminal sequencing of the 18-kDa protein band from OS strain #102 yielded the GVPQ sequence of mature AgfA [11], indicating that the size difference between these protein bands and wild-type AgfA from whole SEF17 (Figure 22A, lane 1) was not due to a failure to cleave the signal sequence. Analysis of the PS strain under the same conditions revealed a faint immunoreactive band of similar size, suggesting that this strain was also expressing AgfA::PT3, but at a much lower level than the two OS strains. Like the two OS strains, amino terminal sequencing of this protein band yielded a major signal of GVPQ. These results demonstrated the isolation of two genetically similar *S. enteritidis* strain types containing *agfA::PT3* which express the chimeric fimbrin protein at different levels.

The system for chromosomal gene replacement used for creation of *Salmonella* strains containing recombinant *agfA* was also used for creating *Salmonella* strains containing recombinant *sefA*. The *sefA* gene encodes SefA, the major subunit protein for SEF14 fimbriae produced by group D *Salmonella* spp. (Baumler and Heffron, 1995). SEF14 is a thin fimbriae like TAF, but unlike the TAF operon, the SEF14 operon encodes proteins which show homology to chaperone and usher proteins from other fimbrial systems (Clouthier et al., 1993). Therefore, SEF14 is proposed to assemble via the chaperone/usher pathway (Hultgren et al., 1996) and growth of the

fimbrial fiber is probably achieved from the base by addition of the subunits from the periplasmic side of the outer membrane (Mol and Oudega, 1996).

SefA as a carrier of the PT3 epitope Ten different 16 amino acid segments within SefA were chosen for replacement with the PT3 epitope and are highlighted in Figure 23. These replacement regions were chosen using several criteria: primary sequence alignment, region S1 (black); hydrophilicity, flexibility and accessibility plots, region S10 (orange); experimentally determined B-cell epitope regions, regions S2, S3, S4, and S5 (blue); and TnphoA mutagenesis data, regions S6, S7, S8 and S9 (green). In total, all 117 of 144 residues within SefA were replaced with the PT3 sequence in at least one of the chimeric fimbrial constructs.

Generation of *S. enteritidis* strains containing the *sefA::PT3* genes All recombinant *sefA::PT3* genes were generated by PCR, sequenced and introduced into the chromosome of *S. enteritidis*, replacing the *W<sup>+</sup>* *sefA* gene, using the procedure described for *agfA*.

Only *S. enteritidis* strains containing *sefA::PT3* #1, 2, 4, 5, 6, 8, 9, 10 in the chromosome were obtained. Western blots were used to analyze *S. enteritidis* strains containing *sefA::PT3* in the chromosome. The recombinant *S. enteritidis* strains S1, S2, S4, S5, S6, S8, S9, and S10 were grown on CFA plates at 37°C for 24 h and were analyzed for production of recombinant SefA proteins containing the PT3 epitope by SDS-PAGE and western blotting.

In contrast to the results with *agfA*, NO recombinant SefA fimbrial proteins could be detected in any of the recombinant *Salmonella* strains containing recombinant *sefA*. These data demonstrated that SefA was not a suitable carrier of heterologous (foreign) peptide sequences and could not tolerate substitution of its residues from the N- to C-terminus of the protein.

Since none of the recombinant SefA fimbrial proteins were able to be expressed in *Salmonella*, this provides evidence that fimbriae which assemble via the chaperone/usher pathway would not be good carriers of heterologous (foreign) peptide sequences. In addition, this finding further proves the utility and uniqueness of the AgfA/TAF presentation system described (i.e., the ability of AgfA to accept major

substitutions throughout its sequence and still have the ability to assemble into fimbrial fibers at the cell surface).

## Discussion

The invention described herein provides an efficient and facile strategy for the replacement of wild-type genes in the *S. enteritidis* chromosome with *in vitro*-altered versions. This gene replacement method allowed for efficient, site-specific chromosomal gene replacement without the need for selective markers in the target gene(s) or special bacterial strains for recombination, and avoided the introduction of non-target DNA sequences. The method was used to construct *S. enteritidis* strains containing chimeric *sefA* and *agfA* fimbrial genes which carry foreign DNA encoding the PT3 epitope from *L. major*. The *sefA::PT3* and *agfA::PT3* genes presented here represent the first chimeric fimbrial genes reported for the genus *Salmonella*.

The gene replacement method reported in this study employs pHSG415, derived from a temperature-sensitive pSC101 replicon [20]. Although other gene replacement methods using temperature-sensitive pSC101 replicons [18,30] have been reported, their results were less favorable than those reported here. The method of Hamilton *et al.* [18] results in final strains containing freely replicating plasmids which must be cured before selecting gene replacements, whereas the present method results in a high proportion of final strains which have lost the excised plasmid altogether and can be screened directly by PCR. The method of Link *et al.* [30] includes the *Bacillus subtilis* *sacB* system to enable direct selection for excision and loss of integrated plasmids. However, when creating deletion mutants of *hdeA* in *E. coli* without the use of selectable markers, these authors reported lower frequencies than are reported here (Table 8). In addition, the *sacB* system is complicated by the frequency of Suc<sup>R</sup> revertants [24,26].

A closer look at the properties of pHSG415 can help explain why this gene replacement method is so efficient. In contrast to pSC101, pHSG415 was shown to be extremely unstable in liquid culture in the absence of selection pressure, with as few as 60% of cells carrying the plasmid after 24 hr [5]. These authors speculated that the difference between pSC101 and pHSG415 was due to the absence of most of the

*par* locus in pHSG415. The pSC101 *par* locus has been very well characterized; it has been shown to alter the binding of proteins within the origin region [23] and thus to enhance DNA replication [32]. In addition, it contains a preferential binding site for DNA gyrase [48] and alters the negative supercoiling of DNA [35]. Through a combination of these effects the *par* locus promotes partitioning of plasmids to daughter cells at the time of cell division [34]. Due to the deletion of the *par* locus, pHSG415 is proposed to have a defect in its segregating properties causing unequal partitioning of plasmid molecules to daughter cells at the time of cell division [5]. The present method uses the unstable properties of pHSG415 to advantage, and in the absence of selection pressure, integrated plasmids are lost immediately after the second crossover event or are retained for several generations and then lost. This would explain why an additional growth period of 48 hours (after the initial 72 hours) was sufficient to result in a high percentage of Ap<sup>s</sup> colonies when grown at 28°C. Thus, it is possible to replace *sefA* and *agfA* in the chromosome of a wild-type strain of *S. enteritidis* without any antibiotic resistance markers in the target genes at an efficiency of 30% and 10%, respectively.

It is possible that the high gene replacement frequencies observed simply reflect the relative ease of *sefA* or *agfA* replacement. However, a recent study by Edwards *et al.* [14] reported the replacement of *sefA* or *agfA* within *S. enteritidis* at lower frequencies than reported here, even with the use of a Km<sup>R</sup> marker in the recombinant genes. This supports the utility of the present method and demonstrates that the high replacement frequencies reported here are not simply due to the ease of *sefA* or *agfA* replacement. Therefore, this method has broad application and appeal for gene replacement in *Salmonella* and other enteric bacteria capable of supporting the replication of pSC101-derived plasmids. In addition, these results suggest that the use of similar "unstable" plasmids in other organisms could represent a more generalized mutagenesis strategy.

The *sefA::PT3* and *agfA::PT3* genes presented here both carry a foreign DNA segment encoding PT3, a Th<sub>1</sub>-restricted T cell epitope comprising residues 154-168 from the GP63 protein of *L. major* [25]. This epitope was chosen because it was shown to be immunoprotective in Balb/c mice [41] and because studies with *Salmonella* vaccine strains expressing GP63 have demonstrated that oral vaccination against

*Leishmania* infection is possible [33]. Therefore, PT3 is a good candidate for developing and testing a heterologous fimbrial vaccine system in *Salmonella*. The subunit proteins of SEF14 and SEF17 fimbriae, SefA and AgfA, respectively, were chosen as the carriers of PT3 because they can be expressed at high levels and are surface-exposed [8,11], properties proven to be advantageous for other heterologous epitope presentation systems [28]. Moreover, SEF14 and SEF17 represent distinct classes of fimbriae in *S. enteritidis* 3b [31] and differ in their primary fimbrin sequence, probable tertiary structure, expression patterns, mode of assembly, and biochemical properties.

Two *S. enteritidis* strains that contained *sefA*::PT3 were identified, genetically characterized and analyzed for expression of the chimeric fimbrin proteins. While SefA::PT3 protein was produced in *E. coli*, indicating that the *sefA*::PT3 gene construct had the correct coding sequence, the chimeric protein could not be detected in *S. enteritidis*. This could be due to a number of factors: alteration in the DNA topology of the chromosome effecting transcription initiation; production of an unstable RNA transcript; or expression of a significantly misfolded and rapidly degraded protein, due to the positioning of PT3 in the N-terminal region of SefA, a region important for dimerization of wild-type SefA subunits [6]. Experiments to identify more permissible sites for foreign epitope replacement within SefA are currently underway.

Three *S. enteritidis* strains that contained *agfA*::PT3 were identified, genetically characterized and analyzed for expression of the chimeric fimbrin proteins. In contrast to the *sefA*::PT3 mutants, two of these strains were shown to produce the chimeric fimbrin protein at high levels. These strains displayed a distinct orange, non-aggregative (smooth) (OS) phenotype when plated on TCR medium, in contrast to the red, aggregative (rough) (RR) phenotype displayed by *S. enteritidis* 3b. Closer analysis of the AgfA::PT3 protein demonstrated that it had unexpected properties; whereas wild-type AgfA required pre-treatment in 90% formic acid to enter polyacrylamide gels, the chimeric AgfA::PT3 protein was readily seen by SDS-PAGE without formic acid treatment. The third strain containing *agfA*::PT3 had properties quite different than the other two. It produced much lower levels of chimeric AgfA::PT3 protein under the growth conditions tested and gave a third distinct phenotype when plated on TCR

medium, displaying pink, non-aggregative (smooth) (PS) colonies. This PS strain was shown to contain no sequence errors within *agfA::PT3* and surrounding region (950 bp), thereby suggesting that gene replacement within the *agfBAC* operon of *S. enteritidis* can somehow affect fimbriae biosynthesis. The PS phenotype was similar to that previously reported for SEF17-deficient *TnphoA* mutants of *S. enteritidis* 3b [10]. Römling *et al.* [38] observed similar pink, smooth colonies for *S. typhimurium* on CR media and showed that a single base pair change in the *agfD* promoter sequence was responsible for the mutant phenotype and lack of AgfA production. Allen-Vercoe *et al.* [1] have also recently described AgfA<sup>-</sup> *S. enteritidis* mutants with a pink, smooth phenotype on CR media and have characterized these strains as expressing a new, as yet undetermined fimbrial type. In light of these recent findings, the nature of the differences between the OS and PS *agfA::PT3* strains are currently under investigation.

*SefA::PT3* and *agfA::PT3* represent the first chimeric fimbrial genes reported for the genus *Salmonella*. These genes were replaced at the sites in the chromosome originally occupied by the wild-type fimbrial genes so as to maintain the appropriate relationship with any potential upstream regulatory sequences. Thus, the recombinant *S. enteritidis* strains that have been created are genetically identical to the W<sup>+</sup> strain with the exception of the 48 bp foreign DNA sequence. The gene replacement strategy presented allows for the rapid generation of similar *S. enteritidis* vaccine strains without the need for antibiotic resistance markers and/or the screening of thousands of colonies for a “rare” double crossover event. Strains created in this manner can then be used in future vaccine studies without the complications associated with extraneous DNA elements.

25 REFERENCES CITED IN EXAMPLE 2

Bäumler A.J. et al. (1995). *J. Bacteriol.*, 177, 2087-2097.

Clouthier S.C. et al. (1993). *J. Bacteriol.*, 175, 2523-2533.

- [1] Allen-Vercoe E., Dibb-Fuller M., Thorns C.J., Woodward M.J. SEF17 fimbriae are essential for the convoluted colonial morphology of *Salmonella enteritidis*. *FEMS Microbiol. Lett.* 1997, 153, 33-42.
- 5 [2] Bakker D., van Zijderveld F.G., van der Veen S., Oudega B., de Graaf F.K. K88 fimbriae as carriers of heterologous antigenic determinants. *Microb. Pathog.* 1990, 8, 343-352.
- 10 [3] Bäumler A.J., Heffron F. Identification and sequence analysis of *lpfABCDE*, a putative fimbrial operon of *Salmonella typhimurium*. *J. Bacteriol.* 1995, 177, 2087-2097.
- [4] Cárdenas L., Clements J.D. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. *Vaccine* 1993, 11, 126-135.
- 15 [5] Caulcott C.A., Dunn A., Robertson H.A., Cooper N.S., Brown M.E., Rhodes P.M. Investigation of the effect of growth environment on the stability of low-copy-number plasmids in *Escherichia coli*. *J. Gen. Microbiol.* 1987, 133, 1881-1889.
- [6] Clouthier S.C., Collinson S.K., Lippert D., Ausio J., White A.P., Kay W.W. Periplasmic and fimbrial SefA from *Salmonella enteritidis*. *Biochem. Biophys. Acta* 1998, 1387, 355-368.
- 20 [7] Clouthier S.C., Collinson S.K., White A.P., Banser P.A., Kay W.W. tRNA<sup>Arg</sup> (*fimU*) and Expression of SEF14 and SEF21 in *Salmonella enteritidis*. *J. Bacteriol.* 1998, 180, 840-845.
- [8] Clouthier S.C., Müller K.-H., Doran J.L., Collinson S.K., Kay W.W. Characterization of three fimbrial genes, *sefABC*, of *Salmonella enteritidis*. *J. Bacteriol.* 1993, 175, 2523-2533.
- 25 [9] Collinson S.K., Clouthier S.C., Doran J.L., Banser P.A., Kay W.W. *Salmonella enteritidis agfBAC* operon encoding thin, aggregative fimbriae. *J. Bacteriol.* 1996, 178, 662-667.
- [10] Collinson S.K., Doig P.C., Doran J.L., Clouthier S., Trust T.J., Kay W.W. Thin, aggregative fimbriae mediate binding of *Salmonella enteritidis* to 30 fibronectin. *J. Bacteriol.* 1993, 175, 12-18.

- [11]Collinson S.K., Emödy L., Müller K.-H., Trust T.J., Kay W.W. Purification and characterization of thin, aggregative fimbriae from *Salmonella enteritidis*. *J. Bacteriol.* 1991, 173, 4773-4781.
- [12]Coulson N.M., Fulop M., Titball R.W. Effect of different plasmids 5 on colonization of mouse tissues by the aromatic amino acid dependent *Salmonella typhimurium* SL 3261. *Microb. Pathog.* 1994, 16, 305-311.
- [13]Curtiss III R., Kelly S.M., Tinge S.A., Tacket C.O., Levine M.M., Srinivasan J., Koopman M. Recombinant *Salmonella* vectors in vaccine development. *Dev. Biol. Stand.* 1994, 82, 23-33.
- 10 [14]Edwards R.A., Keller L.H., Schifferli D.M. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. *Gene* 1998, 207, 149-157.
- [15]Evans D.G., Evans D.J.J., Tjoa W. Hemagglutination of human group A erythrocytes by enterotoxigenic *Escherichia coli* isolated from adults with 15 diarrhea: correlation with colonization factor. *Infect. Immun.* 1977, 18, 330-337.
- [16]Feutrier J., Kay W.W., Trust T.J. Purification and characterization of fimbriae from *Salmonella enteritidis*. *J. Bacteriol.* 1986, 168, 221-227.
- [17]Flynn J.L., Weiss W.R., Norris K.A., Seifert H.S., Kumar S., So M. Generation of a cytotoxic T-lymphocyte response using a *Salmonella* antigen-delivery 20 system. *Mol. Microbiol.* 1990, 4, 2111-2118.
- [18]Hamilton C.M., Aldea M., Washburn B.K., Babitzke P., Kushner S.R. New method for generating deletions and gene replacements in *Escherichia coli*. *J. Bacteriol.* 1989, 171, 4617-4622.
- [19]Harlow E., Lane D. Antibodies: a laboratory manual. Cold Spring 25 Harbor, N. Y.: Cold Spring Harbor Laboratory, 1988.
- [20]Hashimoto-Gotoh T., Franklin F.C.H., Nordheim A., Timmis K.N. Specific-purpose plasmid cloning vectors: I. Low copy number, temperature-sensitive, mobilization defective pSC101-derived containment vectors. *Gene* 1981, 16, 227-235.
- 30 [21]Hone D., Attridge S., van den Bosch L., Hackett J. A chromosomal integration system for stabilization of heterologous genes in *Salmonella* based vaccine strains. *Microb. Pathog.* 1988, 5, 407-418.

- [22]Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., Pease L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* 1989, 77, 61-68.
- [23]Ingmer H., Cohen S.N. The pSC101 *par* locus alters protein-DNA interactions *in vivo* at the plasmid replication origin. *J. Bacteriol.* 1993, 175, 6046-6048.
- [24]Jäger W., Schäfer A., Pühler A., Labes G., Wohlleben W. Expression of the *Bacillus subtilis* *sacB* gene leads to sucrose sensitivity in the gram-positive bacterium *Corynebacterium glutamicum* but not in *Streptomyces lividans*. *J. Bacteriol.* 1992, 174, 5462-5465.
- [25]Jardim A., Alexander J., Teh H.S., Ou D., Olafson R.W. Immunoprotective *Leishmania major* synthetic T cell epitopes. *J. Exp. Med.* 1990, 172, 645-648.
- [26]Kaniga K., Delor I., Cornelis G.R. A wide-host-range suicide vector for improving reverse genetics in Gram-negative bacteria: inactivation of the *blaA* gene of *Yersinia enterocolitica*. *Gene* 1991, 109, 137-141.
- [27]Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (London)* 1970, 227, 680-685.
- [28]Levi R., Arnon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. *Vaccine* 1996, 14, 85-92.
- [29]Levine M.M., Galen J., Barry E., Noriega F., Chatfield S., Sztein M., Dougan G., Tacket C. Attenuated *Salmonella* as live oral vaccines against typhoid fever and as live vectors. *J. Biotech.* 1996, 44, 193-196.
- [30]Link A.J., Phillips D., Church G.M. Methods for generating precise deletions and insertions in the genome of wild-type *Escherichia coli*: application to open reading frame characterization. *J. Bacteriol.* 1997, 179, 6228-6237.
- [31]Low D., Braaten B., van der Woude M. Fimbriae. In: *Escherichia coli and Salmonella*. (Ed Neidhardt, F. C.). American Society for Microbiology, Washington DC, 1996, pp. 146-157.
- [32]Manen D., Goebel T., Caro L. The *par* region of pSC101 affects plasmid copy number as well as stability. *Mol. Microbiol.* 1990, 4, 1839-1846.

- [33]McSorley S.J., Xu D., Liew F.Y. Vaccine efficacy of *Salmonella* strains expressing glycoprotein 63 with different promoters. *Infect. Immun.* 1997, 65, 171-178.
- [34]Meacock P.A., Cohen S.N. Partitioning of bacterial plasmids during 5 cell division: a *cis*-acting locus that accomplishes stable plasmid inheritance. *Cell* 1980, 20, 529-542.
- [35]Miller C.A., Beaucage S.L., Cohen S.N. Role of DNA superhelicity in partitioning of the pSC101 plasmid. *Cell* 1990, 62, 127-133.
- [36]Mol O., Oudega B. Molecular and structural aspects of fimbriae 10 biosynthesis and assembly in *Escherichia coli*. *FEMS Microbiol. Rev.* 1996, 19, 25-52.
- [37]Müller K.-H., Trust T.J., Kay W.W. Fimbriation genes in *Salmonella enteritidis*. *J. Bacteriol.* 1989, 171, 4648-4654.
- [38]Römling U., Sierralta W.D., Eriksson K., Normark S. Multicellular and aggregative behaviour of *Salmonella typhimurium* strains is controlled by mutations 15 in the *agfD* promoter. *Mol. Microbiol.* 1998, 28, 249-264.
- [39]Rosner J.L. Formation, induction and curing of bacteriophage P1 lysogens. *Virology* 1972, 48, 679.
- [40]Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, N. Y., Cold Spring Harbor Laboratory, 1989.
- 20 [41]Spitzer N., Jardim A., Lippert D., Olafson R.W. Long term protection of mice against *Leishmania major* with a synthetic peptide vaccine. *Vaccine* 1998, In press.
- [42]Stentebjerg-Olesen B., Pallesen L., Jensen L.B., Christiansen G., Klemm P. Authentic display of a cholera toxin epitope by chimeric type 1 fimbriae: 25 effects of insert position and host background. *Microbiology* 1997, 143, 2027-2038.
- [43]Strugnell R.A., Maskell D., Fairweather N., Pickard D., Cockayne A., Penn C., Dougan G. Stable expression of foreign antigens from the chromosome of *Salmonella typhimurium* vaccine strains. *Gene* 1990, 88, 57-63.
- [44]Tabor S., Richardson C.C. A bacteriophage T7 RNA 30 polymerase/promoter system for controlled exclusive expression of specific genes. *Proc. Natl. Acad. Sci. USA* 1985, 82, 1074-1078.

[45]van Die I., van Oosterhout J., van Megan I., Bergmans H., Hoekstra W., Enger-Valk B., Barteling S., Mooi F. Expression of foreign epitopes in P-fimbriae of *Escherichia coli*. *Mol. Gen. Genet.* 1990, 222, 297-303.

- [46]Verma N.K., Ziegler H.K., Stocker B.A.D., Schoolnik G.K.  
5 Induction of a cellular immune response to a defined T-cell epitope as an insert in the flagellin of a live vaccine strain of *Salmonella*. *Vaccine* 1995, 13, 235-244.

[47]Verma N.K., Ziegler H.K., Wilson M., Khan M., Safley S., Stocker B.A.D., Schoolnik G.K. Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin of *Listeria monocytogenes* by attenuated *Salmonella*. *Vaccine* 1995, 13,  
10 142-150.

[48]Wahle E., Kornberg A. The partition locus of plasmid pSC101 is a specific binding site for DNA gyrase. *EMBO J.* 1988, 7, 1889-1895.

[49]Xu D., McSorley S.J., Chatfield S.N., Dougan G., Liew F.Y.  
Protection against *Leishmania major* infection in genetically susceptible Balb/c mice by  
15 GP63 delivered orally in attenuated *Salmonella typhimurium* (AroA<sup>-</sup>AroD<sup>-</sup>).  
*Immunology* 1995, 85, 1-7.

20

### EXAMPLE 3

#### DEMONSTRATION OF THE VACCINE POTENTIAL OF *S. ENTERITIDIS* DISPLAYING CHIMERIC FIMBRINS CONTAINING A T CELL EPITOPE FROM *LEISHMANIA MAJOR*.

##### Introduction

25 Several strains of *S. enteritidis* carrying chromosomal chimeric fimbrin genes (*agfA::PT3*, above) were developed. The corresponding chimeric AgfA::PT3 proteins were expressed and assembled into SEF17 fimbriae as described above. These strains display the PT3 T cell epitope from the gp63 protein of *L. major* in large

quantities at the *S. enteritidis* cell surface. Recent work with the PT3 epitope proved that a single immunization of peptide in adjuvant was able to protect BALB/c mice against challenge with *L. major* (Spitzer *et al.*, 1998). Thus, the *S. enteritidis* strains containing *agfA::PT3* genes are promising candidates for the protection of BALB/c  
5 mice against *L. major* infection.

Infection of BALB/c mice with *L. major* has been very well studied. The immune response generated in BALB/c mice in response to *L. major* infection is reviewed in Locksley *et al.* (1999). To summarize, BALB/c mice are highly susceptible to *L. major* infection, whereas most other inbred mouse strains develop immunity and  
10 are able to control infection. Upon infection of BALB/c mice with *L. major* the majority of parasite-specific CD4 T cells (T helper cells or Th) generated are of the type 2 variety (Th2 cells) which push the immune response toward phagocyte-independent immunity and antibody production. In contrast, mice that resist *L. major* infection generate a majority of Th1 cells which are required for activation of phagocyte-  
15 dependent immunity or cell-mediated immunity. The balance between susceptibility and resistance to *L. major* infection seems to rely on the relative numbers of these two Th subspecies. It should be noted that the PT3 epitope was demonstrated to specifically induce proliferation of CD4 T cells of the Th1 subset (Jardim, 1994).

#### Materials and Methods

20 Animals. Inbred BALB/c mice were initially obtained from The Jackson Laboratory (Bar Harbor, ME) and bred at the McGill Research Institute (Montréal, Québec). Mice used for *L. major* vaccine trial were 8-10 weeks of age.

Bacterial Strains, Parasites, Media and Growth Conditions. *S. enteritidis*

27655 strain 3b has been previously described (Feutrier *et al.*, 1986). *S. enteritidis* strains A4, A5, and A8 were described above. *Leishmania major* carrying a reporter gene (Ha *et al.*, 1996) to simplify measurement of parasite number was used as the 5 virulent challenge strain.

For analysis of fimbrial production, *S. enteritidis* A4, A5, and A8 were grown in 10 ml T broth (Collinson *et al.*, 1991) or trypticase soy broth (TSB; Becton-Dickinson) statically or 200 rpm for 6, 24 or 48 h at 37 C. To prepare *S. enteritidis* for immunization of BALB/c mice, cells were grown in 5 ml TSB for 6 h at 37°C, 250 rpm 10 and 100 µl used to inoculate 100 ml T broth and incubated for a further 48 h at 37°C and 200 rpm. Cell density was determined by dilution plating onto trypticase soy agar (TSA). Subsequently, cultures were diluted to appropriate cell density in phosphate buffered saline (PBS) and used for immunization of BALB/c mice.

*L. major* was grown in SDM-79 medium (Brun and Schönenberger, 15 1979) supplemented with 10% fetal bovine serum and 5 µg/mL hemin.

Preparation of Protein Samples For SDS-PAGE. *S. enteritidis* A4, A5, A8 and 3b broth cultures were normalized to 1 A<sub>600</sub> and 1 ml cells were harvested, resuspended in 200 µl of SDS-PAGE sample buffer supplemented with 0.2 M glycine (pH 2), and boiled for 10 min. This cell extract was clarified by spinning in a 20 microcentrifuge (13,200 rpm, 5 min.) and used directly for SDS-PAGE analysis. The insoluble glycine-extracted cell material recovered by centrifugation was washed with dH<sub>2</sub>O and treated with 90% formic acid (Collinson, 1991; Collinson, 1993) before analysis by SDS-PAGE.

Gel Electrophoresis and Immunoblotting Procedures. SDS-PAGE was carried out according to the method of Laemmli (1970) with a 5% stacking gel and 12% resolving gel. Proteins separated by SDS-PAGE were electrophoretically transferred to nitrocellulose using an LKB Multiphor II Electrophoresis System (Pharmacia Biotech).

- 5 Proteins were detected by Western blot techniques using SEF17-specific immune serum and goat-anti-rabbit immunoglobulin G-alkaline phosphatase conjugates (Cedarlane) as described previously (Collinson et al., 1991).

Vaccination of Mice With *S. enteritidis*. BALB/c mice were deprived of food 16-18 h and water 1 h before vaccination. Immediately before administration of  
10 *Salmonella* or PBS, mice were administered 50 µl of 1% sodium bicarbonate orally. Two groups of 15 mice (males and females) were each then immunized orally with  $10^5$  CFU of *S. enteritidis* A4 or 3b in 200 µl PBS. Two groups of control animals received 200 µl PBS only. Two weeks after the first vaccination, one *S. enteritidis* 3b group received a second dose of  $10^3$  *S. enteritidis* 3b whole cells in 200 µl PBS, one *S.*  
15 *enteritidis* A4 group received a second dose of  $10^3$  *S. enteritidis* A4 whole cells in 200 µl PBS, and one control group received 200 µl PBS only. All oral inoculations were carried out with a stainless steel gavage needle without an anaesthetic. Mice were monitored daily for signs of infection.

Challenge With *L. major*. 5 vaccinated mice from each of the six  
20 vaccinated groups were challenged with  $10^7$  live *L. major* in 50 µl of PBS four or six weeks after the first vaccination or with  $5 \times 10^6$  live *L. major* in 50 µl of PBS eight weeks after first vaccination by subcutaneous injection in the right hind footpad. Infected footpad and noninfected footpad sizes were measured each week after *L. major*

infection until the end of the experiment using DigiMax electronic calipers. The net value for footpad inflammation (in millimeters) was calculated by subtracting the diameter of the noninfected footpad from the diameter of the infected footpad. Ulceration of infected footpads was also noted.

5 At the end of the experiment, all mice were sacrificed by overexposure to CO<sub>2</sub>. Blood was collected by cardiac puncture and the spleen was removed. In addition, the popliteal ganglion from the right leg, the large lobe of the liver, the infected and noninfected hind paws were removed, frozen in liquid nitrogen and stored at -80°C until further analysis. The mouse blood samples were stored at 4°C for 24 h,  
10 clotted material was spun down for 20 min at 13,200 rpm, and the immune serum was removed and stored at 20°C until use.

Estimation of Total Numbers of *L. major* in Infected Mouse Tissue.

Estimation of total numbers of *L. major* in the infected popliteal ganglion was performed by a limiting dilution assay (Titus, R. G. *et al.* 1985) and measurement of  
15 reporter gene activity following the procedure outlined by Bérubé *et al.* (1996).

Measurement of Antibody. PT3- or AgfA-specific antibodies were measured by the ELISA method (Engvall and Carlsson, 1976) involving 96-well DNA-bind plates (Corning-Costar) coated with either PT3 peptide, polymerized SEF17 or depolymerized SEF17 pre-treated with 90% formic acid at a concentration of 1 µg/well.  
20 Immune serum from each BALB/c mouse was tested in triplicate at a dilution of 1 in 100.

Statistics. Statistical significance was analyzed by determining the standard error of the mean (n = 5). If the mean values +/- standard error for different

groups of mice did not overlap, the results were considered significant (Duncan *et al.*, 1977).

## Results

5                   Optimizing Expression of SEF17 Fimbrial Fibers Displaying the PT3 Epitope. To determine the optimal conditions for expression of chimeric SEF17 fibers, *S. enteritidis* strains A4, A5, A8 were grown in TSB and T broth for 6, 24 or 48 h, static or shaking at 200 rpm. The cell pellets were harvested and the amount of cell-associated fimbrial material was determined by SDS-PAGE and immunoblotting.

10 Strains A4, A5 and A8 all produced maximal amounts of cell-associated AgfA::PT3 when grown for 48 h in T broth, shaking at 200 rpm (Table 9). The *S. enteritidis* 3b parental strain produced large amounts of cell-associated AgfA under most T broth conditions and was generally less variable in the amount detected with the cell pellet (Table 9). Cell-associated AgfA or AgfA::PT3 were not detected when strains were

15 grown in TSB (data not shown).

Strain A4 has been characterized further than other strains containing *agfA::PT3* (data not shown). Therefore, *S. enteritidis* A4 was chosen to be tested as a vaccine against *L. major*.

20 Table 9. Expression of cell-associated chimeric SEF17 under different growth conditions.

### Production of cell-associated SEF17<sup>b</sup>

	<u>6 h</u>	<u>24 h</u>	<u>48 h</u>
--	------------	-------------	-------------

Strain <sup>a</sup>	0 rpm <sup>c</sup>		200 rpm		0 rpm		200 rpm	
	0 rpm	200 rpm	0 rpm	200 rpm	0 rpm	200 rpm	0 rpm	200 rpm
3b	-	-	+++	+++	+++	+++	+++	+++
A4	-	-	+	++	+	++		
A5	-	-	++	+	++	++	+++	
5 A8	-	-	+	+	+	++	+++	

<sup>a</sup> *S. enteritidis* 27655-3b strains: parental strain 3b; *agfA::PT3* (A4, A5, A8).

<sup>b</sup> *S. enteritidis* strains were assessed for production of cell-associated chimeric SEF17 production after growth in T broth by SDS-PAGE and immunoblotting as described in Materials and Methods.

10 Presence of AgfA::PT3 on immunoblots was scored as follows: equal to parental 3b AgfA levels (+++); slightly reduced levels (++)

significantly reduced levels (+); not detectable (-).

<sup>c</sup> 0 rpm refers to static growth and 200 rpm refers to shaken cultures.

15 **Vaccine Dosage and Route of Delivery.** Preliminary experiments to test the virulence of *S. enteritidis* 3b in BALB/c mice showed that a safe oral vaccination dose was  $10^5$  organisms/mouse. After administration of this dose to BALB/c mice, no deaths were recorded after 10 days and no CFUs of *S. enteritidis* were detected in the spleens and livers of mice after 28 days of infection (data not shown).

20 **Vaccination of BALB/c Mice and Subsequent Challenge With *L. major*.**

The experimental outline for *S. enteritidis* vaccination and *L. major* challenge is shown in Table 10. BALB/c mice were vaccinated once with  $10^5$  cells of *S. enteritidis* A4 or 3b. Control mice were administered an equal volume of PBS orally. Two weeks later, selected groups of mice received a second oral dose of  $10^3$  cells of *S. enteritidis* A4 or 25 3b. Vaccinated mice were challenged in the footpad with *L. major* either 4, 6 or 8 weeks after the first vaccination and footpad swelling was monitored. Four weeks after *L. major* challenge, group 1 mice (challenged 4 weeks after first vaccination) were

sacrificed; there were no major differences in footpad inflammation between any of the mice (data not shown). There was notable increase in footpad inflammation with group 2 and 3 mice vaccinated with *S. enteritidis* A4 as compared to PBS-vaccinated control mice (Fig. 24 A-D). The largest difference between these two groups was observed in 5 group 3 mice challenged with *L. major* 8 weeks after vaccination (Fig. 24 C, D). In general, footpad inflammation in mice vaccinated with *S. enteritidis* 3b or A4 was very similar.

Table 10. *S. enteritidis* vaccination of BALB/c mice and challenge with *L. major*.

10	Inoculum <sup>a</sup>	<u>Vaccination<sup>b</sup></u>		<u><i>Leishmania major</i> challenge<sup>c</sup></u>		
		Day 0	Day 14	Week 4	Week 6	Week 8
	PBS	15 <sup>d</sup>	-	5	5	5
	3b	15	-	5	5	5
15	A4	15	-	5	5	5
	PBS	15	15	5	5	5
	3b	15	15	5	5	5
	A4	15	15	5	5	5

20 <sup>a</sup> *S. enteritidis* 27655-3b strains: parental strain 3b; A4 (*agfA::PT3#4*).

<sup>b</sup> Oral immunization of BALB/c mice with *S. enteritidis* 3b or A4 by gavage: 10<sup>5</sup> CFU in 200 µl PBS administered at Day 0, 10<sup>3</sup> CFU in 200 µl PBS administered at Day 14.

<sup>c</sup> Subcutaneous injection of live *L. major* into the right hind footpad of vaccinated BALB/c mice: 10<sup>7</sup> parasites in 50 µl PBS administered at Week 4 or 6, 5 x 10<sup>6</sup> parasites in 50 µl PBS administered at Week 8.

25 <sup>d</sup> Numbers listed in table refer to numbers of BALB/c mice in each group.

Parasite Load in the Popliteal Lymph Nodes. At the end of the *L. major* challenge experiment, mice were sacrificed and the right popliteal lymph nodes

removed. Lymph node cells were homogenized and parasite load was evaluated by limited dilution assay (Titus *et al.*, 1985) and measurement of reporter gene activity. Total reporter gene units and reporter gene units per mg of organ are represented for the 30 group 3 BALB/c mice challenged with *L. major* 8 weeks after vaccination (Fig. 25  
5 A, B). Popliteal lymph nodes from mice vaccinated once with *S. enteritidis* A4 had significantly lower reporter gene activity than the PBS-vaccinated control mice (Fig. 25B; group 3-3 versus 3-1). However, reporter gene activity levels for group 3-3 were higher than mice from control group 3-2, which received one dose of wild-type *S.*  
enteritidis 3b. More promising results were obtained for mice from group 3-6, which  
10 received two doses of the vaccine strain, *S. enteritidis* A4. Reporter gene activity levels in the lymph node tissue from these mice were significantly lower than both the PBS-vaccinated and *S. enteritidis* 3b-vaccinated groups of mice (Fig. 25B, groups 3-4, 3-5). This indicated that two vaccinations of BALB/c mice with *S. enteritidis* A4, which displays the *L. major* PT3 epitope at the cell surface, was enough to reduce the overall  
15 numbers of parasites.

Measurement of Antibody Levels in Mouse Serum. Immune sera from infected BALB/c mice were screened by ELISA for recognition of antigens carried by the *S. enteritidis* vaccine strain A4, specifically PT3 peptide and SEF17/AgfA (Fig. 26 A-C). The strongest antibody response against PT3 (Fig. 26A) and polymerized SEF17  
20 (Fig. 26B) was observed in mice from group 3-6, the group which received two vaccinations of *S. enteritidis* A4. These mean values were boosted by the strong response of one individual mouse in this group (data not shown). When immune sera were tested against SEF17 fimbriae which had been depolymerized into AgfA

monomers by treatment with 90% formic acid (Fig. 26C), group 3-6 again had a strong antibody response. These results indicated that several mice vaccinated with *S. enteritidis* A4 had produced antibodies specific for chimeric SEF17 fimbriae carrying the PT3 epitope.

5

## Discussion

In summary, two oral vaccinations with *S. enteritidis* A4, displaying chimeric fimbriae containing the PT3 epitope from *L. major* gp63, caused a reduction in overall numbers of *L. major* in the popliteal lymph nodes with respect to *S. enteritidis* 10 3b- or PBS-vaccinated control mice. This was recorded even though footpad inflammation had significantly increased in the *S. enteritidis* A4 vaccinated mice with respect to control mice. Also, mice from the *S. enteritidis* A4 vaccinated group developed a significant humoral immune response against both the PT3 epitope as well as the AgfA protein which was carrying it. Therefore, there is clear evidence that 15 presentation of the PT3 epitope in the context of SEF17 by *S. enteritidis* A4 was successful.

Several studies have reported vaccination of BALB/c mice against *Leishmania* by administering recombinant *Salmonella* vaccine strains producing the gp63 protein from *L. major* (González *et al.*, 1998; McSorley *et al.*, 1997; Xu *et al.*, 20 1995). The authors correlate a decrease in footpad inflammation after *L. major* challenge with decreased parasite loads and protection against *L. major* infection. Olivier *et al.* (1998) correlated decreased footpad inflammation in vaccinated BALB/c mice with a drop in parasite load in the popliteal lymph nodes. Here a similar drop in

Copyright © 2008, IAPress

parasite load in the popliteal ganglion of vaccinated mice occurred, but footpad inflammation had increased.

These differences may be due to the use of *S. enteritidis* as the carrier vaccine strain. *S. enteritidis* has been widely studied as a vaccine candidate chiefly to immunize poultry in a effort to reduce *Salmonella* load in chicken and egg products destined for human consumption. *S. enteritidis* can produce a sublethal, chronic infection in mice that is cleared over time (unpublished data), however, this *Salmonella* serotype is not normally studied as a carrier of heterologous antigens for vaccine efficacy trials in mice. It is not well characterized whether *S. enteritidis* will reach the appropriate mouse tissues to achieve optimum immune response against foreign epitopes which it is carrying. Hence, it is unknown what effect oral vaccination with *S. enteritidis* has on the BALB/c mice prior to challenge with *L. major*. In addition, *S. enteritidis* 3b has not been specifically attenuated for vaccine purposes.

Of all the *Salmonella* serovars available, *S. typhimurium*, the causative agent of murine typhoid, and *S. typhi*, the causative agent of human typhoid are the most well characterized with respect to vaccine development (Chatfield *et al.*, 1992; Chatfield *et al.*, 1993; Curtiss *et al.*, 1994; Roberts *et al.*, 1994; Levine *et al.*, 1996). Presentation of our chimeric fimbriae in the context of one of these well-characterized vaccine strains may lead to even greater success with the epitope delivery system described herein. Assembly of chimeric SEF17 fimbriae in these strains would also occur since the *agfA* operon and assembly systems are highly conserved among the Salmonellae (Römling *et al.*, 1998; Baumler *et al.*, 1997; Collinson *et al.*, 1996). Nevertheless, vaccination of BALB/c mice with *S. enteritidis* presenting the *Leishmania*

PT3 epitope resulted in generation of a specific immune response against the heterologous epitope and an overall reduction of *L. major* cell numbers in the vaccinated host.

#### REFERENCES CITED IN EXAMPLE 3

5

- Bäumler, AJ, et al. (1997). *Journal of Bacteriology*, **179**: 317-322.
- Berube, P, et al. (1996). *J Virol*, **70**: 4009-4016.
- Brun, R and M Schönenberger (1979). *Acta Trop.*, **36**: 289-292.
- Chatfield, S, et al. (1993). *FEMS Immunol Med Microbiol*, **7**: 1-7.
- Chatfield, SN, et al. (1992). *Microb Pathog*, **12**: 145-151.
- Collinson, SK, et al. (1996). *J. Bacteriol.*, **178**: 662-667.
- Collinson, SK, et al. (1993). *J. Bacteriol.*, **175**: 12-18.
- Collinson, SK, et al. (1991). *J. Bacteriol.*, **173**: 4773-4781.
- Curtiss III, R, et al. (1994). *Dev. Biol. Stand.*, **82**: 23-33.
- Duncan, RC, et al. (1977). *Introductory biostatistics for the health sciences*, John Wiley & Sons.
- Engvall, E and HE Carlsson (1976). In: Feldmann C, et al., ed. *Immunoenzymatic techniques*. Amsterdam, North-Holland.
- Feutrier, J, et al. (1986). *J. Bacteriol.*, **168**: 221-227.
- Gonzalez, CR, et al. (1998). *Vaccine*, **16**: 1043-1052.
- Ha, DS, et al. (1996). *Mol Biochem Parasitol*, **77**: 57-64.
- Jardim, AJ (1994). Immunological and biochemical characterization of the major surface membrane proteins: gp63 and the lipophosphoglycan associated protein of *Leishmania*, University of Victoria.
- Laemmli, UK (1970). *Nature (London)*, **227**: 680-685.
- Levine, MM, et al. (1996). *J. Biotech.*, **44**: 193-196.
- Locksley, RM, et al. (1999). *J Infect Dis*, **179 Suppl 2**: S305-308.
- McSorley, SJ, et al. (1997). *Infect. Immun.*, **65**: 171-178.
- Olivier, M, et al. (1998). *J Biol Chem*, **273**: 13944-13949.

- Roberts, M, et al. (1994). *Salmonella as carriers of heterologous antigens. Novel Delivery Systems for Oral Vaccines*, CRC Press Inc.
- Römling, U, et al. (1998). *Journal of Bacteriology*, **180**: 722-731.
- Spitzer, N, et al. (1999). *Vaccine*, **17**: 1298-1300.
- 5 Titus, RG, et al. (1985). *Parasite Immunol*, **7**: 545-555.
- Xu, D, et al. (1995). *Immunology*, **85**: 1-7.

## CLAIMS

1. A recombinant *agfA* gene in which a segment of the gene has been replaced by a segment of a foreign DNA sequence, that foreign sequence encoding a foreign epitope or antigen.

2. A recombinant *agfA* gene in which one or more segments of the gene have been replaced by segments of foreign DNA sequence(s), the foreign sequence(s) encoding a foreign epitope(s) or antigen(s).

3. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing recombinant AgfA fimbrin proteins in a strain of *Salmonella*.

4. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing recombinant AgfA fimbrin proteins in a strain of *E. coli*.

5. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing recombinant AgfA fimbrin proteins in a strain of Enerobacteriaceae.

6. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing stable fimbriae comprising recombinant AgfA protein in a strain of *Salmonella*.

7. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing stable fimbriae comprising recombinant AgfA protein in a strain of *E. coli*.

8. The recombinant gene according to any one of claims 1 and 2 wherein the said recombinant *agfA* gene is present in an expression vector construct capable of producing stable fimbriae comprising recombinant AgfA protein in a strain of *Enterobacteriaceae*.

9. The recombinant gene according to any one of claims 1-3, 6 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *Salmonella*.

10. The recombinant gene according to any one of claims 1-3, 6 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *Salmonella*, as a replacement of the native *agfA* gene.

11. The recombinant gene according to any one of claims 1,2,4,7 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *E. coli*.

12. The recombinant gene according to any one of claims 1,2,4,7 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *E. coli*. as a replacement of the native *csgA* gene.

13. The recombinant gene according to any one of claims 1,2,5,8 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *Enterobacteriaceae*.

14. The recombinant gene according to any one of claims 1,2,5,8 wherein the said recombinant *agfA* gene is present in the chromosome of a strain of *Enterobacteriaceae* as a replacement of the native homologous gene.

15. The recombinant gene according to any one of claims 1-14 wherein said recombinant gene is an *agfB* recombinant gene.

16. The recombinant gene according to any one of claims 1-14 wherein said recombinant gene is an *csgA* recombinant gene.

17. The recombinant gene according to any one of claims 1-14 wherein said recombinant gene is an *csgB* recombinant gene.

18. The recombinant gene according to any one of claims 1-14 wherein said recombinant gene is an Enterobacteriaceae homologue of the *agfA* or *agfB* recombinant genes.

19. The recombinant gene according to any one of claims 9, 10 wherein said recombinant strain of *Salmonella* is capable of producing recombinant AgfA fimbrin proteins.

20. The recombinant gene according to any one of claims 11, 12 wherein said recombinant strain of *E. coli* is capable of producing recombinant AgfA fimbrin proteins.

21. The recombinant gene according to any one of claims 13, 14 wherein said recombinant strain of Enterobacteriaceae is capable of producing recombinant AgfA fimbrin proteins.

22. The recombinant gene according to any one of claims 19-21 wherein said recombinant fimbrin protein is a recombinant AgfB fimbrin protein.

23. The recombinant gene according to any one of claims 19-21 wherein said recombinant fimbrin protein is a recombinant CsgA fimbrin protein.

24. The recombinant gene according to any one of claims 19-21 wherein said recombinant fimbrin protein is a recombinant CsgB fimbrin protein.

25. The recombinant gene according to any one of claims 19-21 wherein said recombinant fimbrin protein is a recombinant homologue of an AgfA or AgfB fimbrin protein.

26. The recombinant gene according to any one of claims 9, 10 wherein said recombinant strain of *Salmonella* is capable of producing stable fimbriae comprising recombinant AgfA fimbrin protein.

27. The recombinant gene according to any one of claims 11, 12 wherein said recombinant strain of *E. coli* is capable of producing stable fimbriae comprising recombinant AgfA fimbrin protein.

28. The recombinant gene according to any one of claims 13, 14 wherein said recombinant strain of Enterobacteriaceae is capable of producing stable fimbriae comprising recombinant AgfA fimbrin protein.

29. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant AgfB fimbrin protein.

30. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant CsgA fimbrin protein.

31. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant CsgB fimbrin protein.

32. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant AgfA and AgfB fimbrin proteins.

33. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant CgsA and CsgB fimbrin proteins.

34. The recombinant gene according to any one of claims 26-28 wherein said fimbriae are comprised of recombinant homologue of an AgfA or AgfB fimbrin protein.

35. The use of the SEF17/TAF nucleation dependent assembly system of strains of *Salmonella* for the production of fimbriae comprising recombinant AgfA subunits.

36. The use of the SEF17/TAF homologue curli nucleation dependent assembly system of strains of *E. coli* for the production of fimbriae comprising recombinant CsgA subunits.

37. The use of the SEF17/TAF homologues nucleation dependent assembly systems of strains of Enterobacteriaceae for the production of fimbriae comprising recombinant, AgfA-homologue fimbrin subunits.

38. A method of eliciting an immune response in an animal comprising:

- (a) separating an amino acid polymer comprising a recombinant AgfA protein containing a replacement segment or segments of foreign amino acid sequence or sequences grown on a *Salmonella* host cell from said *Salmonella* host cell; and
- (b) introducing said amino acid polymer into said animal in conjunction with a physiological carrier or diluent.

39. A method of eliciting an immune response in an animal comprising:

- (a) separating an amino acid polymer comprising a recombinant AgfA protein containing a replacement segment or segments of foreign aminoacid sequence or sequences grown on a *E. coli* host cell from said *E. coli* host cell; and
- (b) introducing said amino acid polymer into said animal in conjunction with a physiological carrier or diluent.

40. A method of eliciting an immune response in an animal comprising:

- (a) separating an amino acid polymer comprising a recombinant AgfA protein containing a replacement segment or segments of foreign aminoacid sequence or sequences grown on a Enterobacteriaceae host cell from said Enterobacteriaceae host cell; and

(b) introducing said amino acid polymer into said animal in conjunction with a physiological carrier or diluent.

41. The recombinant gene according to any one of claims 38-40 wherein said recombinant protein is AgfB recombinant protein.

42. The recombinant gene according to any one of claims 38-40 wherein said recombinant protein is CsgA recombinant protein.

43. The recombinant gene according to any one of claims 38-40 wherein said recombinant protein is CsgB recombinant protein.

44. The recombinant gene according to any one of claims 38-40 wherein said recombinant protein is an AgfA or AgfB homologue recombinant protein.

45. A method of eliciting an immune response in an animal comprising:

(a) separating a fimbriae comprising a recombinant AgfA protein containing a replacement segment or segments of foreign amino acid sequence or sequences grown on a *Salmonella* host cell from said *Salmonella* host cell; and

(b) introducing said fimbriae into said animal in conjunction with a physiological carrier or diluent.

46. A method of eliciting an immune response in an animal comprising:

(a) separating a fimbriae comprising a recombinant AgfA protein containing a replacement segment or segments of foreign amino acid sequence or sequences grown on a *E. coli* host cell from said *E. coli* host cell; and

(b) introducing said fimbriae into said animal in conjunction with a physiological carrier or diluent.

47. A method of eliciting an immune response in an animal comprising:
- (a) separating a fimbriae comprising a recombinant AgfA protein containing a replacement segment or segments of foreign amino acid sequence or sequences grown on a Enterobacteriaceae host cell from said Enterobacteriaceae host cell; and
  - (b) introducing said fimbriae into said animal in conjunction with a physiological carrier or diluent.

48. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an AgfB recombinant protein.

49. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an CsgA recombinant protein.

50. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an CsgB recombinant protein.

51. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an AgfA or AgfB homologue recombinant protein.

52. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an AgfA and AgfB homologue recombinant protein.

53. The recombinant gene according to any one of claims 45-47 wherein said fimbriae is comprised of an CsgA and CsgB homologue recombinant protein.

54. A method for directing recombination of a recombinant gene into the chromosome of the homologous species.

55. A method for directing recombination of a recombinant gene back into the chromosome of the homologous species thereby replacing the native copy of that gene.

BACTERIAL FIMBRIAL SYSTEM FOR PRESENTATION OF HETEROLOGOUS  
PEPTIDE SEQUENCES

ABSTRACT OF THE DISCLOSURE

The invention provides a system for creating recombinant *agfA* fimbрин genes and performing chromosomal gene replacements within *Salmonella*, creating *Salmonella* strains which carry the recombinant *agfA* genes at the native position in the chromosome. One embodiment of the invention is exemplified by the expression of a model epitope (PT3) obtained from the GP63 protein of *Leishmania major*, by formation of recombinant *agfA* genes encoding PT3 fusion proteins recombined at 10 different sites throughout the *agfA* gene. These fusions are shown to be expressed in the thin aggregative fimbriae on the surface of bacterial cell. The AgfA fimbрин of *Salmonella* (CsgA for *E. coli*) provides a flexible and stable vehicle for the expression of foreign epitopes in *enterobacteriaceae* and the subsequent thin aggregative fimbriae (curli) expression product provide an ideal organelle for presentation of the foreign epitopes at the cell surface.

PCT/US2007/030000




Figure 1A, 1B and 1C





Figure 2A and 2B

**A** PT3 epitope of *L. major*

**YDQLVTRVVTHEMAHA**  
-----XXXXXXX

**B** AgfA amino acid sequence

			■ A1		
C5e	113	SSVMVRQ	VGFG	NNATANQ Y	131
		-----	---**	*****--	
				A2	
			A10	A7	A1
C5d	91	SDITVGQ	YGGN	NAALVNQ TASD	112
		*-----	<***	*-----	-**<
				A9	
			A6	A10	
C5c	68	STIELTQ	NGFR	NNATIDQ WNAKN	90
		-----	<<<*	**-----	-***<
				A8	
			A5	A9	
C5b	46	SETTITQ	SGYG	NGADVGQ GADN	67
		*-----	-<<*	*-----	****
				A4	A8
C5a	23	STLSIYQ	YGSA	NAALALQ SDARK	45
		-----	-***	-----X-	-****
				A3	
N	1	GVVPQWGGGNHNGGNSSGPD			22
		-----*<*****<<<*****<			

Figure 3A and 3B

**C** Parallel  $\beta$ -helix model of AgfA




Figure 3C




Figure 4A and 4B




Figure 5A, 5B, 5C, 5D, 5E and 5F






Figure 6A and 6B

**Figure 7**



**Figure 8**



**Figure 7 and Figure 8**

(a)

N (22)	C (109)
N (22)	C2a (45)
N (22)	C2b (44)

(b)

C2a 43    A R K S E T T I T Q S G Y G N G A D V G Q G A D N S T I E L T Q N G F R N N A T I D Q W N  
 C2b 88    • K N • D I • Y G • Y • G N • A • L • N • T • S D • S Y M Y R • V • G • • • A N • Y

(c)

N 1    G V V P Q W G G G G N H N G G G N S S G P D

C5a 23	S T L S I Y Q Y G S A N A A L A L Q S D A R K
C5b 46	S E T T I T Q S G Y G N G A D V G Q — G A D N
C5c 68	S T I E L T Q N G F R N N A T I D Q W N A K N
C5d 91	S D I T V G Q Y G G N N A A L V N Q — T A S D
C5e 113	S S V M V R Q V G F G N N A T A N Q Y

(d)              1        3        5        7        9        12        14        16        18  
 S x x x x x Q x x G x x N x A x x x Q (x) x A x x

(e)

C5a	S x i ϕ i x Q
C5b	L S —
C5c	T T —
C5d	E L —
C5e	T V —
	V [M] V

Figure 9A, 9B, 9C, 9D, 9E

1 GVVPQWGHHGNHNGGNSSGP D  
 alx cccccccccc cccccccccc  
 hie cccccccccc cccccccccc  
 gar eeeeeect tccccctt tccccct  
 gib eeeeeeccce eccccccccc  
 nnp e

23 STLSIYQ YGSA NAALALQ SDARK  
 alx ceeeeee cccc hhhhhh hhccc  
 hie ceeeeee cccc hhhhhh hcccc  
 gar eeeeeee eccc hhhhhh hhhh  
 gib eeeeeee echh hhhhhh hhbbc  
 nnp eeeeeee e hhhhhh h

46 SETTITQ SGYG NGADVGQ GADN  
 alx ceeeeec cccc cccccc cccc  
 hie ceeeeee cccc cccccc cccc  
 gar ceeeeee ettc eeeeeee cccc  
 gib ceeeeee eccc ceeeeee cccc  
 nnp eeeee

68 STIELTQ NGFR NNATIDQ WNAKN  
 alx ceeeeec cccc cchhhh hhccc  
 hie ceeeecc cccc ccceeh ccccc  
 gar eeeeeee ttcc ceeeeee ecct  
 gib ceeeeee hcce cchhhh hhbbc  
 nnp eehh

91 SDITVGGQ YGGN NAALVNQ TASD  
 alx ceeeeec cccc chhhhhh cccc  
 hie ceeeeee cccc ceeeeec cccc  
 gar ceeeeee tccc ceeeeee ecct  
 gib ceeeeee eccc cheeee cccc  
 nnp eeee hhhh

113 SSVMVRQ VGFG NNATANQ Y  
 alx ceeeeee eccc cccccc c  
 hie ceeeeee eccc cccccc c  
 gar eeeeeee eccc cccccc e  
 gib ceeeeee eccc cccchch e  
 nnp eeee

Figure 10




Figure 11A, 11B and 11C






Figure 12 A, 12B, 12C and 12D

**Figure 13A and 13B**



**Figure 14A and 14B**



**Figure 13A, 13B, 14A and 14B**

	•	○	•	○	•	○	•	t	t	t	t	•	○	•	○	•	○	•	○	•	t	t	t	t
	i	φ	i									i	φ	i										
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23		
AgfA	S	T	L	S	I	Y	Q	Y	G	S	A	N	A	A	L	A	L	Q	S	D	A	R	K	
	S	E	T	T	I	T	Q	S	G	Y	G	N	G	A	D	V	G	Q	-	G	A	D	N	
	S	T	I	E	L	T	Q	N	G	F	R	N	N	A	T	I	D	Q	W	N	A	K	N	
	S	D	I	T	V	G	Q	Y	G	G	N	N	A	A	L	V	N	Q	-	T	A	S	D	
	S	S	V	M	V	R	Q	V	G	F	G	N	N	A	T	A	N	Q	Y					
CsgA	S	E	L	N	I	Y	Q	Y	G	G	G	N	S	A	L	A	L	Q	T	D	A	R	N	
	S	D	L	T	I	T	Q	H	G	G	G	N	G	A	D	V	G	Q	-	G	S	D	D	
	S	S	I	D	L	T	Q	R	G	F	G	N	S	A	T	L	D	Q	W	N	G	K	N	
	S	S	V	M	T	V	K	Q	F	G	G	G	N	G	A	A	V	D	Q	-	T	A	S	N
	S	S	V	N	V	T	Q	V	G	F	G	N	N	A	T	A	H	Q	Y					

Figure 15

(a)

SMP	328	I ENAIGGSG-ND-VIVGNAANN	347
	248	VLKGGAG-ND-VLFGGGGAD	365
	366	ELWGGAG-KD IFVFSAASD	383

AgfA	23	STLSIYQYGSANAALALQSDARK	45
	46	SETTITQSGYGNNGADVQGQADN	67
	68	STIELTQNGFRNNATIDQWNAKN	90

(b)

PMP	40	VIISKKGDIITIRT-ESPFKNTE	61
	62	ISFKLGQEFEETTADNRKTGSTVTL	86

AgfA	25	LSIYQYGSANAALALQSDARKSE	47
	48	TTITQSGYGNNGADVQGQADNSTIEL	72

(c)

VMO-I	34	FALKVEPSQFGRDDTALNG	52
	87	FSLRSEKSQGGGDDTAANN	105
	138	LQTKVESPQGLRDDTALNN	156

	25	LSI-YQ--YGSANAALALQ	40
	70	IEL-TQ--NGFRNNATIDQ	85
	115	VMV-RQ--VGFGNNATANQ	130

Figure 16A, 16B, 16C






Figure 17A, 17B, 17C





Figure 18A, 18B




Figure 19A, 19B

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □




Figure 20





Figure 21A, 21B



**Figure 22**


**A** PT3 epitope of *L. major*

YDQLVTRVVTHEMAHA


**B** SefA amino acid sequence

	S1	S10	
1	AGFVGNKAVVQAAVTIAAQNTTSANWSQDP		30
		S6	
31	S10	S2	
	GFTGPAVAAGQKVGTLSITATGPHNSVIA		60
	S6		
61	S2	S3	S7
	GKGASVSGGVATVPFVDGQGQPVFRGRIQG		90
	S7	S8	S4
91	ANINDQANTGIDGLAGWRVASSQETLNVPV		120
	S5		
121	S4	S9	
	TTFGKSTLPAGTFTATFYVQQYQN		144


Figure 23A, 23B



**Fig. 24**



*Fig. 25*



*Fig. 26*

## SEQUENCES

SEQ ID #1

agfA DNA sequence

```

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTGGCTGG
CGTCGTTCCACAATGGGGCGCGGCCGTAATCATAACGGCGGCCAATAGTCCGGCCCGG
ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCGCTTGCTCTGCAAAGCGAT
GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA
GGGTGCGGATAATAGTACTATTGAACGTGACTCAGAATGGTTCAGAAATAATGCCACCATCG
ACCACTGGAACGCTAAAAACTCCGATATTACTGTCGGCCAATACGGCGGTAAACGCCGCG
CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCAGGTTGGTTGGCAACAA
CGCCACGGCTAACCACTATTAA

```

SEQ ID #2

agfB DNA Sequence

```

ATGAAAAACAAATTGTTATTATGATGTTGACAATACTGGGTGCGCCTGGGATTGCAACCGC
GACAAATTATGATCTGGCTCGTTCAGAATATAATTTCGCGTAAATGAATTAAGCAAGTCTT
CATTAAATCAGGCGGCCATTATTGGTCAAGTCGGCACGGATAATAGTGCAGAGTACGCCAG
GAAGGATCAAAACTATTGTCGTTATTTCACAAGAAGGAGGAAATAATCGGGCGAAAGTCGA
CCAGGCAGGGATTATAACTTGCCTATTGAGCAAACGGGCAATGCCAACGATGCCAGTA
TATCGCAAAGCGCTTACGGTAATAGTGCAGCTATTATCCAGAAAGGTTCTGGAAATAAGGCC
AATATTACCCAGTACGGTACCGCAGAAAACAGCAGTTGTAGTGCAGAACAGTCGATATGGC
TATTGCGTCACCCAACGCTAA

```

SEQ ID #3

csgA DNA Sequence

```

ATGAAACTTTAAAAGTAGAACGAAATTGCAGCAATCGTATTCTCCGGTAGCGCTGGCAGG
TGGTGGTCCCTCAGTACGGCGGCCGCGTAACCACGGTGGTGGCGGTAAATAATAGGGCCAA
ATTCTGAGCTGAACATTACCACTACGGTGGCGGTAACTCTGCACTGCTCTGCAAACGTGAT
GCCCGTAACCTGACTATTACCCAGCATGGCGCGGTAAATGGTGCAGATGTTGGTCA
GGGCTCAGATGACAGCTCAATCGATCTGACCCAACGTGGCTTGGTAACAGCGCTACTCTG
ATCAGTGGAACGGCAAAATTCTGAAATGACGGTTAACAGTTCGGTGGCAACGGTGCT
GCAGTTGACCAGACTGCATCTAACTCCTCCGTCAACGTGACTCAGGTTGGCTTGGTAACAA
CGCGACCGCTCATCAGTACTAA

```

SEQ ID #4

csgB DNA Sequence

```

ATGAAAAACAAATTGTTATTATGATGTTAACAAATACTGGGTGCGCCTGGGATTGCAACCGC
AGCAGGTTATGATTAGCTAATTCAAGAACATAACTTCGCGGTAAATGAATTGAGTAAGTCTT
CATTAAATCAGGCAGCCATAATTGGTCAAGCTGGACTAACATAATAGTGCAGTTACGGCAG

```

GGAGGCTAAAACTTGGCGGTGCGCAAGAAGGTAGTAGCAACCGGGCAAAGATTGA  
 CCAGACAGGAGATTATAACCTTGCATATATTGATCAGGCGGGCAGTGCCAACGATGCCAGTA  
 TTCGCAAGGTGCTTATGGTAATACTGCGATGATTATCCAGAAAGTTCTGGTAATAAGCA  
 AATATTACACAGTATGGTACTCAAAAAACGGCAATTGTAGTGCAGAGACAGTCGCAAATGGC  
 TATTGCGTGACACAACGTTAA

SEQ ID #5  
 AgfA protein Sequence

MKLLKVAFAAIIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
 ARKSETTIQSGYGNNGADVGQQGADNSTIELTQNGFRNNATIDQWNAKNSDITVGQYGGNNAA  
 LVNQTASDSSVMVRQVFGNNATANQY

SEQ ID #6  
 AgfB protein Sequence

MKNKLLFMLTILGAPGIATATNYDLARSEYNFAVNELSKSSFNQAAIIGQVGTDNSARVRQ  
 EGSKLLSVISQEGGNRRAKVDQAGNYNFAYIEQTGNANDASISQSAYGNSAAIQKGSGNKA  
 NITQYGTQKTAVVVQKQSHMAIRVTQR

SEQ ID #7  
 CsgA protein sequence

MKLLKVAIAAAIVSGSALAGVVPQYGGGNHGGGNNSGPSELNIYQYGGNSALALQTD  
 ARNSDLTITQHGGNGADVGQGSDSSIDLQRGFGNSATLDQWNGKNSEMTVKQFGGGNGA  
 AVDQTASNNSNVTVQVFGNNATAHQY

SEQ ID #8  
 CsgB protein sequence

MKNKLLFMLTILGAPGIAAAAGYDLANSEYNFAVNELSKSSFNQAAIIGQAGTNNSAQLRQ  
 GGSKLLAVVAQEGSSNRRAKIDQTGDYNLAYIDQAGSANDASISQGAYGNTAMI IQKGSGNKA  
 NITQYGTQKTAIVVQRQSOMAIRVTQR

SEQ ID #9  
 PT3 epitope DNA sequence  
 TATGATCAGCTGGTTACCCGTGTTACCATGAAATGGCACATGCA

SEQ ID #10  
 PT3 epitope protein sequence  
 YDQLVTRVVTHEMAHA

SEQ ID #11  
 AgfA::PT3#1 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGCGCGGTAAATCATAACGGCGGCCAATAGTTCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCCTGCTCTGCAAAGCGAT  
 GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
 GGGTGC GGATAATAGTACTATTGA~~ACT~~~~GACT~~CAGAATGGTT~~CAGAAATA~~ATGCCACCATCG  
 ACCAGTGGAACGCTAAAAACTCGATATTACTGT~~CGGCCA~~ATACGGCGGTAA~~TACGCCGCG~~  
CTGGTTAATTATGATCAGCTGGTTACCGTGT~~ACCCATGAAATGGCACATGCAAACAA~~  
CGCCACGGCTAACCAGGTATTAA

SEQ ID #12

AgfA::PT3#1 protein sequence

MKLLKVAFAAIIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
 ARKSETTITQSGYGN~~G~~ADVGQGADNSTIELTQNGFRNNATIDQWN~~AKNS~~DITVGQYGGNAA  
LVNYDQLVTRVVTHEMAHANNATANQY

SEQ ID #13

AgfA::PT3#2 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGCGCGGTAAATCATAACGGCGGCCAATAGTTCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCCTGCTCTGCAAAGCGAT  
 GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
 GGGTGC GGATAATAGTACTATTGA~~ACT~~~~GACT~~CAGAATGGTT~~CAGAAATA~~ATGCCACCATCG  
 ACCAGTGGAACGCTAAAAACTCGATATTACTGT~~CGGCCA~~ATATGATCAGCTGGTTACCCGT  
GTTGTTACCCATGAAATGGCACATGCAAGCGTAATGGTGCGT~~CAGGTTGGTTGGCAACAA~~  
CGCCACGGCTAACCAGGTATTAA

SEQ ID #14

AgfA::PT3#2 protein sequence

MKLLKVAFAAIIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
 ARKSETTITQSGYGN~~G~~ADVGQGADNSTIELTQNGFRNNATIDQWN~~AKNS~~DITVGQYDQLVTR  
VVTHEMAHASVMVRQVGFGNNATANQY

SEQ ID #15

AgfA::PT3#3 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
CGTCTATGATCAGCTGGTTACCGTGT~~TACCCATGAAATGGCACATGC~~ATCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCCTGCTCTGCAAAGCGAT  
 GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
 GGGTGC GGATAATAGTACTATTGA~~ACT~~~~GACT~~CAGAATGGTT~~CAGAAATA~~ATGCCACCATCG  
 ACCAGTGGAACGCTAAAAACTCGATATTACTGT~~CGGCCA~~ATACGGCGGTAA~~TACGCCGCG~~

CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCCTCAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCACTATTAA

SEQ ID #16  
AgfA::PT3#3 protein sequence

MKLLKVAFAIAIVVSGSALAGVYDOLVTRVVTHEMAHASPDSTLSIYQYGSANAALALQSD  
ARKSETTITQSGYGNGADVGQGADNSTIELTQNGFRNNATIDQWNAKNSDITVGQYGGNNAA  
LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #17  
AgfA::PT3#4 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
CGTCGTTCCACAATGGGGCGGCGGCGGTAAATCATAACGGCGGCGGAATAGTTCCGGCCCG  
GACTATGATCAGCTGGTTACCCGTGTTACCCATGAAATGGCACATGCATGCAAAGCGAT  
GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
GGGTGCGGATAATAGTACTATTGAACTGACTCAGAATGGTTCAGAAATAATGCCACCATCG  
ACCAGTGGAACGCTAAAACTCCGATATTACTGTCCGGCAATACGGCGGTAAATAACGCCGCG  
CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCGTCAAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCACTATTAA

SEQ ID #18  
AgfA::PT3#4 protein sequence

MKLLKVAFAIAIVVSGSALAGVVPQWGGGNHNGGGNSGPDOLVTRVVTHEMAHALQSD  
ARKSETTITQSGYGNGADVGQGADNSTIELTQNGFRNNATIDQWNAKNSDITVGQYGGNNAA  
LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #19  
AgfA::PT3#5 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
CGTCGTTCCACAATGGGGCGGCGGCGGTAAATCATAACGGCGGCGGAATAGTTCCGGCCCG  
ACTCAACGTTGAGCATTATCAGTACGGTTCCGCTAACGCTGCGCTTGCTCTGCAAAGCGAT  
GCCCGTAAATATGATCAGCTGGTTACCCGTGTTACCCATGAAATGGCACATGCAGGCCA  
GGGTGCGGATAATAGTACTATTGAACTGACTCAGAATGGTTCAGAAATAATGCCACCATCG  
ACCAGTGGAACGCTAAAACTCCGATATTACTGTCCGGCAATACGGCGGTAAATAACGCCGCG  
CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCGTCAAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCACTATTAA

SEQ ID #20  
AgfA::PT3#5 protein sequence

MKLLKVAFAAAIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
ARKYDQLVTRVVTHEMAHAGQGADNSTIELTQNGFRNNATIDQWNAKNSDITVGQYGGNNAA  
 LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #21

AgfA::PT3#6 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGGCGGCGTAATCATAACGGCGGCGCAATAGTCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCCTGCTCTGCAAAGCGAT  
 GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
 GGGTGC GGATAATTATGATCAGCTGGTTACCCGTGTTACCCATGAAATGGCACATGCAG  
 ACCAGTGGAACGCTAAAAACTCCGATATTACTGTGGCCAATACGGCGGTAAACGCCGCG  
 CTGGTTAACGACCGCATCTGATTCCAGCGTAATGGTGC GT CAGGTTGGTTGGCAACAA  
 CGCCACGGCTAACCACTATTAA

SEQ ID #22

AgfA::PT3#6 protein sequence

MKLLKVAFAAAIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
ARKSETTITQSGYGNADVGQGADNYDQLVTRVVTHEMAHADQWNAKNSDITVGQYGGNNAA  
 LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #23

AgfA::PT3#7 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGGCGGCGTAATCATAACGGCGGCGCAATAGTCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCCTGCTCTGCAAAGCGAT  
 GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
 GGGTGC GGATAATAGTACTATTGAAC TGACTCAGAATGGTT CAGAAATAATGCCACCATCG  
 ACCAGTGGAACGCTAAAAACTATGATCAGCTGGTTACCCGTGTTACCCATGAAATGGCA  
CATGCAAATCAGACCGCATCTGATTCCAGCGTAATGGTGC GT CAGGTTGGTTGGCAACAA  
 CGCCACGGCTAACCACTATTAA

SEQ ID #24

AgfA::PT3#7 protein sequence

MKLLKVAFAAAIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
ARKSETTITQSGYGNADVGQGADNSTIELTQNGFRNNATIDQWNAKNYDQLVTRVVTHEMA  
HANQTASDSSVMVRQVGFGNNATANQY

SEQ ID #25

AgfA::PT3#8 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGGCCGGTAATCATAACGGCGGCCGGCAATAGTTCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCGCTTATGATCAGCTGGTT  
ACCCGTGTTGTTACCCATGAAATGGCACATGCAGGTTATGGTAACGGCGCCGATGTAGGCCA  
GGGTGCGGATAATAGTACTATTGAACTGACTCAGAATGGTTCAGAAATAATGCCACCATCG  
ACCAAGTGGAACGCTAAAAACTCGATATTACTGTCGGCCAATACGGCGGTAAATAACGCCGCG  
CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCAAGTATTAA

SEQ ID #26

AgfA::PT3#8 protein sequence

MKLLKVAFAAAIVVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALYDOLV  
TRVVTHEMAHAGYGNGADVGQGADNSTIELTQNGFRNNATIDQWNAKNSDITVGQYGGNNAA  
 LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #27

AgfA::PT3#9 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGGCCGGTAATCATAACGGCGGCCGGCAATAGTTCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCGCTTGTCAAAGCGAT  
GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATTATGATCA  
GCTGGTTACCGTGTGTTACCCATGAAATGGCACATGCATTCAAATAATGCCACCATCG  
ACCAAGTGGAACGCTAAAAACTCGATATTACTGTCGGCCAATACGGCGGTAAATAACGCCGCG  
CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCAAGTATTAA

SEQ ID #28

AgfA::PT3#9 protein sequence

MKLLKVAFAAAIVVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
ARKSETTITQSGYGNGADYDOLVTRVVTHEMAHFRNNATIDQWNAKNSDITVGQYGGNNAA  
 LVNQTASDSSVMVRQVGFGNNATANQY

SEQ ID #29

AgfA::PT3#10 DNA sequence

ATGAAACTTTAAAAGTGGCAGCATTGCAGCAATCGTAGTTCTGGCAGTGCTCTGGCTGG  
 CGTCGTTCCACAATGGGGCGGCCGGTAATCATAACGGCGGCCGGCAATAGTTCCGGCCCGG  
 ACTCAACGTTGAGCATTATCAGTACGGTCCGCTAACGCTGCGCTTGTCAAAGCGAT  
GCCCGTAAATCTGAAACGACCATTACCCAGAGCGGTTATGGTAACGGCGCCGATGTAGGCCA  
GGGTGCGGATAATAGTACTATTGAACTGACTCAGAATGGTTCAGAAATAATGCCACCTATG  
ATCAGCTGGTTACCGTGTGTTACCCATGAAATGGCACATGCAGGCGGTAAATAACGCCGCG

CTGGTTAACAGACCGCATCTGATTCCAGCGTAATGGTGCCTCAGGTTGGTTGGCAACAA  
CGCCACGGCTAACCAAGTATTAA

SEQ ID #30  
AgfA::PT3#10 protein sequence

MKLLKVAFAAIIVSGSALAGVVPQWGGGNHNGGNSSGPDSTLSIYQYGSANAALALQSD  
ARKSETTIQSGYGNGADVGQGADNSTIELTQNGFRNNATYDQLVTRVVTHEMAHAGGNAA  
LVNQTASDSSVMVRQVGFGNNATANQY